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The ALS-linked gene TDP-43 regulates IFNβ expression through a novel 
mechanism of 3’ UTR-mediated promoter cis-regulation 
 
Abstract 
 
The TAR DNA-binding protein (TDP-43) is a heterogeneous nuclear ribonucleprotein 
that is involved in multiple stages of RNA processing. Mutations in the TDP-43 gene 
and mislocalization of TDP-43 protein have been implicated in a growing number of 
neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and 
frontotemporal lobar degeneration (FTLD). Here, we show that TDP-43 negatively 
regulates innate immune gene expression in response to RNA virus sensing. 
Perturbation of TDP-43 protein expression leads to an increase in antiviral gene 
expression in a variety of human and mouse cells. Crosslinked RNA 
immunoprecipitation (CLIP) experiments revealed that TDP-43 binds to type I interferon 
(IFN) and interferon stimulated gene (ISGs) transcripts. Using massively parallel 3’ UTR 
reporter assays coupled with high throughput sequencing (MPRA-seq), we identified 
polyadenylation signal sequences in the 3’ UTRs of innate immune genes to be 
specifically regulated by TDP-43. Surprisingly, IFN and ISG mRNA decay rates are 
faster in TDP-43-perturbed cells. Using a metabolic labeling approach to measure 
nascent transcript generation, we found that perturbation of TDP-43 expression leads to 
an increase in antiviral gene transcription rates. Additionally, RNA polymerase II (pol II) 
chromatin immunoprecipitation (ChIP) confirmed that there is greater pol II occupancy 
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on innate immune genes when TDP-43 is depleted. Although TDP-43 perturbation has 
no effect on an isolated IFNβ promoter reporter, we found that TDP-43 inhibits IFNβ 
promoter activity when the IFNβ 3’ UTR sequence is inserted downstream of the IFNβ 
promoter element, suggesting a novel mechanism of 3’UTR-mediated promoter cis-
regulation. 
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Introduction 
 
 
This work explores the regulation of the immune response to viral pathogens by 
RNA binding proteins. The larger goal of the Hacohen lab is to identify and 
dissect gene networks that are responsible for innate immune regulation. A 
specific effort has been made to explore RNA binding proteins that have 
previously unknown regulatory functions in our system. My thesis work focuses 
on one such RNA binding protein, TDP-43, that was also identified to be an 
amyotrophic lateral sclerosis (ALS) disease allele during the course of my 
studies. This introduction will present the viral sensing pathway that our work is 
focused on, as well as provide a background for the role of TDP-43 and innate 
immunity in ALS. Finally, the RNA biochemistry approaches that were developed 
in order to adequately study the mechanisms of function of RNA binding proteins 
are introduced.         
 
Section I: The innate immune response to RNA viruses 
 
The human body is equipped with several layers of defenses to evade infection 
by bacteria and viruses. Broadly, there are two main arms of the immune system. 
The innate immune system utilizes invariant, germ-line encoded receptors that 
recognize broad molecular features on pathogens and can respond very rapidly, 
within minutes, to pathogen invasion.  Conversely, adaptive immunity uses a 
complex system of antibody selection to elicit very specific responses against all 
potential pathogen components, and in turn develops a long-term immunological 
memory. This latter process, though more effective at eradicating infectious 
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agents, functions over a course of days rather than minutes. Therefore, both 
innate and adaptive immune players are required to generate a seamless 
response to pathogen insults and to curb the damage caused by future 
encounters with a given pathogen (Janeway’s Immunobiology for review).  
 
The work in this thesis will focus on the innate immune response to viral 
infections specifically. While there are specialized cell types that are categorized 
as either innate (macrophages, dendritic cells) or adaptive (T cells, B cells) by 
the roles that they play in maintaining healthy immunity, the cellular response to 
virus is interesting because all cells of the body must be equipped with viral 
sensing machinery and downstream signaling components that are required to 
combat a viral infection and limit the spread of viral replication. 
 
How viruses are sensed 
 
One of the fastest immune surveillance interactions is the recognition of 
conserved pathogen-associated molecular patterns (PAMPs) by the host’s 
germline-encoded pattern recognition receptors (PRRs). PAMPs tend to be 
molecular structures of a pathogen that are so critical for the species’ survival 
that they cannot be easily mutated without compromising reproductive success. 
PRRs, on the other hand, are invariant receptors on the host side that recognize 
these pathogen components and rapidly activate a complex signaling pathway 
that leads to the engagement of either an inflammatory or an antiviral gene 
program. The resulting production of cytokines and chemokines eliminates 
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infected cells and signals to the adaptive immune system to initiate long-lasting 
immunity specific for a given pathogen (Medzhitov 2007). 
 
The two arms of an innate immune response are 1) pro-inflammatory and 2) 
antiviral. Pro-inflammatory cytokines primarily function to initiate and coordinate 
innate immune responses by recruiting professional antigen presentation cells, 
particularly macrophages and dendritic cells, to attack infected cells, process 
pathogenic antigens, and prime T cells to engage antibody-mediated immunity. 
Conversely, the antiviral pathway is initiated by the production of type I 
interferons, specifically IFNα and IFNβ (IFN). These cytokines bind to 
neighboring cells directly through IFNAR1/2, which signals to activate the 
induction of potent interferon stimulated genes (ISGs). Both IFNs and ISGs then 
locally induce transcriptional and post-transcriptional changes in all neighboring 
cells to augment an “antiviral state.” By changing cellular processes such as 
mRNA translation rates, viral replication is inhibited. Furthermore, IFNs and ISGs 
induce upregulation of MHC class I molecules and directly activate various 
components of adaptive immunity (Kawai and Akira 2006). 
 
Toll-like receptors 
 
Toll like receptors (TLRs) are essential pathogen sensors that are, at least 
minimally, expressed by all cells of the body to provide an initial barrier against 
infectious agents. TLRs are type I membrane glycoproteins and constructed of 
an extracellular leucine rich repeat (LRR) region for the recognition of PAMPs, 
linked to a cytoplasmic Toll/interleukine-1 receptor (TIR) domain that mediates 
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downstream signaling. There are currently 13 known TLRs in mice and 10 in 
humans. Each TLR recognizes a unique component of bacteria, virus, or fungi. 
TLR1, 2, and 4-6 are cell surface receptors that recognize PAMPs from bacteria 
and fungi, while TLR3, 7-9 reside within endosomes and recognize nucleic acids 
from viruses (Takeuchi, 2010). Single stranded (ss) and double stranded (ds) 
RNA and DNA from viruses are recognized by distinct TLRs. For example, 
dsDNA from the herpes simplex virus (HSV) is sensed by TLR9 (Krug 2004), 
whereas TLR3 is a critical viral dsRNA sensor (Alexopoulou 2001).  
 
The recognition of ligands by TLRs leads to a rapid induction of either pro-
inflammatory or antiviral gene network responses. Activation of TLRs1, 2, 4-6 
leads to the production of primarily pro-inflammatory cytokines, such as tumor 
necrosis factor (TNF). Conversely, triggering TLR3, 7, and 9 results in an antiviral 
response that leads to type I interferon production (Kumar 2011). TLR signaling 
is mediated by the recruitment of a limited set of TIR domain-containing adaptor 
molecules to TLR cytosolic TIR domains. Key adaptor molecules include MyD88, 
TRIF, TIRAP, and TRAM. The dependency on specific adaptor molecules by 
each TLR for signaling is complex, but can be distilled down to the activation of a 
core set of master transcription factors, such as IRF3/7 and NF-kB, that leads to 
the engagement of either a pro-inflammatory or antiviral response (Kumar 2009). 
Professional immune surveillance cells, such as dendritic cells, express high 
levels of all TLRs to mediate the rapid induction of cytokines and increase 
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antigen presentation of microbial peptides to T cells, which in turn activates 
antigen-specific immune responses (Hemmi and Akira 2005). 
 
 
RIG-I-like receptors 
 
RIG-I-like receptors (RLR) include RIG-I, MDA5, and LGP2 and, unlike TLRs, are 
localized to the cell cytosol to detect RNA from infecting RNA viruses. Again, 
activating RLRs can lead to the induction of both pro-inflammatory and antiviral 
gene network responses. RIG-I and MDA5 contain N-terminal CARD domains 
that are required for downstream signaling. LGP2 lacks a CARD domain, but all 
three have a DExD/H-box RNA helicase domain that is used for ligand 
recognition (Wilkins and Gale 2010). 
 
RIG-I recognizes members of the paramyxoviridae family (Newcastle Disease 
virus, vesicular stomatitis virus), the flaviviridae family (Hepatitis C virus), as well 
as short dsRNA and ssRNA with a 5’ triphosphate. MDA5 recognizes chemically 
synthesized dsRNA and works with RIG-I to elicit appropriate responses to 
certain viral pathogens, such as West Nile Virus (Kumar 2011). LGP2 is thought 
to improve the accessibility of viral RNA to RIG-I and MDA5 recognition to induce 
a more robust antiviral response (Satoh 2010). 
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Table 0.1: Innate immune sensors and their ligands 
 
See Kumar et al., 2011 for review 
 
 
During an active viral infection, viral RNA enters the cytosol and is sensed by 
RLRs. The CARD domains of RIG-I and MDA5 are conformationally activated 
and interact with the CARD-containing adaptor molecule, IPS-1. IPS-1 then 
localizes to mitochondria and peroxisomes to induce downstream signaling. The 
master regulatory transcription factors, IRF1, 3, 7 and NF-kB, are then activated 
and turn on the antiviral gene expression network (Kumar 2011).  
 
Type I interferon and interferon stimulated gene regulation 
 
The innate immune response to viral PAMPs by TLRs and RLRs involves the 
critical activation of type I interferon and interferon stimulated genes. In the 
Receptor Location Ligand 
TLRs   
TLR1/2 Cell surface Triacyl lipopeptides 
TLR2 Cell surface Peptidoglycan, zymosan 
TLR3 Endosome ssRNA, dsRNA, poly I:C 
TLR4 (CD14) Cell surface lipopolysaccride 
TLR5 Cell surface Flagellin 
TLR6/2 Cell surface Diacyl lipopeptides 
TLR7 Endosome ssRNA, imiquimod 
TLR8 Endosome ssRNA, imiquimod 
TLR9 Endosome dsDNA, CpG motifs 
TLR11 (mice) Endosome Uropathogenic bacteria,  
TLR 13 (mice) Endosome 23S rRNA 
RLRs   
RIG-I Cytoplasm Short dsRNA (up to 1 kb), 
5’triphosphate, short poly I:C 
MDA5 Cytoplasm Long poly I:C, ssRNA,  
LGP2 Cytoplasm  
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absence of intact interferon signaling, such as in the interferon alpha receptor 
(IFNAR) knockout mouse, the ability to achieve an antiviral state is abolished and 
susceptibility to viral infection is a significant problem (Muller 1994). When viral 
sensors are triggered by pathogen components, the initial cytosolic signaling 
events culminate in the activation of a core set of critical transcription factors, 
namely IRF3/7, NF-kB, and ATF-2/c-Jun. These transcription factors normally 
reside in the cytosol but, when activated, translocate to the nucleus and 
assemble onto the virus-inducible enhancer of the IFNβ gene promoter. Through 
a coordinated mechanism of recruitment, these transcription factors are joined by 
the transcriptional co-activators, p300 and CREB-binding protein (CBP) (Thanos 
and Maniatis 1995, Wathelet 1998). IFNβ gene transcription is initiated and IFNβ 
protein is secreted from the cell. In both an autocrine and paracrine fashion, type 
I interferons then signal through the IFNAR1/2 to amplify the antiviral response 
and activate genes that contain an interferon-stimulated response element 
(ISRE; sequence: 5’-GAAANNGAAAG/CT/C-3’). Approximately fifty genes 
contain an ISRE and are activated in response to IFN (Darnell 1994, Honda 
2005). 
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Figure 0.1: Type I interferon signaling pathway in response to viral RNA sensing. Toll-like 
receptors (TLRs) or cytosolic nucleic acid receptors (RIG-I, MDA5) sense viral RNA and signal 
through adaptor molecules to activate key transcription factors (IRFs, NF-kB) that are required for 
IFNβ gene expression. IFNβ protein is secreted from the cell and signals though interferon alpha-
receptors 1 and 2 (IFNAR1/2) to amplify the antiviral gene response by activation transcription 
factors that turn on interferon-stimulated response element- (ISRE)-containing genes. 
 
Negative regulators of the type I interferon response 
 
Interferons and ISGs are inherently toxic to cells and their expression is limited to 
an active antiviral response. Many essential negative regulators of the antiviral 
signaling pathway exist to prevent uncontrolled activation of this pathway, which 
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could lead to irreparable tissue damage or autoimmunity. Known negative 
regulators are active at all stages of interferon induction and signaling. For 
example, ISG56 (IFIT1) is one of the first genes to be upregulated in response to 
type I interferon or viral infection. ISG56 was found to interrupt the physical 
association of the cytosolic signaling mediators IPS-1, STING, and TBK1 with 
each other, thus preventing the activation of a key transcription factor for type I 
interferon genes expression, IRF3 (Li 2009). Similarly, several other factors that 
interrupt antiviral signaling upstream of transcription have been identified, such 
as SIRPα (Dong 2008), TRIM30α (Shi 2008), and A20 (Saitoh 2005).  
 
Signal-dependent phosphorylation events are another level that the induction of 
type I interferons is regulated. IκB-kinase-ε (IKKε) and TANK-binding kinase-1 
(TBK1) function to control the phosphorylation of two transcription factors that are 
required to augment IFNβ gene activation, IRF3 and NF-kB (Fitzgerald 2003). 
The NEMO-related protein and ALS disease gene, optineurin (OPTN), negatively 
regulates the function of TBK1 by physically associating with TBK1 and 
preventing the phosphorylation of IRF3 (Mankouri 2010). 
 
Transcriptional repression of IFNβ is not the only mechanism used to control the 
activity of the antiviral gene expression network. The IFNβ mRNA itself contains 
sequences in its coding region and 3’ untranslated region (UTR) that are targeted 
by RNA binding proteins for decay. Both sequences are approximately 20 
nucleotides in length and are significantly enriched in the nucleotides A and U, 
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specifically AUUUA (Raj and Pitha 1993). Such A-U rich elements, or AREs, are 
found in the 3’ UTRs of several other cytokines as well, including TNF and IL-1β, 
and are part of a critical mechanism to rapidly modulate cytokine protein levels 
(Stoecklin and Anderson 2006). 
 
Section I summary 
 
The antiviral signaling pathway is a key defense against viral pathogens.   
Despite the identification of many negatively regulators of type I interferon 
induction, it is clear than more remain to be discovered. This thesis presents a 
project that describes a novel negative regulator of the IFN signaling pathway, 
TDP-43. This work defines where TDP-43 functions as an inhibitor of the antiviral 
pathway as well as the mechanism by which TDP-43 regulates type I interferon 
gene activity.  
 
Section II: The RNA binding protein TDP-43 
 
 
TDP-43 is a multi-functional RNA binding protein 
 
In 2009, our lab published the results of an RNA interference (RNAi) screen in 
which approximately 150 regulators of innate immunity were systematically 
knocked down in primary bone marrow dendritic cells (BMDC). The set of 
targeted known and putative regulators included transcription factors, chromatin 
modifiers, and RNA binding proteins. Gene expression profiles following 
knockdown and challenge with TLR ligands were assessed, and the resulting 
regulatory networks identified the RNA binding protein Fus to be a negative 
regulator of antiviral gene expression. Depletion of Fus resulted in an increase in 
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the expression of approximately 50 antiviral genes but had no effect on the pro-
inflammatory gene pathway (Amit 2009). Based on this work, we became 
interested in another RNA binding protein that shares sequence homology with 
Fus, called TDP43. TDP-43 (gene: Transactivation response DNA binding 
protein of 43 bp, TARDBP) is a 43 kD nuclear RNA binding protein associated 
with a variety of cellular functions, particularly those related to RNA metabolism. 
Subsequent to the publishing of the screen, I found that, like Fus, TDP-43 also 
regulates antiviral gene expression. Interestingly, my work and others have 
demonstrated that TDP-43 and Fus proteins associate with each other and exist 
in a large ribonucleoprotein complex (Kim 2010, Freibaum 2010). My thesis work 
describes how TDP-43 mechanistically functions to control the antiviral response.  
 
TDP-43 is an amyotrophic lateral sclerosis disease gene 
 
 
TDP-43 was found to be the most highly enriched protein in cytosolic 
ubiquitinated protein aggregates in the central nervous system of individuals with 
sporadic and familial amyotrophic lateral sclerosis (ALS) and frontotemporal 
lobar dementia (FTLD) (Arai 2006, Neumann 2006). In addition to the wild type 
protein, truncated forms of TDP-43 and hyperphosphorylated forms were also 
detected. Direct sequencing of the TARDBP gene in patients with these 
neurodegenerative diseases revealed approximately fifty causative point 
mutations (Kabashi 2008, Sreedharan 2008). Now, roughly 5% of sporadic and 
familial ALS is attributed to mutations in TDP-43 (Mackenzie 2010). TDP-43 
protein aggregates have more recently been identified in other 
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neurodegenerative diseases, including Alzheimer’s Disease (AD) (Galimberti and 
Scarpini 2010) and chronic traumatic encephalopathy (McKee 2010). An 
increase in TDP-43 expression has also been found in the central nervous 
system of horses that spontaneously develop an ALS-like neurodegenerative 
disease (El-Assaad 2012). Collectively, neurodegenerative diseases with TDP-43 
protein pathology are now referred to as “TDP-43 proteinopathies.” 
 
TDP-43 has a variety of cellular functions and has the potential to regulate 
immunity at a number of locations along the antiviral signaling and gene 
expression pathway. Previously, TDP-43 has been reported to repress 
transcription, direct splice site selection, traffic mRNA to and from the nucleus, 
control gene expression by stabilization or destabilization of RNA transcripts, and 
regulate microRNA expression. However, the significance of these functions with 
regard to disease pathophysiology is unclear.    
 
TDP-43 is a predominantly nuclear protein (414 amino acids in length) that is 
encoded by the gene TARDBP, located on chromosome 1. TARDBP has six 
exons and encodes up to eleven isoforms, with the most abundant being the 43 
kD isoform (Wang 2004). TDP-43 expression is ubiquitous across cells of the 
body in both rodents and humans (Buratti 2001). TARDBP is also a very 
evolutionarily conserved gene and has found to be required for pluripotency (Wu 
Genesis 2010). The N-terminus of TDP-43 has been shown to interact with 
transcription factors (Swarup 2011) and contains a nuclear localization 
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sequence. TDP-43 contains three putative RNA binding domains: the RNA 
recognition motif 1 (RRM1), RRM2, and a C-terminal arginine-glycine-glycine-rich 
repeat region (RGG) (Da Cruz and Cleveland 2011). Most of the ALS dominant 
missense mutations are localized in the RGG (See Figure 1). The RRM1 of TDP-
43 is indispensible for its binding to UG repeat sequences in RNA transcripts 
(Ayala 2006). 
 
    
 
 Figure 0.2: TDP-43 structural domains and mutations linked to ALS. (From Da Cruz and 
Cleveland, Neurobiology of Disease, 2011), 
 
 
Proteomic analyses of TDP-43 interaction partners show that TDP-43 is heavily 
enriched for associations with many RNA splicing factors (e.g. SF2, TIA-1), 
translation machinery (e.g. PABP2, eEF1A1 and eIF3F), and other proteins that 
regulate mRNA abundance including those in the nonsense mediated decay 
pathway (e.g. UPF1) and mRNA destabilization (e.g. Musashi 2). Importantly, the 
protein association map for two key TDP-43 ALS disease alleles (A315T and 
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M337) is the same as for the wild type TDP-43 protein (Kim 2010, Freibaum 
2010).  
 
TDP-43 is largely nuclear, although low levels of the protein can be found in the 
cytosol under normal conditions (Ayala 2008). In the nucleus, TDP-43 is 
concentrated in perichromatin fibrils around euchromatin, which are sites of 
active transcription and co-transcriptional splicing, but is absent from 
transcription-free Cajal bodies (Lafarga 2009). It has been noted that TDP-43 can 
aggregate in cytosolic stress granules (SG) under induced conditions of stress, 
and that the expression of disease-linked TDP-43 mutants increased the 
accumulation of TDP-43 in SGs (Liu-Yesucevitz 2010). 
 
Some of the known functions of TDP-43 are outlined here: 
 
 
TDP-43 is a transcriptional repressor 
 
Although most of the more recent papers on TDP-43 focus on its RNA binding 
functions, TDP-43 was originally described as a DNA binding protein that 
regulates the human immunodeficiency virus (HIV) type I transactivation 
response (TAR) regulatory element (Ou 1995). TAR is an activation domain in 
the HIV-1 long terminal repeat promoter region that is required for the activation 
of gene expression. In Ou et. al., proteins in a HeLa cell extract were UV 
crosslinked to a labeled TAR DNA probe and TDP-43 was found to bind to the 
TAR DNA sequence. Interestingly, RNA that is transcribed from the TAR region 
is also essential for HIV-1 gene expression but TDP-43 was not found to be 
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specifically associated with TAR RNA. An in vitro transcription assay confirmed 
that TDP-43 was able to repress transcription from the HIV-1 long terminal 
repeat, but not from an adenovirus promoter. 
 
Conversely, a more recent study found that TDP-43 binds to and is a co-activator 
of the NF-kB subunit, p65 (Swarup 2011). When TDP-43 was overexpressed, the 
activity of an NF-kB-dependent promoter reporter was increased significantly, 
both at baseline and in response to LPS stimulation. The N-terminus of TDP-43 
was required for this activity, but none of the RNA binding regions of the protein 
had an effect on transcriptional activation. To rule out a dominant negative effect 
of overexpressing TDP-43, the protein was depleted with siRNA and the NF-kB-
dependent promoter reporter activity was reduced in the absence of TDP-43. The 
authors correlate this function for TDP-43 with the observation that NF-kB-
dependent genes, such as TNF, are abnormally upregulated in the spinal cords 
of ALS patients.  
 
TDP-43 was also identified to be a key protein, along with Fus/TLS, in the 
Microprocessor complex that includes Drosha and DGCR8 (Gregory 2004). This 
complex mediates microRNA (miRNA) biogenesis. Perturbation of TDP-43 is 
associated with changes in miRNA expression, and TDP-43 is directly involved in 
the production of a subset of precursor miRNAs (pre-mirRNAs) (Kawahara 
2012).   
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TDP-43 directs splice site selection 
 
 
One of the first roles ascribed to TDP-43 was its ability to bind to the (TG)m Tn 
polymorphism at the 3’ splice site of the cystic fibrosis (CF) transmembrane 
conductance regulator (CFTR) gene. One of the major causes of CF is an 
aberrant skipping of exon 9 in the CFTR gene, thought to be partially caused by 
a higher frequency of TG repeats at the 3’ splice site among diseased 
individuals. TDP-43 has been show by systematic evolution of ligands by 
exponential enrichment (SELEX) and RNA pull down experiments to 
preferentially bind to RNA transcripts containing UG repeats (Buratti 2001, Ayala 
2005). In the presence of “unfavorable” CFTR (UG)m Tn sequences, TDP-43 was 
found to promote exon 9 skipping, and the depletion of TDP-43 protein from CF 
patient cells resulted in improved exon 9 inclusion (Ayala 2006). 
 
Fiesel et. al. recently published a paper that explored the effects of TDP-43 
depletion on splicing globally using Affymetrix exon arrays. In TDP-43-depleted 
neural cell lines, a key exon junction complex protein, ribosomal S6 kinase 1 
(S6K1) Aly/REF-like target (SKAR) is alternatively spliced (Fiesel 2012). SKAR 
normally functions to recruit S6K1 and facilitates the first round of translation. 
When TDP-43 is absent, the alternatively spliced form of SKAR enhances this 
function, causing a global increase in translation rates and cell size. We have 
likewise observed a significant increase in total cell size and protein content per 
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cell in our own work. The authors postulate that a general defect in regulating 
protein translation might contribute to the marked protein aggregation that is 
observed in ALS and FTLD.   
 
A more broad role for TDP-43 in regulating splicing was reported in a study in 
which TDP-43 was depleted in vivo from mouse striatum and the resulting 
transcriptome was analyzed by RNA sequencing (Polymenidou 2011). The 
depletion of TDP-43 resulted in a downregulation of ~240 genes. Additionally, 
this RNA was applied to splicing-sensitive microarrays and ~800 genes were 
found to be misspliced when TDP-43 was depleted. Rather than directing exon 
skipping, the depletion of TDP-43 from brain cells in this studied largely resulted 
in aberrant exon inclusion. The authors also performed crosslinked RNA 
immunoprecipitation (CLIP) followed by deep sequencing for endogenous TDP-
43 protein from mouse brains to capture the RNA transcript sequences that TDP-
43 binds. When the transcriptome and CLIP sequencing data sets were 
correlated with each other, it was observed that ~100 of the most downregulated 
genes from TDP-43-depleted cells are direct TDP-43 targets, and that TDP-43 
binds these genes primarily at intronic regions. Interestingly, these TDP-43 target 
genes contained very long introns, suggesting a relationship between intron 
length and stabilization by TDP-43.  
 
This paper focused on the effect of TDP-43 depletion on downregulated genes. 
Significantly, antiviral genes are overrepresented in the list of genes that were 
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upregulated in vivo when TDP-43 was depleted from the brain. Since there was 
less than 20% overlap between the upregulated genes and the TDP-43 CLIP 
binding associations (compared to 75% overlap between downregulated genes 
and TDP-43 binding), the authors postulate that many of the these genes are 
upregulated in the absence of TDP-43 by an indirect mechanism. As a side point, 
TDP-43 primarily bound these upregulated genes at their 3’ UTRs, in contrast to 
the intronic binding observed in the downregulated gene set. Looking at these 
data from an innate immune perspective, we realized that the downstream effect 
of dysregulated type I interferon expression would be an increase in the activity 
of the entire antiviral pathway. Since our work has found that TDP-43 negatively 
regulates IFNβ transcript levels directly, the findings in this paper are particularly 
relevant to understanding how TDP-43-mediated dysregulation of innate immune 
pathways might contribute to neurodegeneration. 
 
TDP-43 binds to mRNA and regulates gene expression  
 
Several groups have used a variety of biochemical methods to assess which 
RNA transcripts are directly bound by TDP-43 in an attempt to better understand 
how TDP-43 normally functions in the cell. RNA immunoprecipitation (RIP) and 
UV-crosslinked RNA immunoprecipitation (CLIP) followed by quantitative real 
time PCR (qPCR) or massively parallel sequencing (seq) have been the most 
informative methods used to identify TDP-43 RNA targets.  
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Initial gene expression observations have lead to several gene-focused 
investigations about TDP-43:mRNA binding. For example, depletion of TDP-43 
was found to decrease histone deacetylase 6 (HDAC6) and low molecular weight 
neurofilament (NFL) expression (Fiesel 2009, Volkening 2009). RIP experiments 
targeting endogenous TDP-43 found that HDAC6 and NFL mRNA is associated 
with TDP-43 protein and that TDP-43 binding is enriched at the 3’ UTRs (Kim 
2010, Volkening 2009). 
 
To evaluate the RNA targets of TDP-43 more broadly, several groups have 
published RIP- and CLIP-seq datasets. Don Cleveland’s lab performed CLIP-seq 
on endogenous TDP-43 protein from normal mouse brains and found a 
significant correlation between transcripts that are directly bound by TDP-43 and 
genes that are stabilized by TDP-43 expression (Polymenidou 2011). The TDP-
43 CLIP associations were enriched for genes that are critical for neural 
physiology. The most enriched binding motif for TDP-43 consisted of GU-
repeats, and there was a correlation between the number of GU repeats and the 
strength of TDP-43 binding. In this study, 93% of the TDP-43 binding sites were 
within introns along the length of target pre-mRNAs. Conversely, a similar RIP-
seq library demonstrates a high enrichment for transcripts that encode genes 
related to RNA processing, such as polyA binding protein cytoplasmic 1 
(PABPC1) and splicing factor arginine/serine-rich 1 (SFRS1), and that TDP-43 
preferentially binds these transcripts at their 3’ UTRs (Sephton 2011).  
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Several studies have found that TDP-43 associates with the 3’ UTR of its own 
RNA transcript (Polymenidou 2011, Sephton 2011, Avendano-Vasquez 2012, 
Ayala 2010). Given the toxicity of overexpressing TDP-43, it was suggested that 
TDP-43 might autoregulate its expression post-transcriptionally. Indeed, the C-
terimal domain of the TDP-43 protein was found to bind to the TDP-43 transcript 
3’ UTR and target it for depletion via the exosome-mediated degradation 
pathway (Ayala 2011). Later work has delved deeper into the mechanism of 
TDP-43 autoregulation. Francisco Baralle’s group noted that the overexpression 
of TDP-43 results in the activation of a cryptic polyadenylation signal through a 
process of alternative splice site selection. The inclusion of this alternative PAS 
causes a nuclear retention of the TDP-43 transcript, thereby subjecting it to a 
nuclear mRNA decay mechanism. Furthermore, overexpressed TDP-43 sterically 
inhibits the polyadenylation complex from recognizing the normally favored PAS, 
adding another level to the mechanism of autoregulation (Avendano-Vasquez 
2012). Clearly, TDP-43 is capable of functioning at multiple levels of RNA 
metabolism to regulate gene expression, even at one locus.   
 
Rodent models of TDP-43 function 
To begin to unravel how missense mutations in the gene encoding TDP-43 
protein might contribute to ALS disease pathophysiology, several TDP-43 
transgenic and knockout animal model systems have been developed over the 
past few years. Both gain- and loss-of-function rodent systems have added to our 
understanding of the normal and disease mechanisms of TDP-43 function. 
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The initial rodent models of TDP-43 involved constitutive overexpression of wild 
type human TDP-43 or ALS disease alleles. The first animals created express 
TDP-43 under the control of the mouse prion protein promoter (PrP), which is 
largely active in the brain, spinal cord, and heart (Wegorzewska 2009, Xu 2010, 
and Stallings 2010). Each group also generated mice that express the A315T 
and M33V ALS-linked mutants. The level of expression of TDP-43 in the brain in 
these mice is significantly higher than endogenous levels. All of the mice 
demonstrated motor deficits and early lethality. Interestingly, overexpressing wild 
type TDP-43 leads to identical motor deficits and pathology as overexpression of 
the disease forms. Other groups created similar mouse models using different 
promoter systems: Thy1 promoter (Shan 2010, Wils 2010), Ca2+ /calmodulin-
dependent kinase II promoter (Tsai 2010), and a low expression level bacterial 
artificial chromosome (BAC) transgenic approach (Swarup 2011). A rat model 
using a BAC for TDP-43 overexpression was also created (Zhou 2010). Despite 
variations in wild type or ALS-linked TDP-43 expression that was conferred by 
these different transgenic models, all of the lines resulted in the development of 
motor neuron disease.  
 
An important observation from transgenic TDP-43 rodent models is that the 
localization of TDP-43 protein does not appear to directly correlate with disease 
progression or severity. Mislocalized TDP-43 was initially thought to be required 
for the development of ALS. Immunohistochemical staining of motor neurons 
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from sporadic and familial ALS individuals with anti-TDP-43 antibodies revealed 
a cytoplasmic aggregation of normally nuclear TDP-43 protein (Sasaki 2010). 
However, neural cells in animals that developed ALS-like disease in the 
aforementioned rodent models largely maintained nuclear TDP-43. Therefore, 
the toxic effects of TDP-43 that contribute to motor neuron disease are likely due 
to a nuclear function.  
 
Although TDP-43 remains nuclear in most of the neurons from the various 
transgenic TDP-43 animal models, large TDP-43-free aggregates still formed in 
the cell bodies of motor neurons. Morphological analysis of these cytoplasmic 
inclusions revealed that they contain large numbers of mislocalized mitochondria 
(Shan 2010, Xu 2010). 
 
Several groups also attempted to create viable constitutive Tardbp loss of 
function mouse lines (Wu 2009, Kraemer 2010, Sephton 2011), but in all 
instances the animals died in very early embryogenesis. My own work with the 
Jaenisch lab determined that TDP-43 knock out blastocysts perished around the 
time of implantation, coinciding with a loss of maternal mRNA (unpublished). 
Since TDP-43 seems to be important for development, condition knock out 
models were generated. Philip Wong’s lab at Johns Hopkins University has 
developed several useful inducible TDP-43 knock out lines (Chiang 2010). To 
test the physiological requirements for normal TDP-43 function, the group 
crossed floxed Tardbp mice with a Rosa26-ErCre line in which the Rosa 26 
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promoter is tamoxifen responsive. The animals became increasingly ill and died 
within nine days of tamoxifen induction, showing significant weight loss, 
specifically mesenteric fat loss. Further experimentation determined that TDP-43 
depletion lead to a rapid reduction in the amount of fat stored within adipocytes, 
likely through a TDP-43-directed mechanism of increased fat oxidation.  
 
In order to properly assess the effects of deleting TDP-43 from brain cells, and 
how this perturbation might contribute to ALS, several groups are now creating 
lines to test the effects of knocking out Tardbp in CNS-specific cell types. Again, 
these models will need to be conditional as the animals from constitutive Hb9-
ErCre;TardbpF/F lines are embryonic lethal (Tsao 2012). 
 
An excellent review of the published TDP-43 ALS rodent models to date is 
referenced here: Tsao, et al. 2012. Rodent models of TDP-43: Recent advances. 
Brain Research, 1462; 26-39. 
 
Section II Summary: 
 
Recently, much attention has been turned to TDP-43 given its apparent role in 
multiple debilitating neurodegenerative diseases. TDP-43 mediates a variety of 
cellular processes, but as yet it is unclear which of these functions causes 
neuron death – or if disease is a result of a combination of dysregulated 
functions. My thesis work finds that TDP-43 negatively regulates antiviral gene 
expression and, more specifically, that it does so through 3’UTR-mediated 
mechanism of transcriptional control. We wondered whether the effect of TDP-43 
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on immune regulation contributes to ALS pathophysiology. In the next section, 
the history and key features of ALS will be presented and evidence of innate 
immune dysregulation in ALS will be explored.  
 
Section III: Amyotrophic lateral sclerosis 
 
 
In 1869, the revolutionary French neurologist Jean-Martin Charcot first described 
distinct pathological spinal cord lesions in autopsy material from adult patients 
that had succumbed to a progressive paralytic disease (Goetz 2000). This 
disease, Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease as it is 
commonly known in the United States, is the most common adult onset form of 
motor neuron disease (MND) and has an estimated prevalence of 2 in 100,000 
Americans. ALS is associated with selective degeneration and death of upper 
and lower motor neurons and is characterized by the resulting progressive, 
severe disabling features including broad muscle paralysis and spasticity. 
Despite the devastating nature of this paralysis, ALS individuals typically remain 
cognitively intact throughout disease progression. The time between clinical 
diagnosis of ALS and patient fatality is, on average, three years, with respiratory 
muscle failure being the main cause of death. Motor neuron loss is not the only 
pathologic abnormality in ALS. Advanced disease is also typically accompanied 
by reactive gliosis, intracytoplasmic neurofilament abnormalities, and axonal 
spheroids (Leigh and Swash 1991, Gonatas 1992, Hirano 1984). Unfortunately, 
there is currently no treatment or cure for the ALS despite the causative 
pathology having been identified almost 150 years ago. 
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Approximately 10% of ALS cases are inherited in an autosomal dominant fashion 
(familial ALS; fALS), but the vast majority has no known genetic association 
(sporadic; sALS). There is no discernible difference in pathophysiology or 
disease course between familial and sporadic forms of ALS. As the population 
ages, men and women are seemingly statistically equally affected with the 
disease, though it was initially thought that men were more over represented. 
First symptoms usually present between 50-60 years of age and individuals from 
all races and ethnic backgrounds can be affected. (Reviewed in Cleveland and 
Rothstein 2001). 
 
SOD1 and ALS 
 
Why motor neurons are specifically targeted in ALS remains unknown, but 
progress has been made toward understanding which cell types contribute to 
disease pathology. In 1993, Cu/Zn binding superoxide dismutase 1 (SOD1) was 
identified as the first ALS disease gene (Rosen 1993). Using linkage analysis, 
eleven distinct mutations in SOD1 were found in individuals from thirteen families 
involved in the study. Now, more than 150 ALS-causing mutations have been 
found in the SOD1 gene and largely involve single amino acid substitutions. 
SOD1 mutations account for approximately 20% of FALS cases.  
 
SOD1 is a highly conserved antioxidant enzyme located throughout the cell. 
Structurally, it contains one copper and one zinc binding site, and is critical in 
catalyzing the disproportiation of superoxide to yield hydrogen peroxide and 
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dioxygen. In the absence of a conversion of the superoxide reactive oxygen 
species (or “free radical”) into these less harmful products, superoxide becomes 
highly toxic by aberrantly oxidizing lipids, proteins, and nucleic acids (Valentine 
and Hart 2003). In fact, superoxide is so effective at functioning as a cellular 
damaging agent that the superoxide anion is enriched in the lysosomes of 
phagocytic immune cells to destroy invading pathogens. Furthermore, type I 
interferons induce the production of reactive oxygen species (Seifert 2010), 
which suggests a closer connection between the control of interferon activity and 
the oxidative stress pathway. This connection will be explored further in this 
thesis in Chapter 2.  
 
Although SOD1 is classically thought of as a very different protein from TDP-43 
since it does not have defined RNA binding domains or known to be an inhibitor 
of innate immunity, it does have some functional features that overlap with TDP-
43. For example, SOD1 has been shown to bind the 3’UTR of NFL mRNA 
transcripts and inhibit expression (Volkening 2009), SOD1 ALS mice overexpress 
ISGs in their spinal cords (Wang 2011), and we have found that SOD1 negatively 
regulates type I interferon expression (Chapter 2). 
 
Motor neuron disease is not cell autonomous 
 
One of the greatest developments in understanding ALS pathophysiology using 
transgenic mice was the finding that motor neuron disease is non-cell 
autonomous. Chimeric mouse models demonstrated that, when motor neurons 
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expressing mutant SOD1G93A are surrounded by WT SOD1-expressing cells, 
neurodegeneration is delayed or avoided entirely (Clement 2003). Removal of 
mutant SOD1 from motor neurons delays disease onset but is not sufficient to 
bypass neurodegeneration (Boillee 2006). In an effort to dissect precisely which 
cell types are responsible for conferring motor neuron death, Yamanaka et. al. 
created a transgenic system in which mice carrying an SOD1G37R gene flanked 
by loxP sites were crossed with mice expressing the Cre recombinase in a 
variety of cell types, allowing for the systematic excision of the mutant alleles 
from individual brain cell types. This work determined that mutant SOD1 
expression in motor neurons modulates disease onset, but the mutant allele 
expression in microglia conferred the greatest toxicity post-onset (Yamanaka 
2008). In vitro co-culture experiments using mouse cell lines have found that 
astrocytes are also toxic to wild type motor neurons when they express SOD1 
disease alleles, and this neurotoxicity is more pronounced when both astrocytes 
and motor neurons harbor the SOD1 mutation (Di Giorgio 2007). Elegant follow-
up of this work demonstrated that human embryonic cell line-derived motor 
neurons are similarly subject to in vitro cell death by microglial cells that were 
derived from ALS patient fibroblasts harboring either SOD1 or TDP-43 mutations 
using induced pluripotent stem cell (iPS) technology (Di Giorgio 2008, Bilican 
2012). 
 
Other genes linked to ALS 
 
There is a long gap in time between the identification of SOD1 as an ALS 
disease gene and the discovery of other ALS-linked alleles. However, several 
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new ALS genes have been reported in rapid succession, in particular C9ORF72, 
Fus/TLS, TARDBP (TDP-43), OPTN (optineurin), and ATXN2 (ataxin-2) (See 
Table II). Whereas mutations in SOD1 are associated exclusively with fALS, 
dominant missense mutations in the gene encoding TDP-43 have been identified 
in both sporadic and familial ALS cases (Kabashi 2008, Sreedharan 2008, 
Lagier-Tourenne and Cleveland 2009). 
 
Many of the genes that are mutated in ALS involve RNA processing. For this 
reason, the neurodegeneration field is questioning whether motor neuron death 
is, in part, the result of aberrant RNA metabolism. Furthermore, we noted that 
several of the key ALS disease genes are also involved in innate immune 
regulation. Our lab has found that TDP-43 and Fus are negative regulators of the 
antiviral gene program. Optineurin is a well-characterized negative regulator of 
interferons, and ALS-related optineurin disease alleles are defective in their 
ability to inhibit IRF3 activation, leading to uncontrolled type I interferon activation 
(Sakaguchi 2011). Interestingly, high levels of antiviral gene expression was 
identified in spinal cords from the G93A SOD1 mouse model of ALS (Wang 
2011), and I have found that perturbation of SOD1 expression in HEK293T cells 
leads to a spontaneous increase in type I interferon gene activity (See Chapter 
2). 
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Table 0.2: Known ALS disease genes 
 
 
Links between innate immune alterations and neurodegenerative diseases 
 
Although the brain is an “immune privileged” tissue, the neurons and structural 
cells of the brain maintain innate immune properties that can generate an 
inflammatory environment. For example, glial cells have been shown to confer 
neurodegeneration in mouse models of ALS. Brain microglia are considered the 
“macrophage/dendritic cell of the central nervous system,” are self-renewing, and 
Gene Protein Proportion of 
inherited ALS 
RNA 
processing 
role? 
Innate 
immune 
role? 
Reference 
SOD1 Superoxide 
dismutase-1 
20% Yes Yes Rosen 1993 
C9ORF72 C9ORF72 30-40% Yes No DeJesus-
Hernandez 
2011, 
Renton 
2011 
TLS Fus/TLS 5% Yes Yes Kwiatkowski 
2009, 
Vance 2009 
TARDBP TDP-43  5% Yes Yes Sreedharan 
2008 
OPTN Optineurin 1-2% No Yes Maruyama 
2010 
VCP  Valosin-
containing 
protein 
1-2% No No Johnson 
2010 
TAF15 TAF15 1% Yes No Couthouis 
2012 
UBQLN2  Ubiquilin-2 <1% No  No Deng 2011 
ANG Angiogenin <1% Yes No Greenway 
2006 
ATXN2 
expansions 
Ataxin-2 ? Yes No Elden 2010 
PFN1 Profilin1 ? No No Wu 2012 
RBM45  RBM45 ? Yes No Collins 
2012 
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arise from fetal myeloid precursors (Bjorkqvist 2009). Activated brain microglia 
produce inflammatory cytokines that have been shown to play both 
neuroprotective and neurotoxic roles, which has complicated progress toward 
developing drugs that inhibit immune functions in the CNS (Ransohoff and Perry 
2009). TLRs 1-9 and cytosolic nucleic acid receptors are also expressed at 
varying levels on all cell types of the brain, including neurons, microglia, and 
astrocytes (Okun 2009). Interestingly, there is a connection between the age of 
the brain and the degree of TLR expression: older mouse and human brains 
increase the expression of TLRs, particularly TLR 3 (Letiembre 2007). 
Additionally, the cytokine environment in the brain shifts with age. The CNS of 
younger individuals expresses protective cytokines, such as IL-10, but with age 
there is a regulated increase in the transcription of pro-inflammatory cytokines 
(Godbout 2004, Ye 2001, Lu 2004, Letiembre 2007). It is possible that individuals 
with a genetic defect in a negative regulator of innate immunity (such as TDP-43 
or optineurin) might be particularly susceptible to neuroinflammation when this 
switch in immune gene expression occurs. This might explain why many 
neurodegenerative diseases present late in life.  
 
Some have questioned whether ALS is the result of a viral infection. Transcipt 
levels of the nucleic acid sensors TLR3 and RIG-I are markedly upregulated in 
the brains of ALS individuals (Jackson 2006). In fact, the entire antiviral pathway 
seems to hyperactivated in ALS since levels of active, phosphorylated protein 
kinase R (PKR) are over 3000% higher in the spinal cords of ALS individuals (Hu 
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2003). Several groups have shown levels of retroviral reverse transcriptase to be 
as high in the serum and CSF of ALS patients as in individuals infected with the 
HIV virus (Steele 2005, MacGowan 2007, Verma 2006). However, follow-up 
studies have failed to find a pathogenic link. Additionally, a recent profiling of 
RNA from ALS spinal cords revealed that transcript levels corresponding to 
inherited active human endogenous retroviruses (HERVs) are significantly higher 
in brain tissue from ALS cadavers (Douville 2011).        
 
The contribution of defects in the immune system to neurodegenerative disease 
has become more appreciated in the past few years. Pathologic microglial 
activation has been observed in the brains of individuals with Alzheimer’s 
disease, Parkinson’s disease, Huntington’s disease, and ALS (Lobsiger and 
Cleveland 2007), and overactive innate immune pathways in ALS are 
increasingly reported (Butovsky 2012, Wang 2011, Polymenidou 2011, Swarup 
2011, Papadimitriou 2010). There is a growing effort to understand how 
dysregulated immunity contributes to neurodegeneration since 1) existing drugs 
that target various aspects of the immune system can be tested in clinical trials 
for disease like ALS – which currently has no effective treatment, and 2) immune 
biomarkers can serve as clinical indications of disease severity and progression.  
 
Elevated levels of the pro-inflammatory cytokines TNF and IL-6 have been 
identified in the cerebrospinal fluid of humans and mice with ALS, and in 
circulating blood serum of patients with ALS (Moreau 2005, Weydt 2004, Poloni 
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2000, Hensley 2003). Although drugs targeting TNF pathway, including 
thalidomide, showed promising results in SOD1 mouse models of ALS (Kiaei 
2006), they failed in phase II clinical trials 
(http://www.clinicaltrials.gov/ct/show/NCT00231140). The antiviral arm of the 
innate immune signaling pathway is also dysregulated in ALS, but we are not 
aware of any trials that are specifically targeting antiviral mediators. There was a 
mild improvement in survivorship of an SOD1 mouse model when these animals 
were crossed to IFNAR1/2 knockout mice (Wang 2011). One important piece of 
work was recently published showing that TDP-43 functions as a co-activator of 
the p65 subunit of the transcription factor NF-kB. Many innate immune genes are 
regulated by NF-kB, including type I interferons. The authors found that treating 
ALS mice with the NF-kB inhibitor Withaferon A reduced ALS disease symptoms 
(Swarup 2011). 
 
Section III Summary: 
 
ALS is a devastating disease with no known treatment or cure. However, 150 
years after being described, the disease still holds more questions than answers. 
There are many innate immune features of ALS, although the antiviral pathway 
has not been deeply explored. On the pro-inflammatory side of investigation, high 
levels of the cytokine TNF has been found in the serum of ALS patients and in 
mouse models of ALS. However, there is evidence indicating that antiviral 
responses are more active in ALS patients as well. For example, there is higher 
expression of two key viral sensors, TLR3 and RIG-I, in the brain cells of ALS 
patients. Additionally, a microarray analysis of PBMC from sporadic ALS patients 
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found the expression of several interferon stimulated genes (ISGs) to be higher 
in patient cells.  
 
Section IV: Functional coupling among RNA processing 
machinery 
 
RNA processing factors are highly functionally coupled 
 
 
TDP-43 has been associated with a variety of cellular functions including 
regulating transcription, alternative splicing, and mRNA stability (see Section II of 
this Introduction for details and references). The commonality among these 
functions is RNA processing. Although the three main steps of gene expression – 
transcription, pre-mRNA splicing, and 3’ end processing – are biochemically 
distinct processes, increasing experimental evidence shows that they are 
coordinated and often interdependent. 
 
This section will present a synopsis of links associating all stages of RNA 
processing. In Chapter 1, we will present data showing that TDP-43 binds to 
mRNA transcripts that encode innate immune genes, often at their 3’ UTRs. 
Furthermore, TDP-43 exerts an effect on transcriptional elongation that is 
dependent on the polyadenylation signals that are present in these 3’ UTRs. We 
propose that TDP-43 is a factor that links transcription to 3’ end processing. 
Although this is an unusual mechanism, it is not inconceivable given the level of 
coordination among RNA processing factors.    
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Pre-mRNA splicing factors are concentrated in nuclear speckles, particularly 
perichromatin fibrils (also known as the nuclear location of nascent transcripts), 
throughout the nucleoplasm. This collection of splicing apparatus is so large that 
it can be visualized by electron microscopy without antibody labeling (Monneron 
and Bernhard 1969). Poly(A)-binding protein II, one of the principle binding 
partners of TDP-43, is present in these nuclear speckles, as are RNA 
polymerase II (pol II), SR-proteins, and the cleavage factor CstF. In fact, all 
nuclear mRNA processing events appear to occur at the site of transcription 
(Krause 1994, Wansink 1993, Iborra 1996, Mortillaro 1996, Carmo-Fonseca 
1991, Neugebauer 1997, Schul 1996, Misteli 1997). 
 
RNA processing is coordinated by transcriptional elongation 
 
 
Coordination between transcription and processing begins at initiation. One of 
the most well characterized mechanisms of cis-regulation is promoter structure. 
Cell specificity is in part maintained by the coordinated recruitment of distinct 
combinations of factors to gene promoters. Promoter structure can also dictate 
downstream alternative splicing events. For example, promoter architecture can 
be involved in the recruitment of splicing factors to exonic splicing enhancers 
(Cramer 1999). More recent findings in yeast have shown that a gene’s promoter 
sequences can also regulate mRNA decay of the transcript when it is transported 
to the cytosol (Bregman 2011). This is thought to provide a mechanism for the 
cell to coordinate the rates of mRNA synthesis and decay. RNA binding proteins 
that mediate this process are referred to as “synthedegradases.” 
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Once transcription is activated, factors associated with all levels of RNA 
processing interact. Transcription and pre-mRNA processing machinery are not 
only colocalized, but also physically associate with each other. The carboxy-
terminal domain (CTD) of RNA pol II is highly phosphorylated at YSPTSPS 
repeat sites to engage active transcriptional elongation (Dahmus 1996). The RS 
domains of SR splicing factors bind to this hyperphosphorylated CTD and allow 
for a local accumulation of splicing and polyadenylation machinery co-
transcriptionally. A form of pol II lacking the CTD results in deficient pre-mRNA 
splicing and 3’ end processing (Mortillaro 1996, Yuryev 1996, Vincent 1996, Du 
1997, Kim 1997, Dantonel 1997). The CTD is also involved in directing 5’ 
methylguanosyl (5’mG) cap addition to pre-mRNAs. The two key enzymes that 
mediate the 5’mG cap mRNA modification, RNA guanylyltransferase and 
guanine-7-methyltransferase, physically associate with phosphorylated CTD, and 
without this association 5’ cap formation is severely impaired (McCracken 1997, 
Cho 1997, Yue 1997). CTD regions have been dissected and distinct segments 
of the CTD have been found to regulate the individual pre-mRNA processing 
events - capping, splicing, and polyadenylation (Fong and Bentley 2001). 
 
Transcription has also been shown to remotely control translation initiation in 
yeast. The RNA binding proteins Rbp4p and Rbp7p interact with the processing 
pol II, then travel with the mRNA transcript to the cytosol where they are involved 
in either directing the transcript to be decayed or they augment translation 
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initiation (Harel-Sharvit 2010). However, their initial communication with the 
polymerase is required for these later functions. Therefore, the authors suggest 
that some RNA binding proteins function as “mRNA coordinators” that function at 
all levels of mRNA processing, from promoter to decay or translation, to directly 
regulate gene expression. 
 
Transcriptional elongation is affected by RNA processing 
 
Transcriptional elongation is directly regulated by splicing factor recruitment. The 
elongation factor P-TEFb is recruited to promoters by transcription factors. It, in 
turn, recruits TAT-SF1, another elongation factor, that then recruits SR proteins 
to nascent transcripts (Fong and Zhou 2001). The presence of these splicing 
factors increases the efficiency of transcription elongation, and genes with introns 
are more efficiently transcribed than their intron-less counterparts (Ares 1999).  
 
Interestingly, pre-mRNA processing machinery interdependency is taken to 
another degree as 3’ end processing is found to be dependent on adequate 5’ 
cap formation (Lewis 1995, Flaherty 1997). Conversely, deleting the AAUAAA 
polyadenylation signal from a 3’UTR results in defects in alternative splicing and 
transcriptional termination (Niwa and Berget 1991, Connelly 1988). In general, 
failures in 3’ end formation results in an inability of the pre-mRNA to be released 
from transcription sites and undergo nuclear export (Vinciguerra and Stutz 2004). 
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Biochemistry of polyadenylation 
 
 
The formation of the 3’ end of a RNA transcript is a multi-step process involving a 
massive, 85-protein complex (Shi 2009). All protein-coding pol II-transcribed 
mRNAs contain a 3’ end consisting of ~200 adenosine residues (except for 
replication-dependent histone genes). The presence of the poly(A) tail aids in 
nuclear export, translation, and maintenance of mRNA stability. For example, 
shortening the stretch of poly(A)’s leads to enzymatic degradation of the 
transcript (Guhaniyogi and Brewer 2001). Cis elements in the sequence at the 3’ 
end of the pre-mRNA direct the polyadenylation process. Hexameric 
polyadenylation signal sequences (PAS), in particular the classic sequence 
encoded by AAUAAA, signals the site for the first step of 3’ RNA end processing: 
cleavage. Cleavage occurs between the PAS and a downstream sequence 
element (DSE), which tends to be a GU-rich motif. The cleavage and 
polyadenylation specificity factor (CPSF), in a complex with other related 
proteins, then docks at the PAS. The cleavage stimulatory factor (CstF) interacts 
with the DSE, and then cleavage factors (CF) - I and -II are recruited to the pre-
mRNA substrate. The cleavage factors stimulate cleavage but the poly(A) 
polymerase (PAP) is actually required for productive cleavage of the transcript 
and release of the polymerase to recycle back to the promoter. The CPSF and 
PAP work together to add the poly(A) tail, with the help of PABP II which 
increases PAP processivity. See Figure 3 and Proudfoot et. al., 2002 for details 
on this process. 
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Figure 0.3: Polyadenylation is a multi-step process involving RNA cleavage and poly(A) 
synthesis.  (Adapted from Proudfoot 2002). 
 
Genes often contain more than one PAS and the mechanism of PAS selection 
remains a subject of for more research. Just as alternative splicing increases the 
diversity of gene expression, alternative polyadenylation can change the 
dynamics of expression as well. For example, there is a very nice literature 
demonstrating that rapidly-cycling cells (such as cancer cells) express transcripts 
with shorter 3’UTRs, using more proximal PAS, effectively “hiding” cis regulatory 
sequences in the 3’UTR that would otherwise target the transcripts for depletion 
(Sandberg 2008).  
 
It is clear that there is cross talk between splicing and polyadenylation. For 
example, the IgM gene encodes a “weak” internal PAS in an intron. The usage of 
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this PAS is repressed by the presence of an upstream strong 5’ splice site. 
Therefore, the PAS-containing intron is spliced out to inhibit termination at that 
site and thus force the usage of a downstream PAS (Zhao 1999).   
 
Recommended reviews on this literature are: Bentley 2002; Maniatis and Reed 
2002; Neugebauer 2002; Proudfoot 2002. 
 
Section IV summary: Is TDP-43 an “mRNA coordinator?” 
 
Why are these complex mechanisms relevant to TDP-43? TDP-43 is a known 
splicing factor. In addition to the obvious splicing factor interactions, TDP-43 has 
been shown to bind PABP II and translation initiation factors, to bind mRNAs at 
intron-exon junctions and at 3’ UTRs, to regulate translation rates, and to 
regulate alternative PAS usage (Jernej Ule lab, data presented at a conference in 
October of 2012). Furthermore, we have noted that TDP-43 often associates with 
AU-rich sequences in 3’UTRs, as well as GU-rich downstream elements that are 
involved with polyadenylation. 
 
Just as a promoter can affect alternative splicing and transcription elongation can 
affect efficient 3’ pre-mRNA end processing, we wondered whether sequences in 
the 3’ UTR can effect transcriptional elongation. The work in this thesis finds that 
1) TDP-43 binds to the 3’ UTR of the IFNβ transcript 2) TDP-43 regulates the 
activity of an IFNβ 3’ UTR reporter and that the PAS sequence is required for this 
regulation and 3) the PAS in the IFNβ 3’ UTR is required for TDP-43 to inhibit 
IFNβ promoter activity. We also noted that IFNβ mRNA decay is faster in the 
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absence of TDP-43, suggesting that TDP-43 also regulates the stability of the 
transcript. 
 
There is only one instance of 3’UTR-mediated promoter regulation in mammalian 
cells in the literature. (Le Cam 1995). Two related proteins, serine protease 
inhibitor (spi) 2.1 and 2.3 are inversely expressed during an inflammatory 
response. A major difference in the sequences of these two genes is that the spi 
2.3 3’ UTR contains a 384-bp extension. By generating constructs that localized 
the spi 2.3 3’ UTR extension to positions upstream or downstream of the spi 2.3 
promoter, the authors found that this 3’ UTR sequence repressed spi 2.3 
promoter activity. 
 
I introduced the term “mRNA coordinator” earlier. TDP-43 has been shown to 
function along all stages of gene expression – transcription, splicing, 
polyadenylation, translation, and decay. Perhaps its ability to regulate IFNβ 
transcription is part of a larger function that regulates gene expression. This 
might be even more important in an immune context. In response to a viral 
infection, the cell must quickly respond and engage an antiviral state. However, it 
is equally important for the cell to downregulate this response to prevent long-
term damage. One way that cytokine levels are regulated is through a 
mechanism of mRNA decay using 3’UTR-mediated signals. We found that the 
PAS is required for the regulation of IFNβ by TDP-43. Perhaps productive 3’ pre-
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mRNA end processing is required for TDP-43 to dampen transcriptional 
elongation. 
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CHAPTER 1: The ALS-linked gene TDP-43 regulates IFNβ 
expression through a novel mechanism of 3’UTR-mediated 
promoter cis-regulation 
 
Raquel P. Deering, Schraga Schwartz, Raktima Raychowhurdy, Jacob 
Dockterman, Nancy Kedersha, Alexander Melnikov, Li Wang, Xiaolan Zhang, 
Aviv Regev, Tarjei Mikkelsen, and Nir Hacohen 
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Abstract 
 
The TAR DNA-binding protein (TDP-43) is a heterogeneous nuclear ribonucleprotein 
that is involved in multiple stages of RNA processing. Mutations in the TDP-43 gene 
and mislocalization of TDP-43 protein have been implicated in a growing number of 
neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and 
frontotemporal lobar degeneration (FTLD). Here, we show that TDP-43 negatively 
regulates innate immune gene expression in response to RNA virus sensing. 
Perturbation of TDP-43 protein expression leads to an increase in antiviral gene 
expression in a variety of human and mouse cells. Crosslinked RNA 
immunoprecipitation (CLIP) experiments revealed that TDP-43 binds to type I interferon 
(IFN) and interferon stimulated gene (ISGs) transcripts. Using massively parallel 3’ UTR 
reporter assays coupled with high throughput sequencing (MPRA-seq), we identified 
polyadenylation signal sequences in the 3’ UTRs of innate immune genes to be 
specifically regulated by TDP-43. Surprisingly, IFN and ISG mRNA decay rates are 
faster in TDP-43-perturbed cells. Using a metabolic labeling approach to measure 
nascent transcript generation, we found that perturbation of TDP-43 expression leads to 
an increase in antiviral gene transcription rates. Additionally, RNA polymerase II (pol II) 
chromatin immunoprecipitation (ChIP) confirmed that there is greater pol II occupancy 
on innate immune genes when TDP-43 is depleted. Although TDP-43 perturbation has 
no effect on an isolated IFNβ promoter reporter, we found that TDP-43 inhibits IFNβ 
promoter activity when the IFNβ 3’ UTR sequence is inserted downstream of the IFNβ 
promoter element, suggesting a novel mechanism of 3’UTR-mediated promoter cis-
regulation. 
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Introduction 
 
In 2006, the 43 kD transactive response DNA-binding protein (TDP-43) was 
found to be the most abundant protein in cytosolic inclusions that characterize 
amyotrophic lateral sclerosis (ALS) and fronto-temporal lobar dementia (FTLD) 
(Neumann 2006). Since then, genomic sequencing of the gene that encodes 
TDP-43 (TARDBP) in patients with ALS and FTLD has identified several dozen 
dominant missense mutations that cause neurodegenerative disease (Gitcho 
2008, Sreedharan 2008, Kabashi 2008, Yokoseki 2008, Van Deerlin 2008). TDP-
43 immunoreactive inclusions have also been identified in other 
neurodegenerative diseases, including Alzheimer’s, Huntington’s, and 
Parkinson’s diseases as well as chronic traumatic encephalopathy (Amador-Ortiz 
2007, Nakashima-Yasuda 2007, Schwab 2008, McKee 2010).  
 
Disease-causing mutations are almost exclusively found in the RNA binding 
domains of TDP-43. Therefore, understanding how TDP-43 normally functions 
has become a priority. TDP-43 has already been shown to play a variety of roles 
in regulating gene expression, including transcriptional repression, alternative 
slice site selection, and mRNA stability. Early work found that TDP-43 repressed 
transcription from the HIV-1 long terminal repeat region (TAR). TDP-43 also 
regulates spermatogenesis by binding to 5’-GTGTGT-repeat sequences on the 
antisense strand of the SP-10 promoter and preventing premature expression of 
the gene. Conversely, TDP-43 is a co-activator of the NF-kB subunit, p65, and 
promotes the expression of many immune genes (Swarup 2011).   
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The best-characterized functions for TDP-43, however, are its roles in RNA 
processing. TDP-43 promotes exon skipping in the cyctic fibrosis 
transmembrance conductance (CFTR) gene (Ayala 2006) and was found to 
globally regulate the splicing of neuronal genes that contain very long introns 
(Polymenidou). In addition to binding to the 3’ UTR of its own transcript for 
autoregulation (Avendano-Vasquez 2012), TDP-43 also promotes the 
stabilization of histone deacetylase-6 (HDAC6) and neurofilament (NFL) 
transcripts by binding to their 3’ UTRs (Fiesel 2009, Kim 2010, Volkening 2009).    
 
Our lab found that the expression of type I interferons and other interferon-
stimulated antiviral genes (ISGs) is upregulated in TDP-43-depleted cells. We 
previously identified another ALS disease gene, Fus/TLS, to be a potent negative 
regulator of antiviral responses (Amit 2009). Optineurin is a known negative 
regulator of antiviral gene expression and mutations in the optineurin gene are 
causative of a percentage of familial ALS cases (Maruyama 2010). Furthermore, 
increased ISG expression has been noted in human ALS and an SOD1 ALS 
mouse model (Wang 2011). The misregulation of antiviral genes, therefore, might 
contribute to ALS pathogenesis.  
 
All cells of the body are equipped with intracellular viral sensing machinery and 
can elicit an antiviral response to the nucleic acid components of invading 
viruses. Following viral sensing, a series of signaling events activate key 
 46 
transcription factors and transcriptional co-activators that culminates in the 
transcription of type I interferons, specifically interferon (IFN) β  (Thanos and 
Maniatis 1995). Although levels of IFN β in most virally infected tissues remain 
relatively low, IFN β protein is a potent activator and amplifier of the entire 
downstream antiviral response. Hence, understanding how type I interferon 
production is regulated is critical for understanding the mechanism of 
misregulation in disease processes.    
 
In order to determine how TDP-43 functions as an inhibitor of the antiviral 
pathway, we used crosslinked RNA immunoprecipitation (CLIP) experiments to 
identify transcripts that are bound by TDP-43 during an active antiviral response. 
RNA target analysis determined that TDP-43 binds to the 3’ UTR of the critical 
type I interferon, IFNβ. We also found that TDP-43 binds directly to other antiviral 
gene transcripts. Massively parallel 3’UTR reporter assays revealed that 
polyadenylation signal sequences (PAS) are required for TDP-43-mediated 
regulation of antiviral genes. Rather than regulating mRNA stability, however, 
TDP-43 functions as a repressor of IFNβ transcription. We report a surprising 
mechanism in which the PAS in the IFNβ 3’ UTR is required for TDP-43 to 
appropriately repress IFNβ promoter activity. In the absence of TDP-43, pol II 
accumulates on the transcription start site and along the gene body of IFNβ and 
interferon-stimulated genes (ISGs). It has been previously published that the 
splicing factor SC35 functions as a positive regulator of transcriptional elongation 
(Lin 2008), and that appropriate 3’ end processing is required for alternative 
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splicing and transcriptional termination (Niwa and Berget 1991, Connelly and 
Manley 1988).  
 
We propose an analogous mechanism in which a splicing factor negatively 
regulates transcriptional elongation, but requires 3’ end processing signals to 
regulate promoter activity.  
 
Results 
 
Perturbation of TDP-43 expression induces the antiviral gene program 
Our lab found that Fus, a protein with regions of sequence homology to TDP-43, 
is a strong negative regulator of the antiviral gene program in response to viral 
pathogen sensing (Amit et al. 2009). Given the sequence similarities between 
Fus and TDP-43, we tested whether TDP-43 similarly regulates antiviral gene 
expression. Type I interferons, namely IFNβ and IFNa, are potent antiviral genes 
that function to induce and amplify the entire antiviral gene program. Therefore, 
monitoring the expression of IFNβ is a good proximal measure of the activity of 
an antiviral response. Puromycin-selectable lentiviruses encoding small hairpin 
RNAs (shRNA) that target TDP-43 were used to deplete protein levels in primary 
bone marrow dendritic cells (BMDC) and IFNβ gene expression was assessed by 
quantitative real-time polymerase chain reaction (qPCR) following Sendai virus 
(SeV) infection. Like Fus perturbation, the depletion of TDP-43 led to a marked 
increase in IFNβ gene expression (Figure 1A). Since all cells of the body are 
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equipped with the cellular machinery to sense and respond to viral infection, we 
tested whether the depletion of TDP-43 in a non-immune cell demonstrated a 
similar phenotype. siRNA oligonucleotides targeting TDP-43 were transfected 
into mouse lung fibroblasts (MLF) or a human osteosarcoma cell line (U2OS). 
Indeed, the depletion of TDP-43 resulted in an increase in both IFNβ expression 
as well as the transcript levels for a key interferon-stimulated gene (ISGs), 
CXCL10 (Figure 1B). We tested the effect of depleting TDP-43 from a variety of 
human and mouse cells, including primary human lung fibroblasts and primary 
mouse microglia, and found a consistent interferon and ISG phenotype (S. Figure 
1A-C). Additionally, others have published that the depletion of TDP-43 in vivo 
from mouse brains using anti-sense oligonucleotides results in a spontaneous 
upregulation in the expression of many key ISGs (Polymenidou 2011).   
 
To confirm that greater functional interferon protein is produced when TDP-43 is 
depleted, we used a type I interferon-sensitive bioassay to test the supernatants 
of cells that were infected with either a control shRNA or a hairpin targeting TDP-
43. In this assay, a reporter cell line that stably expresses an interferon 
stimulated response element (ISRE) fused to a luciferase reporter (ISRE-luc) 
detects all type I interferons present in cell supernatants. Following shRNA 
infection and puromycin selection, cells were infected with the negative-sense 
ssRNA PR8 strain of the influenza A virus (influenza A/PR8). Supernatants from 
TDP-43-depleted cells induced higher total ISRE activity than cells that were 
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infected with a control lentiviral vector (Figure 1D), indicating a greater 
accumulation of functional type I interferon proteins.  
 
We next tested whether overexpression of TDP-43 would have the reciprocal 
effect of TDP-43 depletion.  TDP-43 overexpression is rapidly toxic to cells. 
Therefore, we wanted to use an inducible system to control the level and duration 
of TDP-43 expression. We generated a U2OS cell line in which human TDP-43 
containing a GFP tag is tetracycline-inducible. Upon the addition of tetracycline, 
GFP fused to either wild type human TDP-43 (GFP-TDP-43) or an ALS-linked 
TDP-43 mutation (GFP-TDP-43A315T) was expressed. After 24 hours, 
overexpressed TDP-43 protein remained restricted to the nucleus (S. Figure 2A). 
Surprisingly, the overexpression of both wild type and disease-associated TDP-
43 induced higher antiviral gene activity (Figure 1F).  
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Figure 1.1: Perturbation of TDP-43 expression leads to increased type I interferon and 
interferon-stimulated gene expression.  
 
(A) mRNA levels (qPCR: relative to GAPDH abundance) of IFNb in TDP-43-depleted 
BMDCs. Cells were infected with SeV (MOI 1) for 6 hrs. Error bars represent the standard  
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Figure 1.1 (Continued): 
error of the mean (SEM). (*p<0.05, **p<0.01, ***p<0.001). Data represents six biological and 
two technical replicates from one mouse. 
(B-C) mRNA levels (qPCR) of IFNb (left) and CXCL10 (right) in TDP-43-depleted mouse lung 
fibroblasts (MLF)(B) and U2OS cells (C). Cells were infected with SeV (MOI 2) for 16 hrs. 
Data represents three independent experiments. 
(D) Luciferase bioassay testing type I interferon production of TDP-43-depleted cells. Culture 
supernatants of MLF (left) and U2OS cells (right) that were infected with influenza A/PR8 
(A/PR8) virus at various MOI (0, 0.1, 0.5, 1, 2, 5) for 24 hrs were tested on type I interferon-
sensitive HEK293T cells expressing an ISRE-luciferase reporter (ISRE-luc). Error bars 
represent the SEM. Data represents three independent experiments. 
(E) mRNA level (qPCR) of TDP-43 in MLF infected with A/PR8 (squares) or transfected with 
viral RNA (vRNA) isolated from A/PR8 (circles) over a time course (0, 1, 2, 4, 6, 8, 10, 12 
hrs). Data represents two independent experiments in MLF and experiments in multiple cell 
types. 
(F) mRNA levels (qPCR) of IFNb (left) and CXCL10 (right) in U2OS cells when TDP-43 is 
overexpressed. U2OS cells transduced with a gene encoding wild type TDP-43 (WT TDP-43) 
or an ALS-linked TDP-43 disease allele (TDP-43A315T) under the control of a tetracycline 
inducible promoter were treated with tetracycline (0.25 ug/ml) for 24 hrs to induce TDP-43 
overexpression. Cells were infected with SeV (MOI 2) for 16 hrs. Data represents three 
independent experiments. 
(G) Type I interferon production of cells overexpressing TDP-43 ALS disease alleles and 
domain mutants. A schematic of TDP-43 domain mutations (left). HEK239T cells were 
transfected with plasmid DNA encoding WT TDP-43, ALS disease alleles (TDP-43A315T, TDP-
43M337V), or TDP-43 domain mutants. Cells were infected with SeV for 16 hrs and culture 
supernatants were tested on ISRE-luc cells. Error bars represent the SEM. Data represents 
three independent experiments. 
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The dominant negative TDP-43 overexpression phenotypes were puzzling to us. 
TDP-43 has been found to be highly ubiquitinated and phosphorylated in ALS 
and FTLD-U cytosolic aggregates (Neumann 2006), and the Q/N-rich TDP-43 C-
terminal domain causes it to aggregate in vitro and in vivo (Udan and Baloh 
2011). We wondered whether overexpressed TDP-43 was similarly modified and 
aggregating, thus preventing TDP-43 from functioning normally. Proteins from 
lysates of HEK293T that were transfected with wild type TDP-43 or two ALS 
disease alleles were separated on SDS-PAGE gels and TDP-43 protein was 
probed using specific antibodies by Western blot. We found that the TDP-43 
antibody recognized a high molecular weight protein smear indicating that 
overexpressed TDP-43 is highly ubiquitylated (S. Figure 2B). Furthermore, the 
induction of TDP-43 overexpression in the U2OS cell line resulted in a depletion 
of the endogenous TDP-43 protein band migrating at 43 kD, consistent with the 
finding that TDP-43 regulates its own transcript stability by its 3’ untranslated 
region (3’ UTR) (S. Figure 2C) (Polymenidou 2011, Avendano-Vasquez 2012). It 
is possible that the overexpression of TDP-43 not only depletes endogenous 
TDP-43 transcript, but also is rendered non-functional by post-translational 
modifications that target the protein for degradation and by aggregation. This 
might explain why TDP-43 overexpression recapitulates the knock down 
phenotypes.   
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Expression of TDP-43 is induced following viral pathogen sensing 
 
We wondered whether TDP-43 is regulated in response to viral pathogen 
sensing. MLF were either infected with influenza A/PR8 or were transfected with 
total viral RNA that was isolated from influenza A/PR8 (vRNA). The expression of 
TDP-43 increased following sensing of both whole influenza virus and isolated 
viral RNA (Figure 1E). Transfection of immunostimulatory DNA (ISD) also led to 
similar induction of TDP-43 gene expression (S. Figure 3A).  
 
TDP-43 expression in the human U2OS cell line was also tested in response to 
RNA virus sensing. Cytosolic levels of TDP-43 did not change over time but 
nuclear TDP-43 increased approximately 20% in response to influenza A/PR8 
infection (S. Figure 3B) and SeV (data not shown). Although the protein levels do 
not match the transcriptional upregulation of TDP-43, it is likely that virally 
mediated translational repression and TDP-43 autoregulation effect total protein 
levels. Furthermore, we and others find that increased TDP-43 protein levels are 
toxic and are likely tightly regulated. On the other hand, in an inducible TDP-43 
knock out system TDP-43 heterozygous mice maintain the same TDP-43 protein 
levels as homozygotes, suggesting that TDP-43 levels are carefully controlled 
and compensated in heterozygotes (Chiang 2010). 
 
TDP-43 is a largely nuclear protein, although it has been shown to shuttle 
between the cytosol and nucleus, and can relocalize to cytosolic stress granules 
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under conditions of induced stress (Liu-Yesucevitz 2010). However, we did not 
see a redistribution of TDP-43 to TIAR-positive stress granules following a time 
course of viral sensing (S. Figure 3B). Our lab has shown that TDP-43 
undergoes post-translational changes in response to pathogen sensing, 
however. Phosphoproteomic analysis of TDP-43 peptides from primary bone 
marrow dendritic cells (BMDC) stimulated with lipopolysaccharide (LPS) 
demonstrated that serines 292 and 273 of TDP-43 are highly phosphorylated at 
time points between 120-360 minutes following pathogen sensing (Chevrier 
2011). Other sites of TDP-43 phosphorylation have been reported in the context 
of neurodegenerative disease, but these sites appear to be unique to pathogen 
sensing. 
 
TDP-43 functions downstream of IFNβ transcription 
 
In order to determine which domains are required for TDP-43 to inhibit type I 
interferon activity, we generated TDP-43 expression constructs in which we 
systematically deleted sequence regions that encode for key functional domains 
of the human TDP-43 protein fused to an mCherry tag. HEK293T cells were 
transfected with plasmids encoding TDP-43 disease alleles or domain mutants. 
All of the tagged TDP-43 proteins were retained in the nucleus, except for the N-
terminal domain mutant, which lacks a nuclear localization signal (S. Figure 4).  
The supernatants from these cells were tested for type I interferon activity using 
the interferon-sensitive ISRE-luc reporter cell line. Overexpression of WT TDP-43 
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or ALS disease alleles resulted in an increase in type I interferon expression 
following A/PR8 infection (Figure 1F). Deleting either the RNA recognition motif 
(RRM)-1 or RRM2 did not fully reduce the level of interferon activity. However, 
type I interferon production was brought down to normal levels when the C-
terminal arginine-glycine-glycine rich (RGG) domain was absent. Presumably, 
the presence of the C-terminal RGG domain is required for TDP-43 to maintain 
its toxic effects.  
 
In order to determine where TDP-43 is functioning as an inhibitor of antiviral 
signaling, we disrupted various points along the innate immune signaling 
pathway. TDP-43 function is dependent of intact cytosolic viral sensing since 
depleting TDP-43 from MEFs that lack the signaling adaptor MAVS completely 
abolishes the induction of IFNβ (S. Figure 5). Interferon regulatory factor 3 (IRF3) 
is a master transcription factor for type I interferon expression. Normally, no type 
I interferon is produced in response to SeV infection in IRF3-/- cells. However, 
the depletion of TDP-43 from IRF3-/- cells restores type I interferon gene 
induction in an IRF3-independent mechanism (Figure 2A). TDP-43 does not 
appear to involve an increase in cytosolic nucleic acid sensing or signaling since 
IRF3 phosphorylation does not increase in TDP-43-depleted cells (Figure 2F). 
IRF7 is another master regulator of type I interferon induction. We tested the 
effects of TDP-43 depletion in IRF3/IRF7 double knockout cells and found that, 
although the absence of both of these transcription factors significantly reduces 
type I interferon expression, the depletion of TDP-43 induces type I interferon in 
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an IRF3- and IRF7- independent fashion (Figure 2B). Depletion of TDP-43 in 
IFNR-/- cells completely abolishes ISG expression, indicating that type I 
interferon expression is required for TDP-43 to regulate the expression of ISGs 
(Figure 2C). 
 
It was recently observed that TDP-43 functions as an activator of the p65 subunit 
of NF-kB (Swarup 2011). Since the IFNβ promoter contains an NF-kB-dependent 
element, we wondered if TDP-43 was directly acting on the IFNβ promoter. To 
explore this, we tested the effect of TDP-43 perturbation on a series of 
transfected IFNβ promoter elements (PRD II, NF-kB-dependent; PRD III/I, IRF3/7 
dependent; and the entire minimal enhancer element) driving a luciferase 
reporter. Neither the depletion of TDP-43 nor the overexpression of WT TDP-43 
or TDP-43 disease alleles resulted in an increase in the NF-kb- dependent or 
independent IFNβ promoter elements in our system (Figure 2D,G). However, 
TDP-43 depletion does increase the activity of a promoter reporter containing an 
ISRE (Figure 2E). Additionally, depletion of TDP-43 results in both a baseline 
and viral sensing-induced increase in STAT1 phosphorylation (Figure 2F). This is 
consistent with our observation that perturbation of TDP-43 expression increases 
type I interferon production. To confirm that TDP-43 is not directly associated 
with any relevant promoter DNA elements, we performed genome-wide TDP-43 
chromatin immunoprecipitation of both endogenous TDP-43 and overexpressed 
TDP-43 protein fused to a 3x flag tag followed by high throughput sequencing 
(ChIP-seq), but found no significant DNA enrichment compared to positive 
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controls (data not shown). From these experiments, we concluded that TDP-43 is 
not binding to the IFNβ promoter directly. The increase in IFNβ transcript levels 
lead us to interrogate whether TDP-43 was regulating RNA transcripts directly.  
 
 
Figure 1.2: TDP-43 acts as an inhibitor of type I interferon expression downstream of 
cytosolic antiviral signaling. 
  
(A) mRNA levels (qPCR) of IFNb in IRF3-/- mouse embryonic fibroblasts (MEF). TDP-43 was 
depleted from wild type (WT) MEFs and IRF3-/- MEFs with shRNA and cells were infected 
with SeV (MOI 2) for 16 hrs. Data represents six biological and two technical replicates from 
one mouse. Error bars represent the SEM. *p<0.05, **p<0.01. 
(B) mRNA levels (qPCR) of IFNb in IRF3/7-/- BMDCs. Methods and statistics same as in (A) 
but cells were infected with SeV (MOI 1) for 6 hrs. 
(C) mRNA levels (qPCR) of CXCL10 in IFNR-/- BMDCs. Methods and statistics same as in 
(B). 
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Figure 1.2 (Continued): 
(D) Luminescent IFNb promoter enhancer activity in TDP-43-depleted cells. HEK293T cells 
were transfected with siRNA targeting a control sequence or TDP-43 and then cells were 
transfected with expression plasmids encoding either the complete minimal IFNb enhancer 
(left), the PRD II enhancer domain (middle), or the PRD III/I enhancer domain (right), all 
driving a firefly luciferase reporter. Cells were infected with SeV (MOI 5) for 18 hrs to induce 
antiviral gene expression. All luminescence values are normalized to an internal firefly renilla 
control. Data is representative of five experiments. 
(E) Luminescent ISRE promoter activity in TDP-43-depleted cells. HEK293T cells were 
transfected with siRNA targeting a control sequence or TDP-43 and 48 hrs later transfected 
with a plasmid encoding an ISRE-containing promoter driving a luciferase. Cells were 
infected with SeV (MOI 5) for 18 hrs to induce antiviral gene expression. Data is 
representative of six experiments. 
(F) Western blot for pIRF3 and pSTAT1 in TDP-43-depleted cells. HEK293T cells were 
transfected with siRNA targeting a control sequence, Fus, or TDP-43. Seventy-two hours 
later, cells were infected with SeV (MOI 5) for 6 hrs. Lysates were processed, run on SDS-
PAGE gels, and probed with antibodies specific for pIRF3 (top), pSTAT1 (middle), or actinβ 
(bottom). Data is representative of three experiments. 
(G) Luminescent IFNb promoter enhancer activity in TDP-43 overexpressing cells. Methods 
same as in (D) but HEK293T cells were transfected with expression plasmids encoding an 
empty vector control (pmCherry), WT TDP-43, TDP-43A315T, or TDP-43M337V. Data is 
representative of four experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
TDP-43 associates with the 3’ UTRs of type I interferon and ISG transcripts 
 
Several reports have shown that TDP-43 directly binds to mRNA (Polymenidou 
2011, Sephton 2011, Ayala 2011). There is some evidence demonstrating that 
TDP-43 preferentially binds to GU-rich RNA sequences (Buratti 2001, Ayala 
2005), but the presence of this putative consensus sequence is not required for 
TDP-43 to interact with the many of its RNA binding partners (Polymenidou 2011, 
Sephton 2011). We wondered if TDP-43 regulates type I interferon and ISG 
expression by directly binding to these genes’ mRNA transcripts. To find in vivo 
RNA targets of TDP-43 in our system, we performed ultraviolet (UV) irradiation 
crosslinked RNA immunoprecipitation followed by high throughput sequencing 
(CLIP-seq) on both endogenous and overexpressed human TDP-43 protein. 
Technical limitations associated with the UV crosslinking efficiency of the CLIP 
protocol and the activity of the commercially available TDP-43 antibody required 
us to overexpress TDP-43 in order to enrich for associations with low-expression 
antiviral genes. To bypass the toxicity of overexpressing TDP-43, we induced its 
expression in U2OS cell lines expressing GFP-tagged wild type TDP-43 or a 
GFP-tagged TDP-43A315T disease variant in a tetracycline-responsive system. 
Viral RNA was transfected into cells to induce the RNA sensing pathway and 
resulting RNA-protein interactions were immobilized by crosslinking the cells with 
UV radiation (265 nm). We then performed immunoprecipitations using 
antibodies that targeted either endogenous TDP-43 or TDP-43-GFP under 
conditions of high RNase A digestion to isolate RNA fragments that are 
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specifically bound to the TDP-43 protein. The sizes of RNA isolated from each 
TDP-43 CLIP ranged from 40-150 bases in length. RNA sequencing libraries 
were generated for both the isolated CLIP RNA as well as the total input RNA 
and single-end Illumina sequencing was performed.  
 
We determined differential enrichment by comparing TDP-43 CLIP library 
enrichment to total input RNA abundance and subtracting any background signal 
from the GFP control CLIP. By selecting a threshold of 4-fold enrichment or 
greater, we identified many coding and non-coding genes to be enriched for 
TDP-43 binding (Table 1), with significant overlap in binding sites between the 
wild type TDP-43 CLIP and TDP-43A315T disease allele CLIP. The majority of 
TDP-43 interactions occurred in the 3’ UTR of target transcripts (A complete list 
of CLIP targets is provided in S. Table 1 online). Strikingly, the most enriched 
binding motif for the overexpressed forms of TDP-43 was not the canonical GU-
rich binding motif but rather a more AT-rich motif (Figure 3B). The endogenous 
TDP-43 CLIP hexameric binding motif, however, was the preferred GTGTGT 
sequence. We noticed that overexpressed forms of TDP-43 associated with 3’ 
UTRs more frequently (61.8-62.4%) than the endogenous form (26.4%). We 
wonder if this shift in motif enrichment is due to a higher occupancy of 
overexpressed TDP-43 on 3’ UTRs, which are AU-rich in nature. Given the 
overlap in binding associations between WT and ALS-linked TDP-43, the 
functional differences conferred by mutations in the TDP-43 protein are likely 
independent of binding site recognition and 3’ UTR occupancy. 
 61 
Table 1.1: CLIP binding enrichment 
 
 
We found enrichment for GFP-TDP-43 binding in the 3’UTRs of several antiviral 
genes including IFIT1 and CXCL10 (Figure 3A). The reads associated with the 
endogenous TDP-43 CLIP for these genes were many fold fewer, however, so 
we were not able to determine enrichment. We also confirmed that TDP-43 binds 
its own 3’UTR in our system as well as to the transcript of the related ALS-linked 
protein, Fus/TLS. IFNβ was too lowly expressed in these cells to achieve 
adequate CLIP-seq enrichment to meet our cut-off for statistical significance. 
Although all cells are equipped with the machinery to respond to virus, type I 
interferon expression is carefully regulated during the course of an antiviral 
response to prevent toxicity.  
 
We found that qPCR was a more sensitive assay for assessing relative CLIP 
enrichments for low-expression genes. To validate that the GFP-TDP-43 CLIP-
seq findings were relevant for endogenous TDP-43, we performed CLIP 
experiments under slightly lower RNase A conditions and used qPCR as a read-
out. Based on binding site enrichment from the GFP-WTTDP-43 CLIP-seq, 
primers were designed against the 3’ UTRs of several genes of interest. We also 
tested primers that targeted internal regions of the genes. We confirmed that 
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endogenous TDP-43 specifically associates with IFNβ and ISG 3’ UTRs 
compared to the RNA binding proteins Ezh2 and Fus (Figure 3C). Furthermore, 
TDP-43 was more enriched in 3’ UTR associations than for internal regions of the 
transcripts, indicating that even under lower RNase A conditions the CLIP 
protocol was robust. 
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Figure 1.3: TDP-43 binds to type I interferon and ISG transcripts in vivo. 
 
(A) Intergrative Genomics Viewer screen shot of TDP-43 UV-crosslinked immunoprecipitation 
(CLIP) binding peaks on CXCL10 and IFIT1 transcripts. U2OS cells expressing GFP, GFP-
WTTDP-43, or GFP-TDP-43A315T under tetracycline control were transfected with influenza 
A/PR8 viral RNA (A/PR8/vRNA) for 18 hrs to induce antiviral gene expression. The cells were 
UV crosslinked (265 nm) and either total RNA was isolated for RNA sequencing (purple) or  
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Figure 1.3 (Continued): 
CLIP-seq was performed. Sequencing reads corresponding to GFP (gray), GFP-WTTDP-43 
(green), GFP-TDP-43A315T (aqua) or endogenous TDP-43 (blue) CLIP enrichments are shown 
by orange boxes. Massively parallel reporter assay significant tiles are shown by black boxes.  
(B) Enriched sequence motifs corresponding to WT TDP-43, TDP-43A315T, and endogenous 
TDP-43 CLIP associations. 
(C) qPCR for TDP-43 CLIP enrichment. U2OS cells were transfected with A/PR8/vRNA for 
18 hrs and CLIP with antibodies targeting Ezh2, Fus, and TDP-43 was performed under low 
RNase A conditions. qPCR was performed using primers targeting 3’ UTR and internal 
sequences of IFNα, IFNβ, CXCL10, and IFIT1. CLIP enrichments are normalized to an IgG 
CLIP background control and significance is relative to Ezh2 and Fus CLIP binding. Data is 
representative of three experiments. *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
 
As further validation that TDP-43 specifically associates with some of the 3’ 
UTRs of transcripts that it regulates, we performed crosslinked RNA pull down 
assays (XL-RPD) for in vitro transcribed RNA sequences. The 3’ UTRs of 
GAPDH, beta actin, and several genes encoding innate immune cytokines were 
in vitro transcribed and biotin was added to their 3’ ends. The biotin-labeled 3’ 
UTR baits were then individually incubated with lysates from U2OS cells that 
were stimulated with transfected vRNA, and RNA-protein interactions were 
stabilized by UV irradiation. To reduce nonspecific RNA interactions, the lysates 
were treated with high-concentration RNase A. The biotin-labeled RNA baits 
bound to interacting proteins were then isolated with streptavidin-coated 
magnetic beads and TDP-43 protein was probed with a specific antibody. TDP-
43 was not recovered by a nonsense probe or a GAPDH 3’UTR probe, but was 
associated with all of the other immune cytokine 3’ UTRs testeds, indicating that 
TDP-43 has broad RNA binding activity in an in vitro assay but maintains some 
specificity (S. Figure 6A). 
 
TDP-43 affects 3’UTR transcripts at alternative polyadenylation signals 
 
The 3’UTRs of type I interferons and ISGs do not contain the known GU-rich 
TDP-43 consensus binding sequence and our CLIP experiments indicated that 
AU-rich sequences were enriched in TDP-43 binding. In order to examine which 
3’ UTR RNA sequences are susceptible to TDP-43 regulation, we used a 
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massively parallel reporter assay (MPRA) system (Melnikov 2012) to sequence 
the relative abundance of barcoded 3’ UTR elements from fifty genes, including 
interferons, ISGs, and several other genes shown to be regulated by TDP-43 
perturbation (S. Table 2). We first used custom arrays to synthesize 
approximately fifty thousand oligonucleotides that contained a library of 3’ UTR 
regulatory elements coupled to unique ten base pair DNA tags for individual 
identification. The oligonucleotide pool was then cloned into a vector that 
contained an invariant CMV promoter, an arbitrary luciferase open reading frame 
(ORF), an SV40 polyadenylation signal, and an identifying sequence tag. This 
entire plasmid pool was transfected into HEK293T cells and total RNA was 
isolated thirty-six hours later. To determine the relative activities of each 3’ UTR 
element, we sequenced and counted the tags on the recovered mRNAs and the 
original plasmid pool, and then generated ratios of these two counts (Figure 4A).  
 
We calculated the distribution of medians from the control samples and the TDP-
43-depleted samples to generate a relative abundance for a given 3’ UTR 
element. By focusing on barcoded elements that were increased at least 1.5 fold 
in the TDP-43-depleted samples compared to controls, we identified RNA 
elements corresponding to twenty-seven genes that were significantly stabilized 
in the TDP-43-depleted cells (Figure 4B, S. Table 2). Interestingly, all of the 3’ 
UTR elements that were stabilized in the absence of TDP-43 were enriched for 
AU-rich elements (ARE) and often contained polyadenylation signals (PAS), 
particularly the canonical PAS (AAUAAA). For example, the 3’ UTR of TDP-43 
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has four known PAS and all of the reporter elements that were enriched in the 
TDP-43-depleted sample contained one of each of these PAS (Figure 4D). 
Likewise, the only PAS present in the shorter CXCL10, IFNa, and IFNβ 3’ UTRs 
were stabilized in the absence of TDP-43 (Figure 4C and S. Figure 7B). 
Destabilization was specific, however, since not all 3’ UTR elements containing 
PAS were affected. The PAS-containing sequence in the actinb 3’ UTR was not 
differentially affected by TDP-43 (Figure 4C). TDP-43 is known to regulate the 
stability of cyclin-dependent kinase-6 expression (Cdk6)(Ayala 2008), 
presumably through a mechanism of mRNA destabilization. Tiles corresponding 
to regions of the Cdk6 3’ UTR were the most significantly destabilized sequence 
elements when TDP-43 was depleted in the MPRA. Although the preferred 
binding site for TDP-43 is thought to be GU-repeats, AREs were enriched in the 
Cdk6 tiles that were stabilized by TDP-43.  
 
Many of the genes that were dissected in the MPRA experiments were not 
expressed in the U2OS cells that were used for the CLIP-seq analysis. However, 
among these genes, there was an overlap between TDP-43-CLIP occupancy on 
their 3’UTRs and the RNA sequence that was stabilized by TDP-43 in the MPRA 
experiments. Ten out of the twenty-seven 3’ UTRs that showed significant signal 
in the MPRA were also expressed in U2OS cells and were significantly enriched 
in TDP-43-CLIP binding. Six of the 3’ UTRs corresponding to the ten expressed 
genes showed a direct overlap between the CLIP binding site and the sequence 
tile that is destabilized in the absence of TDP-43 (S. Table 2).     
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Figure 1.4: TDP-43 affects RNA sequences containing polyadenylation signals. 
(A) Schematic of massively parallel reporter assay (MPRA) system. HEK293T cells were 
transfected with siRNA targeting a control sequence or TDP-43. 24 hrs later, cells were 
transfected with a plasmid pool encoding 55,000 DNA-tagged 200mer sequence tiles 
corresponding to 3’ UTR sequences of 49 genes of interest.  
(B) The log ratio of MPRA mRNA sequence tags that were differentially enriched (red) versus 
depleted (green) in the absence of TDP-43. The mRNA/plasmid tag ratios were normalized 
by multiplying by the ratio of the total number of plasmid and mRNA tag counts from the 
corresponding sequencing libraries. To estimate the relative abundance of each distinct UTR 
tile, the median of 32 mRNA/plasmid tag ratios were compared.  
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Figure 1.4 (Continued): 
(C) mRNA sequence enrichment for MPRA tiles corresponding to actinβ and CXCL10 3’ UTR 
sequences in TDP-43-depleted cells. Control cells (blue dots), TDP-43-depleted cells (red 
dots). 
(D) mRNA sequence enrichment for MPRA tiles corresponding to TDP-43 3’ UTR sequences. 
A schematic of the TDP-43 gene structure showing the arrangement of exons (gray boxes), 
the 3’ UTR (white box), and polyadenylation signals (black lines).  
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Alternative PAS usage has been observed to be a major mechanism of gene 
expression regulation, particularly in rapidly proliferating cells (Mayr 2009, 
Sandberg 2008). In order to evaluate whether TDP-43 is directly mediating 
alternative PAS usage or if it is regulating the cell cycle, which in turn regulates 
PAS selection, we repeated the reporter assay with cells that were cycling at 
different rates. We found that there was no significant stabilization of 3’UTR 
elements in the MPRA for lowly proliferating versus highly proliferating cells (S. 
Figure 7A). Therefore, we can attribute the stabilization of RNA elements 
containing PAS in TDP-43-depleted cells to some function of the TDP-43 gene.  
 
We wondered if TDP-43 functions to affect alternative PAS usage. To test this, 
we generated 3’-tag digital gene expression (DGE) RNA sequencing libraries and 
looked at the global effects of TDP-43 perturbation on PAS usage. Depleting 
TDP-43 had no apparent effect on the 3’ lengths of mRNA transcripts (data not 
shown). TDP-43 apparently uses the sequence encoded in the 3’ UTRs of genes 
it regulates to perform a function independent of 3’ end processing. 
  
TDP-43 destabilizes mRNA transcripts at their 3’ UTRs 
 
Although TDP-43 is a known splicing factor, it was unlikely that TDP-43 regulates 
IFNβ expression through a splicing mechanism since IFNβ is a single-exon gene. 
Additionally, the CLIP-seq and MPRA data pointed toward the 3’ UTR as the site 
 71 
of TDP-43 innate immune gene regulation. There are several examples of 
microRNA-independent innate immune cytokine regulation by 3’ UTR 
destabilization (Brown 1996, Deleault 2008). To test if TDP-43 is regulating type I 
interferon and ISG transcript stability by 3’ UTR destabilization, we cloned the 3’ 
UTRs of several relevant genes into a vector driving a destabilized luciferase 
reporter. These 3’UTR reporter plasmids were individually transfected into 
HEK293T cells and their relative activity was measured. The depletion of TDP-43 
had no effect on the stability of a control GAPDH 3’ UTR. Therefore, in addition 
to renilla transfection normalization, the relative expression of all other 3’ UTR 
reporter plasmids were normalized to GAPDH 3’ UTR reporter activity. Cells 
depleted of TDP-43 or overexpressing WT TDP-43 or TDP-43 ALS disease 
alleles demonstrated two- to three-fold greater IFNβ and ISG reporter 
stabilization (Figure 5A).  
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Figure 1.5: Perturbation of TDP-43 affects IFN and ISG transcript stability. 
 
(A) Luminescent 3’ UTR reporter assays in TDP-43-depleted and TDP-43-overexpressing 
cells. HEK293T cells were transfected with siRNA targeting a control sequence or TDP-43 
(left), or were transfected with expression plasmids encoding an empty vector (pmCherry), 
WT TDP-43, TDP-43A315T, or TDP-43M337V. 24 hrs later, cells were transfected with firefly 
luciferase expression plasmids encoding 3’ UTR sequences for innate immune genes. Cells 
were infected with SeV for 18 hrs. Values are normalized to an internal firefly renilla control 
and relative to GAPDH 3’ UTR reporter plasmid activity. Data are representative of three 
experiments. *p<0.05, *p<0.01. 
(B) Relative IFNβ and CXCL10 mRNA levels in TDP-43-depleted cells. Stable HEK293T 
were co-transfected with plasmids encoding 3’UTR sequences driving a luciferase reporter 
under tetracycline control and with siRNA targeting a control sequence or TDP-43. 
Doxycycline (1 ug/ml) was added to culture media over a time course (0, 2, 4, 6, 8, 10 hrs) to 
stop transcription from the reporter plasmids and relative luminescence was measured. 
Relative mRNA levels are given as a percent of total RNA for each condition. Data are 
representative of three experiments. 
(C) Northern blot for CXCL10 3’UTR RNA decay. Same methods as in (B) but total RNA was 
isolated from cells and biotinylated RNA probes targeting the CXCL10 3’UTR transcript were 
used to quantify RNA levels by RNA hybridization. CXCL10 3’ UTR signal normalized to total 
GAPDH 3’UTR transcript levels (bar graph, right). 
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The 3’ UTR reporter assay data coupled with the CLIP-seq binding associations 
suggested that TDP-43 binds to the 3’ UTRs of IFN and ISGs and targets these 
transcripts for decay. To test this hypothesis, we wanted to decouple 
transcription from mRNA decay and measure the effects of TDP-43 on type I 
interferon and ISG RNA decay rates. We cloned the 3’ UTRs of several antiviral 
genes into a vector encoding a destabilized luciferase reporter driven by a 
tetracycline responsive promoter. The addition of doxycycline turned off 
transcription and allowed us to measure relative RNA decay rates across 
conditions. To our surprise, the rates of mRNA decay for IFNβ and ISG 3’ UTRs 
were faster in the absence of TDP-43, which argues against a model of 3’UTR-
mediated transcript destabilization (Figure 5B). To rule out any effects that TDP-
43 might have on the translation rate of the luciferase reporter protein, we 
repeated the experiment but measured mRNA stability by RNA hybridization 
using biotinylated RNA probes. By measuring RNA directly, we still observed a 
faster rate of CXCL10 mRNA decay in TDP-43-depleted cells (Figure 5C). These 
data indicated that TDP-43 normally stabilizes mRNA transcripts, a finding that 
conflicts with the increase in type I interferon and ISG transcript levels that is 
observed when TDP-43 expression is perturbed. 
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TDP-43 affects the transcription rates of type I interferons and ISGs 
 
There have been reports of RNA binding proteins that regulate gene expression 
both transcriptionally and by decay mechanisms (Harel-Sharvit 2010). Such 
proteins, or “synthedegradases,” are thought to couple together RNA metabolism 
processes to more efficiently control the kinetics of a transcriptional response. 
Although we did not see direct enrichment for TDP-43 at promoters by genome-
wide ChIP-sequencing experiments, the rapid IFNβ and ISG mRNA decay rates 
in TDP-43-depleted cells suggests that TDP-43 might be exerting some 
unexpected transcriptional effects on antiviral genes. To test this in a nuclear run-
on assay (NRO), 4-thiouridine (4SU) was pulsed into virally-infected U2OS cells 
and incorporated into nascent mRNA transcripts. The 4SU cysteine sulfhydryl 
groups were then labeled with biotin and the nascent transcripts were isolated 
out of total cellular RNA using streptavidin-coated magnetic beads (Figure 6A). 
The abundance of biotinylated transcripts was compared by qPCR to generate 
ratios of nascent transcript enrichment in normal versus TDP-43-depleted cells. 
Surprisingly, we observed a 5-10 fold increase in IFNβ and CXCL10 transcription 
in the absence of TDP-43 (Figure 6B).  
 
The NRO experiments demonstrated greater IFNβ and ISG transcription rates in 
TDP-43-depleted cells. To validate that there is a true increase in transcription for 
these genes specifically, we performed genome-wide polymerase (pol) II ChIP-
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seq using an antibody that recognizes active, serine 2- and serine 5-
hyperphosphorylated pol II and analyzed pol II occupancy on antiviral genes in 
normal versus TDP-43-depleted U2OS cells. We first performed a genome-wide 
comparison of the median ratios of pol II enrichment at transcription start sites 
(TSS) and across gene bodies for TDP-43-depleted cells versus normal cells. 
Then, we compared the ratios of pol II enrichment for a set of antiviral genes (S. 
Table 3) versus all other genes in normal versus TDP-43-depleted cells. 
Phosphorylation of pol II serine 5 is typically associated with transcription 
initiation at promoter regions and pol II serine 2 phosphorylation is enriched for 
gene bodies (Komarnitsky 2000). There was a marginal trend toward increased 
Pol II serine 5 on the TSS of antiviral genes (p < 0.06), but no change over the 
remaining transcription units (TU; p < 0.3). However, we found approximately 
30% higher pol II serine 2 occupancy on both the TSS and gene bodies of our 
antiviral gene set when TDP-43 is depleted (Figure 6C). This confirms that the 
increase in nascent transcript abundance observed in the NRO experiments is 
associated with greater pol II recruitment and transcriptional elongation.        
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Figure 1.6: Depletion of TDP-43 results in greater IFNβ  and ISG transcription. 
 
(A) Schematic of 4-thiouridine (4SU) nascent transcript labeling protocol.    (B) qPCR of IFNβ 
and CXCL10 nascent transcript levels in TDP-43-depleted cells. U2OS cells were transfected 
with siRNA targeting a control sequence or TDP-43, then infected with SeV (MOI 2) for 16 
hrs. Cells were pulsed with 4SU (0.5 mM) for 5 minutes to label nascent transcripts and 
immediately lysed. Total RNA was isolated and sites of 4SU incorporation were labeled with 
biotin. Biotinylated nascent transcripts were isolated using streptavidin magnetic beads. Error 
bars represent the standard error of the mean (SEM). *p<0.001. 
(C) Box plots for phosphorylated polymerase II (pol II) chromatin immunoprecipitation (ChIP) 
enrichment for antiviral genes in TDP-43-depleted cells. U2OS cells were transfected with 
siRNA and infected with SeV as in (B). ChIP was performed using a antibodies that recognize 
hyperphosphorylated pol II at serine 2 (left) and serine 5 (right). Genome-wide comparison of 
the median ratios of pol II enrichment at transcription start sites (TSS) and across gene 
bodies for TDP-43-depleted cells versus normal cells was performed and the ratios of pol II 
enrichment for a set of antiviral genes versus all other genes in normal versus TDP-43-
depleted cells was assessed. 
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TDP-43 regulates IFNβ promoter activity through the IFNβ 3’ UTR 
polyadenylation signal 
 
Our CLIP-seq data analysis demonstrated that TDP-43 associates with the 3’ 
UTRs of antiviral genes. Surprisingly, we also observed that TDP-43 affects both 
transcription and decay rates of regulated genes. We performed multiple ChIP-
seq experiments in an attempt enrich for DNA sequences that bind to 
endogenous or overexpressed TDP-43 protein, but were not able to uncover any 
specific interactions between TDP-43 and DNA. However, the MPRA results 
suggest that TDP-43 functions on polyadenylation signals in mRNA transcripts. 
 
TDP-43 perturbation had no significant effect on the activity of a luciferase IFNβ 
promoter reporter with a downstream SV40 3’ UTR (Figure 2). We wondered if 
the effect of TDP-43 on transcription is dependent on the presence of the specific 
3’ UTR of the gene that it is regulating. To test this, we modified the original IFNβ 
promoter reporter by inserting the human IFNβ 3’ UTR sequence between the 
luciferase ORF and the SV40 3’ UTR (Figure 7a). We then compared the relative 
activities of these reporter constructs in HEK293T cells that expressed 
endogenous levels of TDP-43 or overexpressed forms of TDP-43. Although 
overexpressing TDP-43 had no effect on the original IFNβ promoter reporter 
construct, overexpression stabilized the IFNβ promoter-driven luciferase activity 
when the IFNβ 3’ UTR sequence was inserted downstream of the luciferase ORF 
(Figure 7A). Deleting the polyadenylation signal from the IFNβ 3’ UTR sequence, 
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however, rescued the derepression of the IFNβ promoter activity by TDP-43. 
TDP-43 does not appear to act directly on DNA since TDP-43 had no effect on 
the reporter when the IFNβ 3’ UTR was placed upstream of the promoter 
sequence. Similarly, the depletion of TDP-43 led to a PAS-dependent regulation 
of the IFNβ promoter activity (Figure 7B).  
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Figure 1.7: TDP-43 requires a polyadenylation signal in the IFNβ  3’ UTR to inhibit IFNβ  
promoter activity. 
 
(A) Luminescent reporter assays in TDP-43-overexpressing cells for various IFNβ enhancer 
reporter constructs. HEK293T cells were co-transfected with plasmids encoding an empty 
vector, WT TDP-43, TDP-43A315T, or TDP-43M337V and the indicated IFNb enhancer driving a 
luciferase reporter: the minimal IFNb enhancer with a standard SV40 3’ UTR (left, black 
bars), the minimal enhancer with the IFNb 3’UTR (middle) with the PAS (green bars) or 
without the PAS (yellow bars), or the minimal IFNb enhancer with the IFNb 3’UTR upstream 
of the promoter region (right) with the PAS (red) or without the PAS (blue). 
(B) The same constructs as in (A) but with HEK293T cells that were transfected with siRNA 
targeting a control sequence or TDP-43. 
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Discussion 
 
 
Understanding defects in both RNA processing factors and misregulated innate 
immune pathways are becoming key areas of focus in neurodegeneration 
research. The work presented here links TDP-43 to the regulation of the antiviral 
gene pathway. TDP-43 is a multifunctional RNA binding protein that has already 
been assigned a variety of roles across all stages of gene expression, but we find 
that it can modulate IFNβ expression by a novel mechanism of cis promoter 
control directed by IFNβ 3’ UTR sequences. More specifically, the PAS in the 
IFNβ 3’ UTR is sufficient to mediate the regulation of the IFNβ promoter by TDP-
43.  
 
IFN β is a short, single-exon gene that is not spliced and in theory would not 
recruit splicing factors. Nonetheless, we were not surprised to find enrichment for 
the 3’ UTR of IFN β  with TDP-43 protein since levels of IFN β can be destabilized 
by an ARE located in its 3’ UTR (Paste 2003) and TDP-43 regulates the 
transcript levels of other genes through 3’ UTR associations (Fiesel 2009, 
Volkening 2009, Kim 2010). However, we were very surprised to find that the rate 
of IFN β and CXCL10 degradation was actually faster in the absence of TDP-43 
(Figure 5c). This finding contradicted our initial hypothesis that TDP-43 normally 
destabilizes IFN β  transcripts and pointed to transcriptional regulation. Nuclear 
run on assays confirmed that more nascent IFN β transcripts are produced in the 
absence of TDP-43, and pol II ChIP experiments demonstrated that there is 
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significantly more pol II on the TSS and gene body of IFN β in TDP-43-depleted 
cells. We also see greater transcriptional activity on many ISGs but presume that 
this is a downstream consequence of higher IFN β levels.      
 
3’ UTRs are better known for their ability to regulate gene expression by 
mechanisms of transcript destabilization. We are only aware of one other 
instance in which a 3’ UTR sequence is required for the repression of promoter 
activity. Sequences encoded in the rat serine protease inhibitor (spi) 2.3 3’ UTR 
were shown to specifically repress transcription from the spi 2.3 gene promoter 
(Le Cam and Legraverend 1995). Although we find a minimal requirement for the 
IFNβ 3’ UTR PAS to confer the effect of TDP-43 on IFNβ enhancer activity 
(Figure 7), no specific sequence motifs in the spi 2.3 3’ UTR were identified to be 
critical for spi 2.3 transcriptional regulation. In fact, multiple fragments of the spi 
2.3 3’ UTR were equally capable of repressing spi 2.3 transcription. 
 
Direct binding of the IFNβ  promoter sequence by TDP-43 seems unlikely. NF-κB 
is one of the transcription factors that drives IFN β promoter activity and TDP-43 
has been found to function as a co-activator of the p65 subunit of NF-κB, but the 
RNA binding domains of TDP-43 are dispensable for this function (Swarup 2011) 
and we find that the c-terminal domain of TDP-43 contributes to IFNβ 
misregulation (Figure 1g). Furthermore, we performed multiple endogenous and 
overexpressed and tagged TDP-43 ChIP-seq experiments to identify DNA 
targets of TDP-43 but were unsuccessful in recovering any specific interactions 
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(data not shown). Based on our data, one very likely possibility is that TDP-43 
does indeed regulate the IFNβ promoter indirectly via a larger complex that is 
tethered to the nascent IFNβ transcript and is not captured by standard ChIP 
crosslinking protocols.  
 
We only investigated the direct effect of TDP-43 on the IFNβ 3’ UTR, but our 
CLIP and MPRA data suggest that TDP-43 might directly regulate other genes 
using a similar 3’ UTR cis mechanism. We found enrichment for TDP-43 binding 
on the 3’ UTRs of key ISGs including IFIT1 and CXCL10. Additionally, MPRA 
sequence tiles corresponding to regions that contain PAS in the IFIT1 and 
CXCL10 3’ UTRs were stabilized in the absence of TDP-43. Further work to 
dissect how global the direct function of TDP-43 on the 3’ UTRs of genes that it 
regulates is warranted.   
 
Proteomic analyses of TDP-43 interaction partners show that TDP-43 is heavily 
enriched for associations with many RNA splicing factors (e.g. SF2, TIA-1), 
translation machinery (e.g. PABP2, eEF1A1 and eIF3F), and other proteins that 
regulate mRNA abundance including those in the nonsense mediated decay 
pathway (e.g. UPF1) and mRNA destabilization (e.g. Musashi 2) (Kim 2010, 
Freibaum 2010). It has been known for some time that extensive functional 
coupling exists among RNA processing factors that mediate biochemically 
distinct stages of gene expression (Maniatis and Reed 2002). In fact, all nuclear 
mRNA processing events appear to occur at the site of transcription (Krause 
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1994, Wansink 1993, Iborra 1996, Mortillaro 1996, Carmo-Fonseca 1991, 
Neugebauer 1997, Schul 1996, Misteli 1997). Not only are gene expression 
processes coupled, they are interdependent. For example, 3’ end processing is 
dependent on adequate 5’ cap formation (Lewis 1995, Flaherty 1997). 
Conversely, deleting the AAUAAA polyadenylation signal from a 3’UTR results in 
defects in alternative splicing and transcriptional termination (Niwa and Berget 
1991, Connelly 1988). Like TDP-43, the splicing factor SC35 has been shown to 
affect pol II processivity and transcriptional elongation (Lin 2008).  
 
Additionally, there is an emerging literature demonstrating that individual RNA 
binding proteins can regulate multiple stages of gene expression, from promoter 
regulation and transcription to mRNA decay and translation. Such proteins are 
termed “RNA coordinators” (Choder 2011). For example, the yeast RNA pol II 
subunits Rbp4p and Rbp7p interact with processing pol II, then bind to and travel 
with the nascent mRNA transcript to the cytosol where they are involved in either 
directing the transcript to be decayed or they augment translation initiation 
(Harel-Sharvit 2010). However, their initial communication with the polymerase 
and “imprinting” is required for these later functions.  
 
We wonder whether TDP-43 functions as an mRNA coordinator. In our model, 
TDP-43 binds directly to the 3’ UTR of nascent mRNA transcripts and uses the 
PAS, likely with 3’ end processing factors, to signal back to the promoter and 
dampen pol II activity. In this way, TDP-43 might function as an mRNA “counter” 
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to rapidly and locally modulate the number of transcripts that are generated from 
the IFNβ locus. IFNβ  is a critical regulator of antiviral immunity and this layer of 
local regulation might serve as another mechanism to limit the toxicity associated 
with an antiviral response.  
 
Since the overexpression and depletion of TDP-43 result in similar phenotypes, 
and both the RNA and protein interaction partners of disease forms of TDP-43 
are similar to WT TDP-43 (Kim 2010), there is a key mechanistic link that is 
missing. Although sequestration of aggregated TDP-43 to the cytosol, as is the 
case in some instances of TDP-43-linked neurodegeneration, would prevent 
TDP-43 from directly interacting with target genes, TDP-43 remains nuclear in 
our experimental system (S. Figure 3). Though much of the overexpressed TDP-
43 protein aggregates and appears to be ubiquitinated (S. Figure 2), we can still 
recover specific interactions by CLIP. TDP-43 has putative prion domains that 
might cause nuclear aggregation and prevent TDP-43 from appropriately 
interacting with other proteins that are recruited to the 3’ UTR PAS (Udan and 
Baloh 2011). The most likely TDP-43 interaction partners would be members of 
the massive eight-five-protein 3’ end processing complex (Shi 2009). Although 
TDP-43 was not identified as a member of this complex, many of its binding 
partners are. Furthermore, TAF15 is a core component of the polyadenylation 
complex, shares sequence homology with TDP-43 and Fus/TLS, and has been 
linked to ALS (Couthouis 2012), suggesting that defects in genes like TDP-43 
that regulate RNA 3’ end processing contribute to neurodegeneration. 
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Our data suggest that if TDP-43 is not able to interact with 3’ end processing 
machinery, than it cannot repress IFNβ promoter activity. This mechanism is not 
totally surprising since the 3’ UTR PAS has been shown to regulate both 
alternative splicing and transcriptional termination (Niwa and Berget 1991, 
Connelly and Manley 1988). These data present a new instance in which the 
PAS also regulates transcriptional elongation (Figure 8). Defective TDP-43-
mediated transcriptional repression might have significant consequences for 
neurodegeneration. A compromise in the ability to downregulate type I interferon 
can be toxic to any tissue, but the large, post-mitotic motor neurons of the central 
nervous system might be even more susceptible to elevated levels of antiviral 
cytokines. There is some evidence that repressing the type I interferon signaling 
in an ALS mouse model slows disease progression (Wang 2011). The pro-
inflammatory arm of innate immune signaling has been targeted for ALS 
therapeutics in the past, but perhaps attention should be turned to the antiviral 
pathways. 
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Figure 1.8: Model: TDP-43 regulates IFNβ  transcriptional elongation through a mechanism 
that involved the polyadenylation sequence in the IFNβ  3’ UTR. TDP-43 normally associates 
with the 3’UTR of IFNb transcripts. In the presence of an intact polydenylation signal in the IFNb 
3’ UTR, TDP-43 is able to repress IFNb promoter activity and transcriptional elongation in vivo 
(top panel). When normal TDP-43 function is perturbed, the ability of TDP-43 to repress 
transcription and IFNb mRNA transcript levels increase, leading to an increase in the expression 
of interferon-stimulated genes as well (middle panel). Increases in toxic antiviral immune 
mediators might contribute to neurodegeneration (bottom panel). 
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Experimental Procedures 
 
Mouse dendritic cells 
Six- to eight- week-old female C57BL/6J mice were obtained from the Jackson 
Laboratories. Bone marrow was collected from femora and tibiae. Bone marrow 
dendritic cells (BMDCs) were derived from plating total bone marrow onto non-
tissue culture treated plastic dishes (Corning) and growing the cells for one week 
in RPMI medium (Gibco, Carlsbad, CA, Invitrogen, Carlsbad, CA) supplemented 
with 10% FBS and 1% L-glutamine, penicillin/streptomycin, MEM non-essential 
amino acids, HEPES, sodium pyruvate, 0.1% beta-mercaptoethanol, and 15 
ng/mL GM-CSF (Peprotech, Rocky Hill, NJ). BMDCs were also generated from 
IRF3/7-/- and IFNR-/- mice (gifts from K. Fitzgerald). 
 
Cell lines 
 
HEK293T cells, U2OS cells, and mouse lung fibroblasts were cultured in tissue 
culture-treated plastic dishes in DMEM media (Gibco, Carlsbad, CA) 
supplemented with 10% FBS and 1% penicillin/streptomycin. The cells were 
grown in an incubator at 37°C. Primary MEFs were generated from C57BL/6J, 
IRF3-/-, and MAVS-/- mice (gifts from J. Kagan). 
 
Viruses 
Sendai virus, Cantell strain (ATCC, Manassas, VA) was used for infections. 
Influenza A virus strain A/PR/8/34 was grown in Vero cells, and virus titers from 
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cell supernatants were quantified using 293T cells transfected with a vRNA 
luciferase reporter plasmid. 
 
Antibodies and reagents 
 
Anti-TDP-43 (ProteinTech Group, Chicago, IL), Fus (AbCam, Cambridge, MA), 
pIRF3 (Cell Signaling, Danvers, MA), pSTAT1 (AbCam) antibodies were used for 
immunoprecipitations and Western blotting. 
 
pmCherry plasmids encoding WT TDP-43, TDP-43A315T, and TDP-43M337V 
were a gift from R. Baloh. 
 
RNA isolation 
 
mRNA was isolated using the RNeasy mini kit according to the manufacturer’s 
instructions (Qiagen, Valencia, CA). RNA was reverse transcribed with the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA). 
 
Total RNA was isolated using phenol:chloroform:isoamylalchohol (Invitrogen, 
Carlsbad, CA). RNA was precipitated overnight at -80°C from the aqueous phase 
by adding an equal volume of 100% isopropanol and 1 ul of glycogen (Thermo 
Scientific, Rockland, Il). The RNA was pelleted by centrifuging for 45 minutes at 
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4°C and then washed with 80% ethanol to retain small RNA species. RNA 
sample quality was assessed on a 2100 Bioanalyzer (Agilent, Palo Alto, CA). 
 
For experiments with very low RNA yield, RNA was reverse transcribed using the 
Sensiscript RT kit (Qiagen). 
 
qPCR measurements 
 
Quantitative real time PCR (qPCR) reactions were performed on the LightCycler 
480 system (Roche, Indianapolis, IN) using the FastStart Universal SYBR Green 
Master Mix (Roche). Every reaction was run in duplicate and endogenous 
GAPDH levels were used for normalization.  
 
For bar graphs, the unpaired 2-tailed student’s T-test was used to compute p 
values, except where stated otherwise. Error bars reflect the standard error of the 
mean (SEM), except where stated otherwise. All statistical analyses were carried 
out using GraphPad Prism 4.0 and the R statistical environment. 
 
shRNA infection 
 
High-titer lentiviruses expressing shRNAs were obtained from The Broad RNAi 
Platform and used to infect cells as previously described (Moffatt et al., 2006). 
Primary BMDC were infected according to previously published protocols (Amit 
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2009). For all other cells, 5000 cells were plated on flat bottom 96-well plates 
(Corning) and 24 hrs later spin-infected with shRNA encoding lentiviruses (MOI 
2-10) supplemented with polybrene (8 ug/ml). 24 hours after infection, the cells 
were selected using puromycin (2 ug/ml) in culture medium. Cells were used in 
experiments after 4 days of selection. 
 
siRNA transfection 
 
siRNAs targeting a negative control sequence or TDP-43 (Dharmacon 
siGenome) were transfected into cells using Lipofectamine RNAiMax (Invitrogen) 
according to manufacturer’s instructions. 
 
Plasmid transfection 
 
Plasmid DNA was transfected using TransIT LT1 reagent (Mirus, Madison, WI) 
according to manufacturer’s protocols. 
 
Luminescent reporter assays 
 
Plasmid DNA encoding luminescent reporter proteins and ORFs  or 3’ UTRs of 
interest were transfected into cells using TransIT LT1 (Mirus). The Dual Glo 
Luciferase Assay System (Promega, Madison, WI) was used to read 
luminescence using the Envision Multilabel Reader (Perkin Elmer, Waltham, 
MA). 
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4-thiouridine metabolic labeling of nascent transcripts 
 
Nascent RNA transcripts were isolated from cells that were metabolically labeled 
using 4-thiouridine (4SU). We labeled U2OS cells following infection with SeV 
with 4SU (final concentration of 500 uM) for pre-defined labeling times. The cells 
were then washed three times in cold PBS and lysed in buffer RLT (Qiagen). We 
isolated mRNA, used EZ-Link HPDP-Biotin (Thermo Scientific, Rockford, Il) to 
covalently link biotin to 4SU residues, and isolated the 4SU-labeled RNA (RNA-
4SU) using biotin capture with streptavidin magnetic beads according to 
previously published protocols (Rabani et al.). Total mRNA and captured 
biotinylated RNA was quantified either by standard qPCR or by Illumina 
sequencing. 
 
UV-crosslinking and Immunoprecipitation and high throughput RNA 
sequencing  
 
Protocol based on UV-crosslinking and immunoprecipitation with high throughput 
RNA sequencing (HITS-CLIP), (Chi et al., 2009). In brief, 100 million U2OS cells 
or U2OS cells stably expressing a tetracycline-inducible vector encoding GFP or 
GFP-WTTDP-43 or GFP-TDP-43A315T were treated with tetracycline (0.25 ug/ml) 
for 24 hrs. Then, the cells were infected with SeV (MOI 5) for 18 hrs to induce an 
antiviral state. The cell media was removed and replaced with PBS and the cells 
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were UV-crosslinked (265 nm) for two rouns of 4000 J, on ice. Cells were 
washed with PBS containing protease inhibitors three times and the cell pellets 
were resuspended in a low salt buffer (100 mM NaCl, 0.1% sodium dodecyl 
sulfate (SDS), 0.5% sodium deoxycholate, 0.5% Nonident P-40) with protease 
inhibitors. Cells were sonicated with a Branson probe sonicator for three cycles 
of 10 seconds (0.7 sec on/1.3 sec off) at 20% power on ice. The lysates were 
then rested on ice for 20 mins. RQ1 DNase (Promega) was added to the lysates 
and incubated at 37° C for 5 min. RNAse A (USB) was added at a concentration 
of 1:1000 and incubated at 37° C for 10 minutes. Lysates were spun and 
supernatants were incubated with protein A Dynabeads that were pre-incubated 
either with anti-TDP-43 (ProteinTechGroup) to immunoprecipitate endogenous 
TDP-43 or with GFP-TRAP beads (Chromo Tek) in low salt buffer. Beads were 
washed with low salt wash buffer three times followed by two washes with high 
salt buffer (500 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.5% Nonident 
P-40).  Proteinase K (5 ug) was added to the washed beads and incubated at 70° 
C for 1.5 hrs. RNA was extracted using standard Phenol/Chloroform extraction 
methods and the resulting RNA pellets were washed with 80% ethanol to retain 
short RNA fragments. RNA sizes were assessed on a 2100 Bioanalyzer (pico 
chip) and the sizes of extracted RNA ranged between 40 – 150 bases. RNA 
libraries were prepared and barcoded according to standard Broad RNA 
sequencing protocols. Single-end Illumina sequencing was performed. 
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Detection of TDP-43 binding sites 
 
We focused our CLIP analysis on the 5’ UTR, exons, and 3’ UTR of genes but 
did not consider intronic regions. The search for enriched peaks in the TDP-43 
immunoprecipitation sample compared to the input control was performed by 
scanning each gene using sliding windows of 100 nucleotides with 50 
nucleotides overlap. The mean coverage for each window was calculated for the 
immunoprecipitated and control samples (MeanWinIP and MeanWinControl, 
respectively). Gene median coverages for immunoprecipitation and input control 
were determined (MedianGeneIP and MedianGeneControl, respectively) to 
robustly estimate background levels. Every window was assigned the following 
unit-less metric, representing the enrichment fold change of immunoprecipitated 
over input control samples after normalization by background. 
 
A robust estimation signal was ensured by setting a limit of mean window 
coverage >20 for the immunoprecipitated sample. The FDR of this method was 
estimated by comparing the number of enriched windows exceeding a set 
threshold using this approach to the number that is obtained if the experiments 
were computationally reversed with input being treated as immunoprecipitate and 
vice versa. For a threshold of 2, corresponding to a fourfold increase with respect 
to control, the FDR was <7%; thus, the winscore threshold was set to 2. All 
overlapping enriched windows were merged and positions with maximal 
immunoprecipitate-positive and immunoprecipitate-negative coverage were 
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identified. If the distance between these two maxima was <100 nucleotides and 
the ratio between the amplitude of these two maxima was less than twofold, a 
putative TDP-43 binding site was defined in the centre of these two maxima, and 
a score was allocated to this peak, peakscore, corresponding to the maximal 
winscore from among all the overlapping windows. When these conditions were 
not met, windows were classified as non-resolved peaks and excluded from the 
analysis, to avoid PCR/sequencing artifacts. The negative control peaks were 
detected as described above: All windows with winscore <0 were selected. 
Control windows were selected from the same genes as the detected TDP-43 
binding peaks (limited to a mean window coverage >20). All overlapping control 
windows matching these criteria were merged and a negative control peak was 
defined in their centre. GFP peaks were subtracted from TDP-43 peaks to 
remove background artifacts. 
For genome-based analysis, the peak-caller MACS51 was used for peak 
detection; the ‘effective genome size’ parameter was adjusted to the calculated 
transcriptome size (1.35 × 108). Peaks were considered if their MACS-assigned 
fold change was >4 and individual FDR value <5%. 
 
Identification and clustering of enriched motifs 
 
In-house method for detecting motifs using all identified peaks. Motifs enriched 
within TDP-43 binding peaks compared with control peaks were identified by 
counting the occurrence of 4–6-nucleotide k-mers in the immunoprecipitate and 
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its corresponding control group. The total number of k-mers of each length within 
every group was counted and the ratio between their prevalence was used to 
calculate the fold change between the two groups. Exact Fisher test was used to 
evaluate the differences in the prevalence of each k-mer between the groups. 
Analysis was limited to motifs enriched more than twofold and with an associated 
Bonferonni-corrected P value < 0.05. To correct for the underlying base 
composition we repeated these analyses using a second set of control 
sequences based on randomly permuting the sequences of the TDP-43 binding 
sites, validating the significance of the found motif. 
 
Massively parallel reporter assays (MPRA): 
 
Oligonucleotide library design and synthesis 
200mer oligonucleotides were designed to contain, in order, the universal primer 
site ACTGGCCGCTTCACTG, a 10 nt variable tag sequence, the Tag-Seq primer 
site AGATCGGAAGAGCGTCG, a 145 nt UTR tile and the universal primer site 
GACAATGCAGGCCTCG. The tile sequences were selected to cover the 
annotated UTRs of 49 RefSeq genes with a step size of 40 nt, and each of the 
resulting 1,683 tiles were linked to 32 distinct tags, for a total oligo library 
complexity of 53,856. The distinct tags were selected from randomly generated 
10 nt sequences, with the following constraints: (1) must contain all four 
nucleotides, (2) must not contain a run of more than four identical nucleotides, 
and (3) must not contain a known mammalian microRNA seed sequence 
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(obtained from http://www.targetscan.org, April 2009). The resulting 
oligonucleotide libraries were synthesized by Agilent, Inc. as previously 
described [8].  
 
Plasmid construction 
To generate the UTR MPRA vector, we obtained a commercially synthesized 
DNA sequence (Genscript) containing, in order, a transcriptional terminator and 
synthetic polyA site derived from pGL4.10 (Promega), the TRE3G Dox-inducible 
promoter (Clontech), the luc2P destabilized luciferase gene, two SfiI sites 
separated by a 38 nt stuffer and the SV40 UTR/polyA signal. This sequence was 
cloned into the EcoRI and BamHI sites of pUC57. 
 
To insert UTR tiles into the MPRA vector, full-length oligonucleotides were 
isolated using PAGE and then amplified and SfiI-tailed using 20-26 cycles of 
emulsion PCR as described in [Schütze et al. Analytical Biochemistry 410 (2011) 
155-157] using Herculase II Fusion DNA Polymerase (Agilent) and primers 
GCTAAGGGCCTAACTGGCCGCTTCACTG and 
GTTTAAGGCCACCGAGGCCAGCTTTGTC to add SfiI sites. The resulting PCR 
products were digested with SfiI (NEB) and directionally cloned into the SfiI 
digested MPRA plasmid using One Shot® TOP10 Electrocomp™ E. coli cells 
(Invitrogen). To preserve library complexity, the efficiency of transformation was 
maintained at >3x108 cfu/µg.  
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Tag-Seq 
mRNA was extracted from total RNA using MicroPoly(A)Purist™ kits (Ambion) 
and treated with DNase I using the Turbo DNA-free™ kit (Ambion). First-strand 
cDNA was synthesized from 400-700 ng mRNA using High Capacity RNA-to-
cDNA kits (Applied Biosystems). 
 
Tag-Seq sequencing libraries were generated directly from 12% of a cDNA 
reaction or 50 ng plasmid DNA by 26 cycle PCR using Pfu Ultra HS DNA 
polymerase 2x master mix (Agilent) and primers 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTC
CGATCT and 
CAAGCAGAAGACGGCATACGAGATXXXXXXXXGTGACTGGAGTTCAGACGT
GTGCTCTTCCGATCTCGAGGTGCCTAAAGG (where XXXXXXXX is a library-
specific index sequence). The resultant PCR products were size-selected using 
2% agarose E-Gel EX (Invitrogen). The libraries were sequenced in indexed 
pools of eight, or individually, using 36 nt single-end reads on Illumina HiSeq 
2000 instruments.  
To infer the tag copy numbers in each Tag-Seq library, all sequence reads were 
examined, regardless of their quality scores. If the first ten nucleotides of a read 
perfectly matched one of the 53,856 designed tags and the remaining 
nucleotides matched the expected upstream MPRA construct sequence, this was 
counted as one occurrence of that tag. All reads that did not meet this criterion 
were discarded. All tags that did not have a count of at least 20 in every 
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sequenced plasmid pool were also discarded. The mRNA/plasmid tag ratios 
were normalized by multiplying by the ratio of the total number of plasmid and 
mRNA tag counts from the corresponding Tag-Seq libraries. To estimate the 
relative abundance of each distinct UTR tile, we compared the median of their 32 
mRNA/plasmid tag ratios.  
 
Chromatin immunoprecipitation 
 
Chromatin immunoprecipitation (ChIP) for endogenous and overexpressed 
3xFlag-TDP-43 were performed according to published protocols (Mikkelsen 
2007). The commercially available antibody was used for endogenous TDP-43 
(ProteinTech Group). Polymerase II ChIP protocol and reagents used were as 
per published protocols (Rahl 2010).    
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CHAPTER 2: The RNA binding proteins Fus and TDP-43 
play roles in innate immunity and ALS disease 
pathophysiology 
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Introduction 
 
Two independent RNAi screens performed in the Hacohen lab identified the 
nuclear RNA binding protein, Fus, to be a negative regulator of the type I 
interferon response (Amit 2009, Shapira 2009). Subsequently, I identified a 
protein with similar structural motifs as Fus, TDP-43, to also be a negative 
regulator of innate immune genes (See Chapter 1). Mutations in both of these 
proteins have been linked to a variety of human neurodegenerative diseases, 
particularly familial amoytrophic lateral sclerosis (ALS). Here, we show that Fus 
and TDP-43 are both transcriptionally and post-translationally regulated in 
response to viral pathogen sensing. Fus and TDP-43 were found to negatively 
regulate type I interferon production as well as RNA polymerase (pol) I and III 
gene expression. Furthermore, the proteins associate with IFN and pol III mRNA 
in vivo. Despite this increase in antiviral gene activity, Fus- and TDP-43- depleted 
cells are impaired in their ability to control influenza A virus, vesicular stomatitis 
virus, and reovirus replication. The defect in controlling influenza virus replication 
is reversed upon the administration of a pol III inhibitor. The overexpression of 
Fus and TDP-43 also fails to inhibit viral replication. The transcriptional regulation 
and physiological functions of Fus and TDP-43 in viral immunity were not 
previously reported, and we believe these genes play a critical role in controlling 
viral immunity through a novel and unknown mechanism. 
 
Interestingly, fibroblasts derived from a familial ALS patient harboring a TDP-43 
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mutation produced more type I interferon in response to influenza virus infection 
than control cells. Additionally, RNA from the frontal cortex of deceased ALS 
individuals’ brains also have a striking antiviral and pol III gene phenotype. As in 
human ALS, a missense mutation in the canine SOD1 protein (E40K) causes an 
upper and lower motorneuron disease called canine degenerative myelopathy 
(DM). We found that the spinal cords of diseased dogs also exhibit higher 
expression of antiviral genes. 
 
There are many connections between the innate immune system and 
neurodegenerative diseases. Our preliminary data suggests that the innate 
immune functions of Fus and TDP-43 might contribute to ALS disease 
pathophysiology.  
 
Background 
  
 
 Fus (human: TLS (translocated in sarcoma); hnRNP P2) is a ubiquitously 
expressed, nuclear RNA binding protein in the TET protein family. Structurally, 
Fus has an N-terminal activation domain, three arginine-glycine-glycine- rich 
repeats, and an RNA recognition motif. This 74 kD protein has been shown to 
bind both DNA and GGUG-rich RNA sequences (Lerga 2001), as well as 
regulate gene transcription (Wang 2008) and alternative splice site selection 
(Hallier 1998). The Manley lab demonstrated that Fus negatively regulates RNA 
polymerase (pol) III activity by competing for binding to the TATA binding protein 
(TBP) (Tan 2009). A Fus knockout mouse on an inbred background did not 
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survive the first 24 hours of life and showed an absence of the B cell 
compartment (Hicks 2000). Mouse embryonic fibroblasts derived from these mice 
were associated with chromosomal abnormalities and high sensitivity to ionizing 
radiation. Fus is a target of the DNA damage response kinase, ATM (Gardiner 
2008). 
 
Mutations in both Fus and TDP-43 have been associated with the development 
of familial ALS (Kwiatkowski 2009; Sreedharan 2008). The TDP-43 protein is 
also associated with other neurodegenerative diseases, including frontotemporal 
lobar degeneration (FTLD), Alzheimer’s Disease (AD) (Galimberti 2010), and 
chronic traumatic encephalopathy (McKee 2010). In 1993, superoxide dismutase 
1 (SOD1) was identified by genome wide association to be the first familial ALS 
disease gene (Rosen 1993). In 2010, the fourth familial ALS gene, optineurin, 
was identified (Maruyama 2010). Optineurin has been independently shown to 
function as both a negative regulator of type I interferon production and as an 
antiviral factor (Mankouri 2010). Very recently, polyglutamine expansions in the 
translational regulator ataxin-2 were also shown to be associated with an 
increased risk for ALS (Elden 2010). Point mutations in the RNA binding domains 
of both Fus and TDP-43 have been linked to familial ALS pathophysiology. 
Furthermore, in many cases, Fus and TDP-43 are mislocalized to the cytosol in 
diseased brain cells. Independent of mutations, a hyperphosphorylated and 
ubiquitinated form of TDP-43 is the primary protein associated with RNA-rich 
cytosolic inclusions observed in ALS and FTLD (Buratti and Baralle 2009). 
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In 2009, Ido Amit from the Hacohen lab published an RNAi screen in which ~150 
transcription factors, chromatin modifiers, and RNA binding proteins that are 
regulated in primary bone marrow dendritic cells in response to pathogen 
sensing, including Fus, were individually knocked down (Amit 2009). The innate 
immune gene profile for each knock down condition was then assessed and an 
innate immune gene network was generated. Fus was found to negatively 
regulate ~50 genes in the antiviral response pathway, including type I interferons. 
To our knowledge, this is the only report demonstrating a role for Fus in the 
innate immune response.  
 
The Manley lab found that Fus regulates RNA pol III gene expression (Tan 
2010). Subsequently, I have observed that TDP-43 also negatively regulates 
both innate immune genes and pol III gene expression, and that cells have an 
increased influenza viral load when Fus or TDP-43 expression is knocked down. 
TDP-43 has not been previously reported to play a role in either the innate 
immune system or in pol III gene regulation.  
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Results 
 
Fus and TDP-43 are regulated transcriptionally and post-translationally following 
pathogen sensing. 
 
The mouse lung fibroblast (MLF) cell line is a good model system to study innate 
immune responses to influenza virus infection. MLFs were either infected with 
influenza A/PR8 (A/PR8) at an MOI of 5 or transfected with RNA isolated from 
A/PR8 for various time points. Gene expression was analyzed by quantitative 
RT-PCR (qPCR). Transcription of Fus and TDP-43 is upregulated in response to 
viral pathogen sensing (Figure 1a). Fus is also regulated in response to LPS 
treatment (100 ng/mL) and poly I:C (50 ug/mL) or immunostimulatory DNA (ISD) 
transfection (120 ng/mL). TDP-43 is regulated only in response to poly I:C and 
ISD transfection (Figure 1b-c). However, the total protein levels of Fus and TDP-
43 do not appear to change over time following pathogen sensing (Figure 1d). 
Since Fus is a target of the kinase ATM, we decided to test if Fus is more 
phosphorylated by ATM following pathogen sensing. MLFs were infected with 
A/PR8 for various time points and immunoprecipitation (IP) of total Fus protein 
was performed. Both total Fus and ATM-phosphorylated Fus was probed using 
anti-Fus and anti-phospho-ATM target antibodies, respectively. Indeed, Fus is 
more highly phosphorylated by ATM following pathogen sensing (Figure 1e). 
Furthermore, phosphorylated peptide mass spectrometry data from another 
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member of the Hacohen lab found that TDP-43 is highly phosphorylated following 
innate immune sensing in primary bone marrow dendritic cells (data not shown). 
 
Figure 2.1: Fus and TDP-43 are regulated in response to pathogen sensing.  (A) Mouse 
lung fibroblasts (MLF) are infected with influenza A virus/PR8 strain (A/PR8) at an MOI 5 or 
transfected with RNA isolated from influenza A virus/PR8 (A/PR8/vRNA) over a time course. 
cDNA libraries were made and gene expression was assessed by quantitative RT-PCR (qPCR). 
(B) MLFs were treated with LPS (100 ng/mL) or transfected with poly I:C (50 ug/mL) over time 
and gene expression was assessed by qPCR . (C) MLFs were transfected with 
immunostimulatory DNA (ISD, 120 ng/mL) over time and gene expression was assessed by 
qPCR . (D) MLFs were transfected with A/PR8/vRNA (300 ng/mL) over a time course. The levels 
of Fus and TDP-43 protein was determined from these cell lysates by Western blotting. (E) MLFs 
were infected with A/PR8 at an MOI 5 for 0, 2, and 6 hours. An immunoprecipitation of an isotype 
control (Rabbit IgG) or Fus was performed. Both the total Fus protein levels and levels of Fus that 
were phosphorylated by ATM was determined by Western blotting and compared to whole cell 
extract (WCE). 
 
 
Fus and TDP-43 are negative regulators of antiviral gene expression  
 
 
Knockdown 
 
To test how innate immune gene expression changes when Fus is depleted, Fus 
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was knocked down in MLF using siRNA. Then, cells were infected with A/PR8 
(MOI 5) for 18 hours and gene expression was analyzed by qPCR. Fus 
knockdown cells expressed higher levels of antiviral genes, monitored here by 
IFNβ and CXCL10 expression (Figure 2a). (See Chapter 1 for details on TDP-43 
perturbation). To test whether more type I interferon protein is produced in these 
cells, Fus and TDP-43 were knocked down in MLF using shRNAs, then infected 
with either A/PR8 or influenza A/deltaNS1 (A/dNS1) at various MOIs for 24 
hours. The supernatants from this experiment were tested on a type I interferon-
sensitive ISRE-luciferase reporter cell line. Fus and TDP-43 knockdown cells had 
higher ISRE activity than controls (Figure 2b).  
 
Overexpression 
 
Overexpression of Fus has been challenging since the protein is very toxic to 
cells if expressed at levels higher than baseline. However, transient transfection 
of HEK293T cells with plasmids encoding either wild type human Fus or ALS-
linked Fus disease alleles has been successful. HEK293T cells were transfected 
with 0.5 ug of plasmid DNA/10^5 cells. Twenty-four hours post transfection, cells 
were infected with A/PR8 for 8 hour and gene expression was analyzed by 
qPCR. Overexpression of wild type Fus results in more IFNβ gene expression 
and the overexpression of ALS-linked Fus disease alleles resulted in significantly 
higher IFNβ expression (Figure 2c). Like TDP-43, overexpressing Fus results in a 
dominant negative phenotype that matches the knock down phenotype. This 
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effect is not completely understood for either protein. Perhaps Fus autoregulates 
its own expression via a 3’UTR destabilizing mechanism like TDP-43 does, or 
perhaps the overexpressed protein is heavily modified rendering it non-functional 
as TDP-43 appears to be. These possibilities remain to be explored. 
 
 
Figure 2.2: Fus and TDP-43 negatively regulate the expression of antiviral genes. (A) 
Mouse lung fibroblasts (MLFs) were transfected with Lipofectamine RNAiMax transfection 
reagent only (no siRNA), an siRNA targeting an irrelevant transcript (siCtl), or Fus (siFus#1 & 2). 
After 72 hours, the cells were infected with A/PR8 (MOI 5) for 18 hours. Then, IFNβ and CXCL10 
mRNA levels were measured by qPCR. *p<0.05, **p<0.01. Data are representative of three 
experiments.  (B) MLFs were infected with puromycin-resistant shRNA lentiviral vectors targeting 
RFP, Fus, or TDP-43. After 5 days of puromycin selection, cell were infected with A/PR8 (left) or 
A/NS1 (right) at MOI 0, 0.1, 0.5, 1, 2, or 5 for 24 hours. The supernatants were then tested on an 
ISRE-luciferase reporter cell line to measure relative type I interferon production. Data are 
representative of three experiments. (C) HEK293T cells were transfected with plasmid DNA (0.5 
ug/10^5 cells) encoding the empty pmCherry vector backbone only (EV), WT Fus, or Fus with 
ALS-associated point mutations (S514R and C515G) for 24 hours. Cells were then infected with 
A/NS1 at an MOI of 5 for 8 hours. Gene expression was assessed by qPCR. Data are 
representative of five experiments. (D) Mouse embryonic fibroblasts (MEF) stably expressing an 
ISRE promoter driving a luciferase reporter (ISRE-luc) were transfected with siRNA targeting Fus 
(siFus), TDP-43 (siTDP-43), SOD1 (siSOD1), and optineurin (siOPTN). Cells were infected with 
A/PR8 (MOI 5) for 18 hrs and luminescence was read. Data are representative of three 
experiments. 
 
 
SOD1 is a negative regulator of antiviral gene expression 
 
There is an increasing understanding that innate immune pathways are involved 
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in neurodegeneration (See Section III of the Introduction). We noted that several 
of the ALS disease genes, namely TDP-43, Fus, and optineurin, were negative 
regulators of type I interferons. Additionally, a transgenic SOD1 ALS mouse line 
was found to have greater interferon-stimulated gene expression in its central 
nervous system (Wang 2010). Therefore, we wanted to test if knock down of 
SOD1 would result in an increase in interferon activity. We knocked down Fus, 
TDP-43, optineurin, and SOD1 proteins using siRNAs from mouse embryonic 
fibroblasts that stably express an interferon-sensitive ISRE-luciferase reporter 
construct (ISRE-luc). We then tested ISRE-luc activity in these cells in response 
to A/PR8 infection. Surprisingly, we found that the depletion of SOD1 resulted in 
both a baseline and viral sensing-induced increase in type I interferon, similar to 
the perturbation of Fus and TDP-43 (Figure 2d). We are not aware of any reports 
showing that SOD1 is a direct regulator of innate immune signaling but more 
work in this area might be informative to the field. 
 
Fus and TDP-43 are negative regulators of viral replication  
 
Since the absence of Fus and TDP-43 is associated with greater type I interferon 
activity, we postulated that Fus and TDP-43 knock down cells would control viral 
replication better than control cells. Surprisingly, there is more A/PR8 viral 
replication when Fus and TDP-43 are depleted (Figure 3a). There is also more 
vesicular stomatitis virus (VSV) when Fus and TDP43 are depleted and slightly 
more reovirus replication when Fus and TDP-43 are depleted (Figure 3b-c).  
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The antiviral effect of Fus and TDP-43 seems to be somewhat independent of 
interferon activity, as the knock down of Fus using siRNAs targeting the human 
transcript in a cell that does not produce interferons, the African Green Monkey 
cell line Vero, was also associated with more A/PR8 replication (the human 
siRNAs targeting TDP-43 in this cell type did not successfully knock down the 
TDP-43 transcript) (Figure 3d).  
 
The overexpression of wild type or disease forms of Fus and TDP-43 was not 
able to rescue the viral phenotype. Overexpression of these genes results in an 
increase of A/PR8 virus replication (Figure 3e-f). We were not surprised that the 
knockdown and overexpression phenotypes were consistent with each other 
since we found a dominant negative phenotype for type I interferon and ISG 
expression. 
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Figure 2.3: Fus and TDP-43 have antiviral effects. (A) MLFs were infected with puromycin-
resistant shRNA lentiviral vectors targeting GFP, Fus, or TDP-43. After 5 days of puromycin 
selection, cells were infected with A/PR8 (MOI 5) for 24 hours. The supernatants were then 
tested on in an influenza A/PR8 vRNA-luciferase (vRNA-luc) reporter assay to quantify the 
presence of replication-competent viral particles. *p<0.05, **p<0.01. Data are representative of 
five experiments. (B) MLFs were infected with shRNA lentiviral vectors targeting the indicated 
genes. After selection, cells were infected with vesicular stomatitis virus (VSV) expressing a 
luciferase reporter (MOI 10). Five hours post-infection, total luciferase activity was measured to 
quantify VSV replication. Data are representative of three experiments. (C) MLFs were infected 
with shRNA lentiviral vectors targeting the indicated genes. After selection, cells were infected 
with reovirus (MOI 3). Seventy hours post infection, the supernatants were applied to reovirus 
plaque assay to measure total reovirus replication. Data are representative of two experiments. 
(D) African Green Monkey Vero cells (Vero) were transfected with human siRNA constructs 
targeting either a negative control (Mission negative, MN) or Fus (siFus). After 72 hours, the cells 
were infected with A/PR8 (MOI of 0, 0.1, 0.5, 1, 2, or 5) for 24 hours. Influenza viral replication 
was then measured using the vRNA-luc reporter assay. Data are representative of two 
experiments. (E-F) HEK293T cells were transfected with plasmid DNA (0.5 ug/10^5 cells) 
encoding the empty pmCherry vector backbone only (EV) or (E) Fus contructs: WT Fus, Fus 514, 
Fus 515; (F) WT TDP-43, TDP-43 A315T, or TDP-43 M337V for 24 hours. Cells were then 
infected with A/PR8 (MOI 5) for 24 hours. Influenza viral replication was then measured from the 
supernatants using the vRNA-luc reporter assay. Data are representative of three experiments. 
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At this point, we are not sure how Fus and TDP-43 are functioning as antivirals. 
In the next section, we present data regarding the regulation of biosynthesis 
genes by both Fus and TDP-43. One possibility is that the roles of Fus and TDP-
43 in regulation of RNA transcripts contribute to viral replication. 
 
TDP-43 is a negative regulators of pol I and III transcription 
 
Tan and Manley recently demonstrated that Fus negatively regulates RNA pol III 
gene expression by associating with the TATA binding protein (TBP) and 
inhibiting its interaction with the RNA polymerase (Tan et al., 2010). The tumor 
suppressor gene, p53, likewise inhibits biosynthesis by controlling pol III activity 
using the same mechanism (Stein et al., 2002). Pol III-transcribed genes are not 
translated and encode non-coding RNAs that are critical for splicing, translation, 
and other aspects of mRNA processing. We wondered if TDP-43 likewise 
regulates pol III-transcribed genes. Pol III-transcribed genes utilize four different 
promoter configurations. To be complete, we monitored how perturbation of TDP-
43 affects the expression of genes using each of these promoter systems. In the 
absence of a stimulus, this pol III inhibition phenotype is subtle. However, 
following pathogen sensing, the absence of TDP-43 results in a tremendous 
upregulation of pol III gene expression (Figure 4a). We also tested whether 
perturbation of TDP-43 affects transcription from polymerase I (pol-I) -transcribed 
genes and found that depleting TDP-43 results in a baseline and viral infection-
induced increase in 18S expression (Figure 4b). The depletion of Fus, however, 
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does not appear to affect pol I-transcribed gene expression. 
 
We wondered whether this increased biosynthesis might be responsible for the 
increase in viral replication when Fus and TDP-43 are knocked down. To test 
this, we titrated a specific RNA pol III chemical inhibitor into MLFs that received 
siRNA targeting Fus and TDP-43. Interestingly, by inhibiting pol III gene activity, 
influenza replication in Fus and TDP-43 knockdown cells was brought down to 
control levels (Figure 4c).  
 
Some work was done to test if TDP-43 regulates pol III transcription by the same 
mechanism that Fus does. However, I was not able to find a direct binding 
association between TDP-43 and TBP, the pol III coactivator that Fus inhibits 
(data not shown). However, I did note that TDP-43 was directly associating with 
pol III-transcribed RNA transcripts. Using a modified low-RNase CLIP protocol, I 
pulled down RNAs that are specifically associated with Fus and TDP-43 in 
resting cells and in cells that were transfected with A/PR8/vRNA to activate the 
antiviral pathway, and then identified the RNA binding partners by qPCR. From 
these experiments, both genes were enriched in pol III transcript binding over 
controls, but that TDP-43 was much more enriched for binding to key pol III-
transcribed genes, such as U6 and 7SL (Figure 4d). We see that TDP-43 
specifically binds to many non-coding RNAs from CLIP experiments under more 
stringent conditions with an Illumina sequencing read out as well. Last week, a 
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paper from the Cleveland lab reported that TDP-43 binds to these transcripts as 
well (Lagier-Tourenne 2012). 
 
Figure 2.4: TDP-43 regulates RNA polymerase I- and III-transcribed genes. (A-B) MLFs were  
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Figure 2.4 (Continued): 
transfected with siRNA targeting TDP-43. After 72 hours, the cells were infected with A/PR8 (MOI 
5) for 18 hours and gene expression was assessed by qPCR. *p<0.05, **p<0.01, ***p<0.001. 
Data are representative of five experiments. (C) MLFs were transfected with siRNA constructs 
targeting Fus and TDP-43. After 72 hours, the cells were infected with A/PR8 (MOI 5) for 24 
hours in the presence of increasing concentrations of an RNA polymerase III inhibitor. Data are 
representative of two experiments. (D) Resting MLFs or MLFs that were transfected with 
vRNA/A/PR8 for 18 hours were UV-crosslinked (265 nm) to immobilize RNA:protein interactions 
in vivo. CLIP under low RNAse conditions was performed using control antibodies and antibodies 
targeting Fus and TDP-43. Relative RNA abundance was assessed by qPCR. Values are 
expressed relative to IgG CLIP RNA enrichment. Data are representative of five experiments. 
 
 
We are not sure how TDP-43 functions mechanistically as an antiviral factor. One 
possibility is that TDP-43 regulates the stability of biosynthesis RNA transcripts 
and in its absence these transcripts accumulate. This would result in greater 
translation of proteins in the cell globally, which has recently been reported 
(Fiesel 2012). We also noted that total RNA and protein content per cell is ~10% 
higher in TDP-43-depleted cells. Typically, viral infection is associated with an 
almost global reduction in protein translation through activation of PKR. In the 
absence of TDP-43 this balance might be disrupted and thus provide a more 
favorable environment for viral replication. I think that this is one of the more 
interesting aspects of this unfinished thesis work and merits further investigation. 
 
Connections between ALS and antiviral gene expression 
 
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a progressive, 
fatal neurodegenerative disease that is characterized by upper and lower motor 
deficits (See Introduction). There are many innate immune features of 
neurodegeneration, although the antiviral arm of the pathway has not been 
deeply explored. We see distinct innate immune phenotypes associated with Fus 
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and TDP-43, and are interested in testing if 1) ALS patient brains have an 
interferon phenotype, 2) if type I interferons play a role in motor neuron cell 
death. 
 
 
Primary cells from ALS patients have greater antiviral gene expression 
 
Primary skin fibroblasts were derived from two living familial ALS patients. One 
patient has a point mutation in Fus (R521C) and the other has a point mutation in 
TDP-43 (M337V). Control and patient fibroblasts were infected with A/PR8 (MOI 
5) for 18 hours and gene expression was analyzed by qPCR. The ALS patient 
cells with a TDP-43 point mutation had higher interferon gene expression in 
response to viral infection than the Fus ALS patient or control cells (Figure 5a). 
 
RNA was generated from fixed and frozen frontal cortex brains samples from 
deceased familial ALS patients and control patients. Complementary DNA 
libraries were constructed for each RNA sample using random nonamers and 
gene expression was analyzed by qPCR analysis. Several of the ALS patient 
brain samples highly expressed antiviral genes, including IFNa, IFNβ, and IFIT1, 
as well as pol III-transcribed genes, including U6 and 7SL (Figure 5b). However, 
not all innate immune genes are upregulated in ALS brains as mRNA levels for 
the pro-inflammatory gene IL-6 do not vary significantly between patients and 
controls. 
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Figure 2.5: ALS brains express higher levels of antiviral- and biosynthesis- related genes. 
 (A) Primary human skin fibroblasts (HFs) were derived from normal aged individuals (Control #1 
and #2) and two ALS patients, one with a point mutation in TDP-43 (M337V) one with a point 
mutation in Fus (R521C). HFs were infected with A/PR8 (MOI 5) for 18 hours and gene 
expression was assessed by qPCR. (B) Purified RNA from frontal cortex samples of deceased 
control cadavers (Ctr l-4) and ALS patient cadavers (ALS 1-6) was obtained from the 
Massachusetts General Hospital Brain Bank. Randomly primed cDNA libraries were generated 
for each sample and gene expression was assessed by qPCR. *p<0.05. All experiments were 
performed once due to limited samples. 
 
ALS dog spinal cords have an antiviral gene expression phenotype 
 
As in human ALS, a missense mutation in the canine SOD1 protein (E40K) 
causes an upper and lower motorneuron disease called canine degenerative 
myelopathy (DM), which pathologically mimics human ALS (Awano 2009). We 
wondered whether the spinal cords of these animals also show an ISG 
phenotype. DM severity is graded according to disease progression (Figure 6a). 
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We profiled innate immune gene expression in the spinal cords of eight DM dogs 
across the range of disease severity. Interestingly, IFNβ, CXCL10, and IFIT1 
expression is upregulated in the spinal cords of dogs with mild to intermediate 
disease, while MX1 and IL-6 expression is higher in dogs with late-stage disease 
compared to controls (Figure 6b). The observation that innate immune gene 
expression varies significantly across disease progression in a dog model of ALS 
suggests that gene profiles might change over time in human ALS patients as 
well. Not only is this important for understanding disease pathophysiology but 
might also have significant implications for biomarker development. 
 
 
 
 
Figure 2.6: ALS dog spinal cords express higher levels of antiviral genes. (A) Canine ALS, 
or degenerative myelopathy (DM), disease severity is graded on a scale from 0 (Normal) to 4. (B) 
RNA was isolated from frozen spinal cord samples from dogs that were euthanized at various 
stages of DM progression (DM1-8) and from age/sex matched canine controls (C1-6). Gene 
expression was assessed by qPCR. 
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Chapter 2 Summary: 
There are two major findings in this body of unfinished work: 1) Fus and TDP-43 
are somehow functioning as broad antiviral proteins and 2) there is a clear 
antiviral gene expression phenotype in primary tissues from ALS patient brains. I 
decided to spend the majority of my thesis effort studying the biochemical 
mechanism of function of TDP-43 because that was the work that I found to be 
more technically challenging and conceptually interesting. However, the 
observations presented in Chapter 2 have potentially important clinical 
implications. In particular, there is a potential to develop a therapeutic that can 
inhibit type I interferons in the CNS of ALS individuals and could delay disease 
progression.  
 
Intrinsic defects in innate immune responses in ALS patients should not be 
restricted to the brain and an evaluation of systemic defects might shed light onto 
the role of intrinsic innate immune defects in disease progression and potential 
treatment options. One on-going effort in the lab stemming from the work 
presented here is to interrogate the innate immune responses of ALS patient 
blood cells to bacterial and viral pathogens. Over the past two years, we have 
worked with Drs. Merit Cudkowicz and James Berry at the MGH ALS clinic to 
collect peripheral blood from ALS individuals. Presently, we have banked 
peripheral blood from ~25 Caucasian non-Hispanic ALS individuals equally 
representing both sexes (average age: 60 yo). Three of the patients have 
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confirmed SOD1 mutations and the remaining 22 are either sporadic cases or 
have not been genotyped. We also worked with Dr. Phil DeJager at the Brigham 
and Women’s Hospital to collect blood from a total of 50 healthy, aged donors 
(average age: 60 yo). Although others have profiled resting ALS PBMC on 
microarrays, our proposed study will monitor dynamic innate immune gene 
expression changes over time in response to pathogens. Furthermore, our lab is 
generating a large data set in which the immune responses of PBMC from 600 
healthy individuals are being profiled to generate a range of “normal” responses to 
pathogens to compare to disease cells.  
 
In our proposed study, blood cells will be 1) cultured in vitro for a week to return 
cells to a resting state and “erase” prior immune memory, 2) exposed to defined 
components of several viral and bacterial pathogens, 3) profiled for hundreds of 
genes that are important for the immune response using the Nanostring high-
throughput gene expression profiling method. As a final analysis, immune 
phenotypes will be correlated with clinical information regarding disease 
progression and we will determine if there is phenotypic correspondence of 
intrinsic immune defects among instances of deliberate ALS disease allele 
expression, naturally occurring disease alleles, and sporadic ALS cases. 
 
Expected outcomes:  
We expect to see a correlation in innate immune phenotypes between deliberate 
and naturally occurring disease allele expression in ALS tissues. Furthermore, we 
 120 
predict that the extent of immune activation will be correlated with disease 
progression. If our hypotheses are correct, then finding the mechanism that 
controls innate immune responses in ALS, and potentially a direct treatment to 
interrupt this pathway, would be an appropriate experimental follow-up in mouse 
models. 
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Experimental Procedures 
 
Cell lines 
 
HEK293T cells, U2OS cells, and mouse lung fibroblasts were cultured in tissue 
culture-treated plastic dishes in DMEM media (Gibco, Carlsbad, CA) 
supplemented with 10% FBS and 1% penicillin/streptomycin. The cells were 
grown in an incubator at 37°C.  
 
Viruses 
 
Sendai virus, Cantell and 52 strains (ATCC, Manassas, VA), were used for 
infections. Influenza A virus strain A/PR/8/34 was grown in Vero cells, and virus 
titers from cell supernatants were quantified using 293T cells transfected with a 
vRNA luciferase reporter plasmid. Vesicular stomatitis virus (VSV) expressing 
luciferase was a gift from S. Whelan. Reovirus and viral titering was performed 
by the Nibert lab at Harvard Medical School.  
 
Virus infection 
 
Influenza A, Sendai virus, VSV, and reovirus was added directly to cell culture 
media for the stated time points and viral replication was measured according to 
virus-appropriate assays. 
 
Antibodies and reagents 
 
Anti-TDP-43 (ProteinTech Group, Chicago, IL), Fus (AbCam, Cambridge, MA), 
pIRF3 (Cell Signaling, Danvers, MA), pSTAT1 (AbCam), pATM target (Cell 
Signaling), and b-actin (AbCam) antibodies were used for immunoprecipitations 
and Western blotting. 
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TLR ligands were from Invivogen (ultra-pure E. coli K12 LPS) and Enzo Life 
Sciences (poly(I:C)).  
 
RNA polymerase III inhibitor (EMD Millipore, Billerica, MA). 
 
pmCherry plasmids encoding WT TDP-43, TDP-43A315T, and TDP-43M337V 
were a gift from R. Baloh. 
 
Influenza virus titering 
 
2x106 293T cells (filtered through a 0.4mm filter) were seeded in 10cm dishes 
andtransfected with a vRNA luciferase reporter plasmid based on prior design 
(Lutz et al.,2005a) using Transit-LT1. Cells were trypsinized at 24h post-
transfection and 104transfected reporter cells were re-seeded in white Costar 
plates. Supernatants (frozen with trypsin) from PR8-infected HBECs were added 
to reporter cells and incubated for 24 hours. Reporter activity was measured with 
firefly luciferase substrate (Steady-Glo,Promega, Madison, WI). Luminescence in 
96-well plates was quantified using the Envision Multilabel reader (Perkin Elmer, 
Waltham, MA) fitted with an automated plate stacker. 
 
RNA isolation 
 
mRNA was isolated using the RNeasy mini kit according to the manufacturer’s 
instructions (Qiagen, Valencia, CA). RNA was reverse transcribed with the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA). 
 
Total RNA was isolated using phenol:chloroform:isoamylalchohol (Invitrogen, 
Carlsbad, CA). RNA was precipitated overnight at -80°C from the aqueous phase 
by adding an equal volume of 100% isopropanol and 1 ul of glycogen (Thermo 
Scientific, Rockland, Il). The RNA was pelleted by centrifuging for 45 minutes at 
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4°C and then washed with 80% ethanol to retain small RNA species. RNA 
sample quality was assessed on a 2100 Bioanalyzer (Agilent, Palo Alto, CA). 
 
For experiments with very low RNA yield, RNA was reverse transcribed using the 
Sensiscript RT kit (Qiagen). 
 
qPCR measurements 
 
Quantitative real time PCR (qPCR) reactions were performed on the LightCycler 
480 system (Roche, Indianapolis, IN) using the FastStart Universal SYBR Green 
Master Mix (Roche). Every reaction was run in duplicate and endogenous 
GAPDH levels were used for normalization.  
 
For bar graphs, the unpaired 2-tailed student’s T-test was used to compute p 
values, except where stated otherwise. Error bars reflect the standard error of the 
mean (SEM), except where stated otherwise. All statistical analyses were carried 
out using GraphPad Prism 4.0 and the R statistical environment. 
 
shRNA infection 
 
High-titer lentiviruses expressing shRNAs were obtained from The Broad RNAi 
Platform and used to infect cells as previously described (Moffatt et al., 2006). 
Primary BMDC were infected according to previously published protocols (Amit 
2009). For all other cells, 5000 cells were plated on flat bottom 96-well plates 
(Corning) and 24 hrs later spin-infected with shRNA encoding lentiviruses (MOI 
2-10) supplemented with polybrene (8 ug/ml). 24 hours after infection, the cells 
were selected using puromycin (2 ug/ml) in culture medium. Cells were used in 
experiments after 4 days of selection. 
 
Plasmid transfection 
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Plasmid DNA was transfected using TransIT LT1 reagent (Mirus, Madison, WI) 
according to manufacturer’s protocols. 
 
siRNA transfection 
 
siRNAs targeting a negative control sequence or TDP-43 (Dharmacon siGenome 
Smartpool) were transfected into cells using Lipofectamine RNAiMax (Invitrogen) 
according to manufacturer’s instructions. 
 
Luminescent reporter assays 
 
Plasmid DNA encoding luminescent reporter proteins and ORFs  or 3’ UTRs of 
interest were transfected into cells using TransIT LT1 (Mirus). The Dual Glo 
Luciferase Assay System (Promega, Madison, WI) was used to read 
luminescence using the Envision Multilabel Reader (Perkin Elmer, Waltham, 
MA). 
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CHAPTER 3: Msi2 maintains self-renewal through TGFb 
signaling in hematopoietic stem cells 
 
One of the primary goals for my PhD work was to develop key RNA biochemistry 
techniques with which to study RNA binding proteins, identify their interaction 
partners, and determine their mechanisms of function more broadly. In addition 
to my thesis project, I have been able to apply some of the methods that I 
developed at the Broad to collaborations with other investigators. In particular, I 
have worked on projects investigating the RNA targets of the RNA binding 
proteins Musashi 1 (Jaenisch lab, Whitehead Institute), Musashi 2 (Kharas lab, 
Memorial Sloan-Kettering), and Lin28 (Daley lab, Harvard Medical School). 
These projects are in various stages of manuscript preparation. Chapter 3 of this 
thesis presents work on Musashi 2 that was recently accepted to the journal Cell 
Stem Cell.   
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ABSTRACT 
 
Hematopoietic stem cells are maintained through the regulation of symmetric and 
asymmetric divisions. We report that conditional ablation of the Msi2 RNA 
binding protein results in reduced HSC numbers due to a loss of quiescence and 
increased commitment divisions. Surprisingly, this was not mediated through a 
general increase in translation of the Msi2 binding target Numb. Instead, global 
transcriptome profiling and RNA target analysis identified direct MSI2 binding 
targets that govern HSC self-renewal, cell cycle and differentiation. Additionally, 
we revealed complex control of the TGF-β pathway by MSI2 in hematopoietic 
cells. Correspondingly, we found HSCs without Msi2 have reduced TGF-β 
signaling and are insensitive to TGF-β-mediated expansion. Msi2 deficiency 
reduced the frequency of myeloid-biased HSCs and transplants exhibited 
diminished myeloid reconstitution. Taken together, these results provide insight 
into the role of Msi2 in hematopoiesis and uncover a link between hematopoietic 
stem cell self-renewal and Msi2-mediated control of developmental pathways.  
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INTRODUCTION 
Hematopoiesis is a tightly regulated process in which different cell lineages are 
generated from hematopoietic stem cells (HSC). HSCs can self-renew and give 
rise to more differentiated progenitor cells through symmetric and asymmetric 
cell division, respectively(Beckmann et al., 2007; Wu et al., 2007). Progenitors 
can further differentiate into more committed cell subsets that generate the 
mature lymphoid and myeloid compartments. In order to support a normal 
hematopoietic system, HSCs must maintain a delicate balance between self-
renewal and differentiation. However, little is known about the developmentally 
conserved programs that regulate this balance. 
 
The Musashi (Msi) family of RNA binding proteins, including Msi1 and Msi2, 
contribute to the control of symmetric and asymmetric stem cell division, regulate 
stem cell function, and play a role in cell fate determination (Okano et al., 2005). 
In Drosophila, Musashi was first identified to be important for sensory neuron 
development, where it is essential for asymmetric division of neuroblasts into 
daughter cells with neuronal and non-neuronal potential(Nakamura et al., 1994). 
Loss of Musashi function results in defective asymmetric division and the 
formation of two non-neuronal daughter cells at the expense of commitment to 
the neuronal lineage(Nakamura et al., 1994). In vertebrates, Msi1 and Msi2 are 
evolutionarily conserved, harboring two tandem RNA recognition motifs (RRMs) 
and a carboxyl-terminal poly-A binding protein association domain(Kawahara et 
al., 2008; Okano et al., 2005).  
 129 
 
Msi proteins are thought to function by binding to the 3’ UTRs of target mRNAs at 
a consensus sequence and then blocking translation by hindering access of the 
poly-A binding protein to the elongation initiation complex(Kawahara et al., 2008). 
An inverse relationship between Msi and Numb expression as a result of Msi-
mediated repression of Numb has been demonstrated in a variety of systems, 
including myeloid leukemia cells(Imai et al., 2001; Ito et al., 2010; Kharas et al., 
2010). We and others recently identified Msi2 as an important modulator of 
proliferation and differentiation in both normal hematopoietic stem cells and in 
myeloid malignancies (de Andrés-Aguayo et al., 2011; Hope et al., 2010; Ito et 
al., 2010; Kharas et al., 2010). Analysis of the hematopoietic compartment of 
Msi2 gene trap mice revealed a reduced number of short term HSC (ST-HSC) 
and lymphoid primed myeloid progenitor (LMPP) cells, but no significant defect 
was found in long term HSCs(de Andrés-Aguayo et al., 2011). Although Msi2 is 
most highly expressed in HSCs, and MSI2 overexpression drives quiescent 
HSCs out of G0 and into cycle (Kharas et al., 2010), it remains unclear if and how 
Msi2 affects HSC self-renewal and commitment under homeostatic conditions. 
Furthermore, the critical RNA binding targets of Msi2 in hematopoietic cells that 
regulate self-renewal and lineage commitment remain to be uncovered.  
 
To determine the role of Msi2 in HSCs and to avoid potentially confounding 
compensatory mechanisms by germline Msi2 loss, we generated Msi2 
conditional knockout mice that allow us to study Msi2 function in a cell 
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autonomous manner in adult tissues using spatiotemporally controlled deletion. 
Here, analysis of microarray data of Msi2 conditional knockout mice coupled with 
a MSI2 HITS-CLIP (CrossLinking and ImmunoPrecipitation followed by HIgh 
Throughput Sequencing) profiling data allowed us to identify novel regulatory 
pathways downstream of Msi2 in hematopoietic stem cells. 
 
RESULTS 
In order to assess the role of Msi2 in the hematopoietic compartment, we 
developed a conditional knockout mouse model to study the role of Msi2 in adult 
hematopoiesis. We targeted the Msi2 locus in embryonic stem cells with a 
construct containing loxP sites flanking the first four exons (Figure 1A and S1). 
After deletion of the neomycin resistance selection cassette, an Msi2flox/flox mouse 
colony was established and crossed with Mx1-Cre mice to generate an inducible 
Msi2 loss of function strain (Msi2flox/flox::Mx1-Cre).  To delete the Msi2 gene from 
HSCs, we induced the Cre transgene in Msi2flox/flox::Mx1-Cre mice by three 
polyI:polyC (pIpC) injections, which efficiently excised the Msi2 gene from the 
bone marrow and spleen assessed by southern blot and by qRT-PCR analysis 
within the LSK (Lineagelo c-kit+, Sca+) compartment (Figure 1B-C). Msi2 deleted 
mice will be referred to as Msi2Δ/Δ and control mice either Msi2f/f or Msi2Δ/wt  
 
Msi2Δ/Δ mice had normal peripheral blood counts after 6 and 18 weeks post-pIpC 
injections (Figure S1).  However, after 12-18 weeks the mice had reduced spleen 
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weights and cellularity (Figure 1D and S1). We previously observed alterations in 
myeloid differentiation upon MSI2 overexpression in vivo (Kharas et al., 2010). In 
contrast, we found equivalent frequencies of immature myeloid cell types in the 
bone marrow and in the spleen (Figure S1). Also, we found the frequencies of B-
cells or T-cells in the bone marrow and spleen to be normal compared to controls 
(Figure S1). Furthermore, we tested the progenitor activity using a colony assay 
with Msi2Δ/Δ bone marrow cells (Figure 1E). We found a significant decrease in 
myeloid colony formation with reductions in multilineage progenitors and serial 
replating efficiency (Figure 1E). The decreased cellularity in the spleen and 
decreased colony forming ability indicated a defect in either early stem or 
progenitor function. Thus, we examined the overall frequency and numbers of 
HSCs in these mice. We found reduced frequency and absolute number of LSKs 
and reduced overall numbers of HSCs after 12wks (Figure 1F-G and S1).  
Decreases in LSK numbers were seen at as early as 4 weeks after deletion of 
Msi2 (Figure 1F-G and S1).   
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Figure 3.1: Msi2 conditional knockout have reduced HSC numbers. (A) Targeting schematic 
for Msi2 conditional knockout mice.  (B) Southern blot of indicated genotypes after 4 weeks post 
pIpC treatment in vivo.  (C) Quantitative PCR of Msi2 normalized to Gapdh from LSK (lineage 
low, Sca+ Kit+) sorted cells from 4 week post-pIpC injected mice (n=3 per group).  (D) Spleen 
weights from indicated mice at indicated time points (3-6wk, n=12, 12-18wk, Msi2f/f n=7 
Msi2Δ/Δ n=8). (E) M3434 colony formation assay from BM cells counted at Day 7 CFU-granulocyte  
(G; granulocyte), mixed Granulocyte and monocyte colony (GM), Burst forming units erythroid 
lineage (BFU-E), mixed granulocyte, erythroid monocyte and megakaryocyte  (GEMM), 
megakaryocyte (MEG), (n=4 per group) and Serial replating colony assay (right panel), round of 
replating (R1 or R2), (R1; n=8,10 and R2; 8,6).  (F) Representative flow cytometric analysis from 
mice 3-6-weeks post pIpC (n=12). (G) Absolute number of HSCs and LSKs from indicated mice 
post pIpC, (3-6wk; n=12, 12/18wk; n=6).  Data error bars are SEM and (+p<0.05, *p<0.01, 
**p<0.001).   
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In order to test if Msi2Δ/Δ HSCs are functionally normal, we transplanted the bone 
marrow of Msi2 deleted mice into congenic recipients. After engraftment, we 
observed reduced chimerism at 6 and 16 weeks in the peripheral blood (Figure 
S2).  Similarly, 20 weeks post-transplantation we observed decreased 
engraftment with a more pronounced defect in the myeloid compartment 
observed in the bone marrow and spleen (Figure 2A and S2). At 20 weeks these 
mice had reduced spleen size, decreased bone marrow and splenic cellularity 
after normalizing for chimerism in each mouse (Figure 2B).  Also, we observed a 
significant decrease in chimerism in the HSC and progenitor cell compartments 
(Figure 2C-D).  In order to quantitate the number of HSCs in Msi2Δ/Δ mice, we 
performed a cobblestone area forming cell assay with limiting dilutions of non-
transplanted Msi2Δ/Δ bone marrow (Figure 2E). At 4 weeks we observed a 
significant decrease in the frequency of cobblestone formation in Msi2Δ/Δ 
cultures. These findings indicate that Msi2 maintains the function and normal 
numbers of HSCs. 
 
To further delineate if this phenotype is cell autonomous, we non-competitively 
transplanted cells from both control and Msi2flox/flox::Mx1-Cre bone marrow, which 
was then allowed to engraft normally into congenic recipients.  The mice were 
then injected with pIpC and the peripheral blood was assessed 6 weeks later.  
We observed a reduction in the overall white blood cell count that consisted of 
 134 
decreased myeloid, lymphoid and red blood numbers (Figure 2F).  Mice 
sacrificed at 18 weeks had reduced chimerism in the blood, which was more 
pronounced in the myeloid compared to the lymphoid lineages (Figure 2G and 
S2).  Similar to the transplants performed with Msi2 deleted cell, the decrease in 
chimerism was also observed at the level of the HSC (Figure 2H).  This relative 
defect in both HSCs and myeloid chimerism prompted us to examine the 
frequency of myeloid bias HSCs based assessed by CD150 marker expression.  
In accordance with the myeloid defect we found reduced CD150 high myeloid 
biased HSCs in the primary Msi2 deleted animals compared to control mice 
(Figure 2I). Taken together these results indicate that Msi2 is critical for both 
normal HSC maintenance and maintaining the myeloid biased HSC compartment 
(Beerman et al., 2010). 
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Figure 3.2: Msi2 deficiency decreases repopulating activity in the myeloid compartment 
and HSC cell maintenance. (A) Msi2 deleted bone marrow was transplanted non-competitively  
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Figure 3.2 (Continued):  
and analyzed at 20 weeks for donor chimerism in splenic lymphocytes and bone marrow myeloid  
cells  (n=9). Data error bars are SEM and (**p<0.001). (B) Primary bone marrow transplanted 
animals were sacrificed at 20 weeks post pIpC and indicated organ weights (left panel) and 
(CD45.2+) cell counts from bone marrow (BM) and spleen which have been normalized for 
chimerism, are shown (right panel), (n=9). (C) Representative flow cytometric analysis from mice 
in (B).  (D) Chimerism analysis from mice in (B) measured by CD45.2 staining on indicated 
populations (SLAM; LSK, CD48- CD150+), (n=8,9).  (E) Cobblestone forming assay frequency 
analysis and limiting dilution assay from indicated time points, (n=2,5).  (F) Non-competitively 
transplanted mice were allowed to normally engraft before pIpC injections with 6-week peripheral 
blood analysis, (n=11,13). (G) Mice were analyzed at 18 weeks post pIpC for mature marker 
donor chimerism in the blood (n=4). (H) HSC and progenitor donor chimerism as in (G), (n=4). (I) 
Frequency of myeloid biased HSC in control and Msi2 deleted bone marrows. (n=15).  Data error 
bars are SEM, (+p<0.05, *p<0.01, **p<0.001). 
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Consistent with a loss of stem cell self-renewal, we found that Msi2Δ/Δ mice had a 
reduction in the G0 quiescent population that was identified in both the 
hematopoietic progenitor cells (HPC) and HSCs (Figure 3A).  The quiescent cells 
within the HSC compartment are considered to have higher engraftment potential 
in transplant assays (Passegue et al., 2005).  To test if the loss of Msi2 would 
sensitize the cells to proliferative stress, we challenged mice with 5-FU. There 
was a clear reduction of chimerism in the peripheral blood in the myeloid 
compartment whereas the lymphoid compartment was not significantly affected 
(Figure 3B and S3). We also found loss of chimerism within the myeloid 
progenitors and HSCs in the 5-FU treated mice (Figure 3C-D). Furthermore, we 
detected reduced recovery after 5-FU injection within the monocytes and 
neutrophils in Msi2Δ/Δ compared to controls (Figure S3). Altogether, loss of Msi2 
leads to reduced hematopoietic self-renewal during homeostasis, upon 
transplantation and after replicative stress. 
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Figure 3.3: Msi2 deficiency reduced quiescence and proliferative stress further depletes 
HSCs.  (A) Representative flow cytometry for cell cycle analysis with statistical analysis (lower 
panels), (n=6, 3). (B) Indicated mice were transplanted non-competitively (Figure 2F), injected 
with pIpC, and after 3-weeks were then injected with 5-FU. Peripheral blood chimerism for mature 
populations was analyzed after 40 days post-treatment, (n=5, 8). (C) Donor chimerism of HSC 
and progenitor populations from the bone marrow of mice in (B), (n=6, 5). (D) HSC (SLAM) 
chimerism with or without 5FU injections analyzed at 8-9 weeks same as (C), (n=6, 8) Data error 
bars are SEM and (+p<0.05, *p<0.01, **p<0.001).   
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The reduced quiescence and increased sensitivity to stress prompted us to 
examine if Msi2Δ/Δ HSCs were defective in their ability to undergo lineage 
commitment in a cell-autonomous manner. Indeed, in sorted HSCs and HPCs we 
found decreased colony formation with reductions in multilineage differentiation 
(GEMMs), (Figure 4A).  We performed in vitro proliferation assays on highly 
purified HSCs and HPCs and found reduced cellular output and increased 
commitment based on myeloid differentiation (Figure 4B-C). The reduced output 
and colony formation indicates that Msi2 is required for proper stem cell self-
renewal. 
 
To assess if there was a defect in cell fate determination that could compromise 
self-renewal in Msi2Δ/Δ HSCs, we examined Numb protein levels and distribution 
in HSC daughter pairs as a surrogate readout for asymmetric cell division and as 
a potential direct target of Msi2 binding. Surprisingly, in the Msi2 null HSC or 
HPCs we observed equal levels of Numb. This result indicated that Msi2 
deficiency does not alter the global expression of Numb within an individual cell 
(Figure 4D).  However, we did observe a decrease in the percentage of cells that 
underwent asymmetric Numb segregation in the HPCs and an increase in the 
percentage of cells with symmetric Numb staining in both the HSCs and HPCs 
(Figure 4E-F).  These results suggested that loss of Msi2 altered the cell fate 
decision towards commitment.  
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Figure 3.4: HSCs and HPCs from Msi2 deficient mice have reduced self-renewal divisions 
with differentiation independent of the Numb/Notch axis. 
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Figure 3.4 (Continued): 
(A) Indicated sorted populations were plated in methylcellulose assays from indicated mice HSC 
(left panel), (n=3, +p<0.05 in GEMM), and HPC (right pane), (n=3, *p<0.05 for Gran), colony 
designation is the same as in (Figure 1E).  (B) Normalized cell growth after in vitro culture of  
indicated sorted populations from Msi2 deleted donors (6-9 weeks), (HSC; n=14-15, HPC; n=5).  
(C) Representative flow for mature myeloid markers (left panel) from HSCs grown in (B), Mac 
positive cells from six independent experiments (right panel), (n=13, 14).  (D) Sorted control and 
Msi2 deleted HSCs and HPCs from 4 week pIpC mice cultured in vitro for 36 hours and stained 
for expression of Numb and DAPI, (n=4-5 mice combined HSC; number of cells analyzed, 42, 46, 
HPC; 76, 94).  (E) Representative images for paired Numb daughter assay with DAPI (middle 
panel) and bright-field images (right panel) and experimental scheme for studying asymmetric 
division in HSC/HPCs. (F) Percentage of doublet cells in each type of cell division as in (E), (n=4-
5 independent mice, HSC; 22, 72, HPC; 84, 107).  (G) LSK cells analyzed for the expression of 
indicated Notch targets normalized to Gapdh (n=3-4).   
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Although controversial, Notch signaling has been implicated in self-renewal of 
HSCs and as a critical downstream target of the Msi family through its ability to 
block Numb translation.  Using quantitative PCR for Notch target genes in sorted 
LSK cells from Msi2 deleted mice, we found no statistical difference in the 
expression of genes of the Notch pathway (Notch1, Notch2, Hes1 or Myc) 
(Figure S4). These results prompted us to take a more global approach in 
characterizing the consequence of the loss of Msi2 in hematopoietic cells. 
 
In order to understand which pathways were altered in the Msi2Δ/Δ  hematopoietic 
stem cells, we performed transcriptome profiling 4 weeks after Msi2 deletion.  We 
found several statistically significant gene set enrichment analysis (GSEA) 
signatures that included a loss of self renewal and increased differentiation of 
stem cells toward CMPs, GMPs and MEPs, and pathways signaling pathways 
including Cell cycle, Myc, Ras, Wnt and Tgfb (Subramanian et al., 2005) 
(Krivtsov et al., 2006) (Figure 5A and Supplementary Table 1)  These signatures 
were consistent with the phenotypes we observed in our previous in vitro and in 
vivo experiments.  Although we found no difference in the small selected targets 
of Notch signaling by qPCR, we found a statistically significant reduction in the 
overall pathway based on the GSEA analysis.   
 
Besides alterations in gene expression programs, it remained unclear how Msi2 
was directly maintaining self renewal.  Therefore, we decided to assess Msi2’s 
global RNA binding targets.  Due to the requirement for a large number of cells 
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and the importance of MSI2 in myeloid leukemias, we utilized K562 (CML-BC cell 
line) cells overexpressing a FLAG-tagged version of MSI2 to identify its direct 
RNA-binding targets. Using recently developed technologies, we performed 
experiments with UV-cross-linked and immunoprecipitated MSI2 which was then 
followed by RNA-sequencing (HITS-CLIP) to identify the global direct binding 
associations (Chi et al., 2009).  Our analysis characterized the distribution of 
binding across the genome with a majority of binding found in UTR-specific 
regions. We then calculated a log fold change of binding over the empty vector 
control to quantify the specific regions of interest. Using the entire ranked RNA 
target list we identified GSEA signatures including Cell Cycle, УSelf-renewalФ 
and УHSC to CMP differentiationФ that matched pathways we already identified 
using transcriptome analysis from Msi2 deleted LSKs (Figure 5B).  
 
We re-examined the microarray data to identify a specific pathway or genes that 
may provide further insight into Msi2 function. We ranked and plotted a heat map 
of the top and bottom 40 genes that showed differences in expression (Figure 
S4).  In Msi2-deleted HCS, the most depleted gene based on fold change was 
Tgfbr1 (Figure S4). The TGFbeta pathway has been previously shown to be 
critical for self renewal, quiescence and maintenance of HSCs. Based on 
Ingenuity Pathway Analysis and the TGFb gene set signature we found a 
reduction of expression of upstream and downstream components of the 
pathway (Figure 5C-D). Additionally, when we examined our HITS-CLIP data, we 
found Msi2 also binding directly to multiple components of the TGFb pathway as 
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observed by Ingenuity and GSEA analysis (Figure 5E-F and S5).  Although the 
GSEAs and Ingenuity analysis of the microarray suggested differences in the 
transcript abundance of pathway components, we only observed a trend toward 
reductions with no statistical difference in expression except for an increase in 
Tgfb1 (Figure S5).  The pathway analysis suggested that Msi2 binding acts 
through a post-transcriptional mechanism and modulating multiple nodes within a 
pathway.   
 
Based on the expression and HITS-CLIP data, we examined the functional 
signaling of the Tgfb pathway. An established readout for TGFb signaling is the 
phosphorylation of downstream components such as Smad2/3. We found 
reduced phosphorylation of Smad2/Smad3 in HSCs grown in vitro or directly 
isolated from bone marrow (Figure 5G and data not shown).  Another readout for 
TGFb signaling is the expression of cell cycle regulators p21, p27 and p57.  
Consistent with reduced signaling output of Tgfb we observed a significant 
decrease in p57 expression (Figure 5H). The role of p57 has been recently 
highlighted as a critical regulator of HSC quiescence (Zou et al., 2011) 
(Matsumoto et al., 2011).  Interestingly, we also observed a small but significant 
increase in p27 levels in consistent with a Tgfb pathway-independent mechanism 
and probably a compensatory mechanism for p57 reduction. Loss of p21 or p27 
was not required for growth inhibition of Tgfb in hematopoietic cells(Cheng et al., 
2001). 
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Figure 3.5: Msi2 modulates global gene expression and direct RNA targets uncovering a 
role for self-renewal, differentiation and Tgfb signaling.  (A) Control and Msi2 deleted LSKs 
were sorted, RNA was isolated and then analyzed by microarray.  Ranked fold change between 
control and Msi2 deleted  LSKs analyzed by GSEAs for self renewal gene signatures were 
decreased in Msi2 deleted LSKs while differentiation signatures were increased in 
Megakaryocyte erythroid progenitor (MEP), common myeloid progenitor (CMP) and granulocyte 
monocyte progenitor (GMP) gene signatures  (B) GSEA of the pre-ranked list of all the RNA 
binding targets mapping that have been mapped and log fold was calculated over the control to 
genes analyzed against the indicated gene sets. (C) GSEA analysis of the Tgfb pathway as in 
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Figure 3.5 (Continued): (A). (D) Ingenuity pathway analysis overlapping ranked fold change 
gene expression profiling from (A) over the Tgfb pathway. Green color indicates downregulated 
genes and red color indicated upregulated genes. (E) Ingenuity pathway analysis of all log fold-
change ranked HITS-CLIP RNA targets overlapped with TGFB pathway with red color indicating 
enriched binding over the background and green color indicating negatively enriched binding. (F) 
GSEA analysis of the HITS-CLIP ranked list over the TGFb upregulated gene signature.  (G) 
Sorted HSCs cultured as in Figure 4E were stained with pSmad2/3 specific antibodies and DAPI 
(representative image left panel) and fluorescence was quantified and normalized to the control 
(right panel), (n=3 independent experiments, 38-40 cells quantified per group in total).  (H) QPCR 
expression profiling of TGFb gene targets from control and Msi2 deleted LSKs, (n=5). (I) 
Proliferation assay of HSCs sorted and grown for seven days as in (Figure 4B) and Tgfb1 was 
added at indicated concentrations. Absolute cell numbers were normalized by each samples 
untreated growth.  Data error bars are SEM and (*p<0.01, **p<0.001).  
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Tgfb addition has been shown to be biphasic with high concentrations blocking 
proliferation and low doses leading to increased proliferation in a subset of 
myeloid-biased HSCs (Challen et al., 2010; Kale, 2004; Kale and Vaidya, 2004). 
Finally, we tested if there was a difference in the functional response to TGFb 
signaling in vitro using two different doses of TGFb. The suboptimal Tgfb 
signaling found in steady state conditions in Msi2 deleted HSCs was overcome 
by the addition of high dose of exogenous TGFb based on its equivalent growth 
suppressive effects compared to the control (Figure 5I). In contrast, at the lower 
dose when normal HSCs expand, Msi2 deleted HSCs failed to respond to the 
stimulation indicating diminished sensitivity to proliferative effect of Tgfb1 (Figure 
5J). Overall, this defect in Tgfb signaling and self-renewal pathways corresponds 
to the reduced overall numbers and function of Msi2 deleted HSCs.  
 
 
Figure 3.6. Model of Msi2 function in HSC. (A) Myeloid and lymphoid biased HSCs undergo 
normal self renewal with balanced symmetric and asymmetric divisions giving rise to 
differentiated progeny.. Normal HSCs proliferate in response to low levels of Tgfb signals. (B) 
Deletion of Msi2 in HSCs leads to loss of quiescence and increased symmetric commitment 
towards differentiated progeny. Additionally Msi2 loss leads to reduced myeloid biased HSCs, 
which are unresponsive to Tgfb-induced proliferative signals.  
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DISCUSSION 
In this report, we studied the role of Msi2 in HSCs using a conditional knockout 
murine model. Conditional ablation of Msi2 in the hematopoietic system results in 
dramatic reductions in steady state HSC and HSPC numbers with no changes in 
the maturation of myeloid or lymphoid hematopoietic lineages. We show that 
Msi2 is required for HSC quiescence and for maintaining the balance of self-
renewal and lineage commitment needed to regulate normal hematopoiesis. 
Notably, studies of single HSCs allowed us to uncover how Msi2 maintains stem 
cell identity and to show this was not due solely to regulation of Numb protein 
levels. Applying global RNA target analysis of MSI2 binding in leukemic cells 
combined with transcriptional analysis in mouse HSCs, we identified common 
self-renewal and differentiation pathways. Additionally, using this approach we 
uncovered a novel role for Msi2 in the regulation of TGF-β signaling by 
demonstrating reduced TGF-β signaling output and impaired response to TGF-β 
stimulation in Msi2 deficient HSCs. 
 
Previous studies from our group and others have identified a role for Msi2 in 
hematopoietic development, but it remained unclear how Msi2 functions and 
what pathways Msi2 regulates in hematopoietic cells(de Andrés-Aguayo et al., 
2011; Hope et al., 2010; Ito et al., 2010; Kharas et al., 2010). Our studies are 
consistent with experiments utilizing shRNAs specific to Msi2 that revealed 
reduced engraftment of Msi2 knock-down cells(Hope et al., 2010; Kharas et al., 
2010). The analysis of hematopoietic cells from mice harboring an insertional 
 149 
gene trap at the Msi2 locus demonstrated reduced repopulating activity in vivo 
without an apparent defect in HSCs with hypomorphic levels of Msi2(de Andrés-
Aguayo et al., 2011). Also, the same study suggested that there was a 
proliferative defect in the LMPP compartment. In accordance with this recent 
study, we find reductions in HSPCs, but also find a significant defect in the HSCs 
after genetic ablation of Msi2. Moreover, we demonstrate that this is due to a 
failure in maintaining quiescence and skewing symmetric self-renewal divisions 
towards differentiation. The apparent discrepancy in the defect within the HSCs 
between our two mouse models suggests that the loss of MSI2 may be 
compensated during development or could be due to differences between gene 
trap-mediated insertional disruption and the conditional deletion approach in vivo.  
 
Studies on the Msi family have considered Numb to be a critical downstream 
target of Msi mRNA binding and translational suppression(Imai et al., 2001). 
Numb modulates a variety of pathways, most notably the inhibition of Notch and 
hedgehog pathway components as well as stabilization of p53(Gulino et al., 
2010). However, we found equivalent expression of canonical Notch target genes 
in HSPCs in either our previously described inducible MSI2 knock-in model or in 
Msi2Δ/Δ HSCs (Figure S4 and(Kharas et al., 2010)). Previous studies examined 
the relationship between Msi1 and Numb, predominantly in the neural system; 
more recently the inverse relationship between Numb and Msi2 expression was 
demonstrated in blast crisis leukemic cells (Imai et al., 2001; Ito et al., 2010; 
Kharas et al., 2010). Specifically, MSI2 overexpression resulted in reduced Numb 
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staining in CML-BC murine cells(Ito et al., 2010). We also previously found that 
shRNA depletion of MSI2 led to increased NUMB levels in human CML-BC and 
AML cell lines(Kharas et al., 2010). However, this correlation was not clearly 
seen in HSPCs overexpressing MSI2 (data not shown and (Kharas et al., 2010) 
nor in Msi2Δ/Δ HSCs (Figure 4D). We found that overexpression of MSI2 in 
HSPCs did not decrease Numb staining, but did, however, increase the 
asymmetric segregation of Numb protein into daughter cells after mitosis(Kharas 
et al., 2010).  Conversely, we demonstrated that Msi2Δ/Δ  HSPCs had reduced 
asymmetric segregation of Numb, and in both HSPCs and HSCs we observed 
increased symmetric commitment divisions (Figure 4E-F). This apparent 
difference between the correlation of staining of Msi2 and Numb in both normal 
and leukemic cells, and between the effects of MSI2 deficiency and 
overexpression was also found recently in human samples(Pereira et al., 2012). 
Studies of normal CD34+ cells from healthy bone marrow displayed no 
correlation between MSI2 and NUMB expression, while the same study found 
reduced expression of NUMB in MDS/AML samples with the highest level of 
MSI2 expression(Pereira et al., 2012). It is also unclear if MSI2 regulates NUMB 
expression through indirect transcriptional effects, or through a direct post-
transcriptional mechanism. Our HITS-CLIP data demonstrates that MSI2 does 
not bind NUMB nor does Msi2 knockdown lead to increased protein expression 
after shRNA depletion of MSI2 in K562 cells (data not shown). Nevertheless, the 
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relationship between mRNA/protein expression of NUMB, and MSI2 in both 
normal and leukemic cells should be further examined.  
 
To gain an unbiased understanding of the pathways downstream of Msi2 in 
maintaining proper HSC self-renewal, we employed transcriptome-wide MSI2 
RNA-binding target analysis. A previous global study examining Msi1 using 
native RNA immunoprecipitation (RIP-CHIP) identified targets known to 
contribute to oncogenic transformation(de Sousa Abreu et al., 2009). In our 
study, we utilized a recently developed approach for studying RNA binding 
proteins (HITS-CLIP) that involves UV cross-linking to generate more specificity 
in binding targets through direct interactions between target proteins and 
RNA(Krivtsov et al., 2006). This allowed us to define a global map of MSI2 direct 
RNA targets for the first time. Moreover, integration of our HITS-CLIP data with 
expression data performed in Msi2 deficient hematopoietic stem and progenitor 
cells identified a set of developmental pathways, which are altered through direct 
RNA-protein interactions.  
 
One of the most significant pathways we identified was the TGF-β pathway, 
which has been linked to maintaining both normal and leukemia stem cell self-
renewal. However, similar to the Notch pathway, a clear understanding of how 
TGF signaling alters normal HSC behavior remains elusive. Initial studies in vitro 
with TGF ligands suggested that TGF-β signaling could block proliferation of 
HSCs and maintain quiescence (Sitnicka et al., 1996). Conditional deletion 
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studies of mice deficient of TGF-β1 signaling revealed no detectable alterations 
in the HSC compartment in vivo, but increased proliferation was observed in vitro 
at low concentrations of stimulation within Tgfb1 deficient HSCs(Larsson et al., 
2003; Larsson et al., 2005). In contrast, loss of TGF-βrII or Smad4 resulted in 
reduced chimerism in competitive transplants(Yamazaki et al., 2011). Other 
studies have demonstrated that myeloid biased HSCs and myeloid cell lines 
treated with low levels of TGF in vitro exhibit increased proliferation(Challen et 
al., 2010; Kale, 2004; Kale and Vaidya, 2004). Here we link Msi2 to the TGF-β 
pathway by demonstrating that it can directly interact with mRNAs encoding the 
components and targets of the pathway. We validated these results by 
demonstrating a functional reduction in Smad2/3 phosphorylation, decreased p57 
expression, and insensitivity to the growth stimulatory effects of TGF-β. 
Furthermore, the reduced TGF-β signaling ultimately results in a decrease in 
HSC self renewal and a dramatic reduction in myeloid biased HSCs. This 
observation explains the significant reduction in the mature cells of the myeloid 
lineage compared to the lymphoid lineage (Figure 6). Furthermore, p57 a critical 
downstream target of TGF-β signaling which is important in maintaining 
quiescence in HSCs, is significantly suppressed upon Msi2 deletion(Cheng et al., 
2001; Matsumoto et al., 2011; Scandura et al., 2004).  
 
Our report characterizes Msi2 deletion in the hematopoietic system and uses 
global RNA binding analysis to identify a novel link between Msi2 and TGF-β 
signaling in regulating quiescence, self-renewal and myeloid/lymphoid lineage 
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determination of HSCs. It will be interesting to test if this pathway is retained and 
functionally important for leukemic stem cells or if Msi2 modulates other critical 
pathways in these cells. Taken together, these results have important 
implications for understanding how the activity of RNA binding proteins contribute 
to normal tissue homeostasis and stem cell self-renewal, and how MSI2 and its 
targets contribute to oncogenic transformation.  
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EXPERIMENTAL PROCEDURES 
Quantitative RT-PCR  
mRNA was isolated from FACS-purified populations using TRIZOL (Life 
Technologies) and RNEASY RNA extraction kit (Qiagen), and reverse 
transcribed into cDNA with iSCRIPT (BioRad). Quantitative PCR was performed 
as previously described with indicated primers (Supplementary Table 4) for p21, 
p27, p57, smad2, smad3, smad4, smad7, TGF-βr1, TGF-βr2, TGF-β1, TGF-β2, 
Notch1, Notch2, Hes1, Hey, Myc and Actin.  
 
Msi2 conditional knockout mice 
We cloned one lox P site 3’ of the transcriptional start site and a floxed PGK-
neomycin-resistance cassette 3’ of the fifth intron using a Kpn1 fragment 
encompassing the 3’ region of the Msi2 locus cloned into the pBS backbone. 
(Figure 1A and S1A). The targeting vector was electroporated into V6.5 ES cells 
and G418 resistant colonies were subcloned. Homologous recombinants was 
detected by Southern blotting using 5’ and 3’ external probes, and correctly 
targeted ES clones were transiently treated with Cre to remove the Neo 
resistance cassette (verified by Southern blotting), prior to blastocyst injection of 
conditional 2lox clones. Resulting chimeras were backcrossed to Bl/6 mice and 
the F1 generation was bred to Mx1 Cre mice on a Bl/6 background. Deletion was 
initiated using pIpC (Amersham) by intraperitoneal injections every 3-4 days as 
indicated (150mg/kg) per mouse three times. Cre recombination of the 
conditional 2-lox (floxed) locus to the inactive, 1 lox (null) locus was verified by 
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Southern blotting after cutting genomic DNA with Xba I and hybridization with a 5’ 
external probe. 
 
Non-competitive transplants 
Non-competitive transplants were performed with 1X106 bone marrow cells from 
6-10 week old Msi2flox/flox or littermate control mice, transplanted into lethally 
irradiated B6SJL congenic CD45.1 recipients. In the primary transplants with 
Msi2Δ/Δ bone marrow, transplants were performed 12-16 weeks after Msi2 
deletion. In the cell autonomous transplants, transplanted marrow was allowed to 
engraft for 4-6 weeks before pIpC was administered. Peripheral blood chimerism 
was assessed post-engraftment prior to deletion to verify successful engraftment. 
 
Peripheral blood analysis 
Peripheral blood was collected from the retro-orbital cavity using a heparinized 
glass capillary tube. Complete peripheral blood count analysis including a 
differential blood count was obtained by using Hemavet (Drew Scientific).  
 
Flow Cytometry 
Bone marrow cells or splenocytes were harvested and subjected to red blood cell 
lysis. Fresh or frozen cells were stained with the following antibodies: CD45.2-
FITC and CD45.1-APC, Mac1-PE, Gr1-APC, c-Kit-APC, CD71-PE, Ter119-APC, 
B220-PE, and CD3-APC (Becton-Dickinson) and analyzed on the BD 
FACSCalibur instrument. Staining for multiparameter flow cytometry was 
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performed after a c-kit enrichment using 10 uL of MACS beads (CD117) per 
mouse and then run on an AutoMACs per manufacturer instructions. The cells 
were then stained with the following cocktail: (Lineage; CD3, CD4, CD8, Gr1, 
B220, CD19, TER119 all conjugated with PeCy5), Sca-Pac Blue, CD34-FITC or 
CD45.2 FITC, SLAM-APC, CD48-PE, c-KIT-AlexaFluor 780, FcgRIIb-PeCy7, 
Figure 2D; HPC(Linlo c-Kit+ Sca1-), GMP (LK, FcgRIIbhi CD34+), CMP (LK, 
FcgRIIbmid CD34+), MEP (LK, FcgRIIblow CD34-), B-cells (B220+) and T-cells 
(CD3+) from the spleen were also sorted.  
 
Colony-Forming Assays 
Bone marrow cells were harvested, subjected to red blood cell lysis, and 
resuspended in RPMI/10%FBS/5% penicillin-streptomycin. Cells were plated in 
duplicate in M3434 methylcellulose media (Stem Cell Technologies) at 1x104 
cells/dish for bone marrow and 5x104 cells/dish for spleen cells. Colonies were 
scored after 7 days. If at least 25 colonies were observed per dish, the cells were 
replated in M3434 media at 1x104 cells/dish, and then counted and replated 
every 7 days. 200 sorted HSCs or 500 sorted HSPCs were plated and scored 
after ten and seven days respectively. 
 
Microarray Analysis of Msi2 expression in conditional knockout mice. 
Hematopoietic stem and progenitor cells (Lineagelo ScaI+ c-Kit+) were sorted 4 
week post-pIpC injection. RNA was extracted using TRIZOL and RNEASY RNA 
extraction kit. RNA was then amplified using NUGEN Pico amplification kit, 
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fragmented and hybridized on Mouse Expression Array 430 2.0. Signal 
normalization was performed by RMA method. Data was analyzed using GSEA 
across the complete list of genes ranked by signal-to-noise ratio. (Microarray 
data is representative of n=4 Msi2flox/flox mice and n=4 Msi2Δ/Δ mice.  
 
Immunofluorescence 
HSCs or HSPCs were sorted from primary mice 6 weeks post-pIpC and cultured 
with STIF media in 96 round bottom wells for 16 hours and then treated with 
10nM of Nocodazole for 24 hours. Cells were then cytospun, fixed and methanol 
permeabilized and then stained on slides with anti-Numb (Ab4147 Abcam) and 
secondary antibody (donkey anti-goat Alexa fluor 546, Molecular Probes) with 
DAPI counterstaining(Kharas et al., 2010). Symmetric versus asymmetric 
percentages were assessed based on quantification of the signal intensity of 
each cell (divided by surface area) normalized for background staining using a 
Zeiss Microscope followed by a confirmatory visual inspection that determined 
symmetric commitment versus symmetric renewal. Daughter cells with elevated 
equivalent staining of Numb were counted as symmetric commitment whereas if 
one daughter cell contained more staining than the other cell then the division 
was considered as asymmetric division. If there was low or no staining in the 
daughter pairs, this was scored as a symmetric renewal division. Cells were also 
stained for phospho-Smad2/3 and staining was quantified as above in all cells 
including non-dividing cells. Phospho-Smad2/3 was also performed on HSCs 
directly isolated from animals with similar results. 
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Cobblestone area-forming Assay 
We performed CAFC assays as described in(Moore et al., 1997). In short, we 
plated bone-marrow cells in 96 flat bottom wells in limiting dilutions on top of 
confluent OP9 stroma at the indicated doses of bone marrow cells: 1x104, 4x104, 
8x104, 16x104 with 12 replicates per dose. The number of cobblestone positive 
wells per dose were enumerated and at 2 weeks post-plating. L-Calc software 
(Stem Cell Technologies) was used to calculate frequency and p-values between 
groups. 
 
In vitro HSC and HSPC proliferation Assay  
We sorted 100 HSCs (LSK CD48- CD150+) and 1000 HSPCs (LSK CD150-) into 
SFEM medium containing 10 ng/ml IL-3, 10 ng/ml IL-6, 50 ng/ml SCF, 10 ng/ml 
TPO and 20 ng/ml Flt3L in a round bottom plate and counted at day 7 and 5, 
respectively. Then cells were analyzed using counting beads and indicated 
markers for differentiation by flow cytometry. 
 
Statistical Analyses 
For bar graphs, the unpaired 2-tailed student’s T-test was used to compute p 
values, except where stated otherwise. Error bars reflect the standard error of the 
mean (SEM), except where stated otherwise. All statistical analyses were carried 
out using Graph Pad Prism 4.0 and the R statistical environment.  
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UV-crosslinking, immunoprecipitation and high throughput RNA sequencing 
(HITS-CLIP) 
The protocol used is mainly based on UV-crosslinking and immunoprecipitation 
with high throughput RNA sequencing (HITS-CLIP) published by (Chi et al., 
2009; Krivtsov et al., 2006). In brief, 100 million empty vector control- or Flag-
MSI2- overexpressing K562 cells were UV-crosslinked with 4000 J at 265 nm on 
ice. Cells were washed three times with cold PBS containing protease inhibitors 
and the cell pellets were resuspended in a low salt buffer that is optimized for 
reducing non-specific RNA interactions (100 mM NaCl, 0.1% sodium dodecyl 
sulfate (SDS), 0.5% sodium deoxycholate, 0.5% Nonident P-40) with protease 
inhibitors. Cells were sonicated with a Branson probe sonicator for three cycles 
of 10 seconds (0.7 sec on/1.3 sec off) at 20% power on ice. The lysates were 
then rested on ice for 20 minutes. RQ1 DNase (Promega, Madison, WI) was 
added to the lysates and incubated at 37°C for 5 minutes. RNAse A (USB 
Products, Cleveland, OH) was added at a concentration of 1:1000 and incubated 
at 37°C for 10 minutes. Lysates were spun and supernatants were incubated with 
protein G Dynabeads (Invitrogen, Grand Island, NY) that were pre-incubated with 
anti-Flag M2 Ab in low salt buffer (Sigma, St. Louis, MO). Beads were washed 
with low salt wash buffer three times followed by two washes with high salt buffer 
(500 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.5% Nonident P-40) to 
reduce non-specific protein interactions. Proteinase K (Invitrogen) (5 ug) was 
added to the washed beads and incubated at 70°C for 2 hours. RNA was 
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extracted using standard Phenol/Chloroform extraction methods, the RNA was 
precipitated at 80°C overnight, and the resulting RNA pellets were washed with 
80% ethanol to retain short RNA fragments. RNA sizes were assessed on a 2100 
Bioanalyzer (pico chip) and the sizes of extracted RNA ranged between 40 – 200 
bases in length. RNA libraries were prepared and barcoded at the Broad Institute 
Sequencing core facility and then sent to the core facility at Sloan Kettering 
Institute for single-end Illumina sequencing. A first round of sequencing for one 
control and two replicates produced ~20 million 36-bp alignable reads for each 
library. The second replicate was sequenced for an additional 60 million reads to 
enhance coverage.  
 
Statistical analysis and plots of HITS-CLIP data 
 
To identify potential binding sites, we used a custom R package to call peaks in 
read coverage in the Msi2 HITS-CLIP experiments ((Loeb et al., 2012) and see 
Supplemental Online Methods), and we tested for differential binding between 
Msi2 overexpressing cells and control while correcting for differential expression 
using a joint generalized linear model of HITS-CLIP and RNA-sequencing read 
counts in the candidate peak regions (Supplemental Online Methods).  Peak 
windows that were differentially bound at an FDR threshold of 0.1 were reported 
unless otherwise noted.  Plots of HITS-CLIP maps provide positional read 
coverage after scaling for library size.  For visualization purposes, positional read 
counts are then set to the highest peak within each coverage plot.  Peaks 
identified by the peak calling procedure are shown in color if they are significantly 
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bound (red, FDR < 0.05; magenta, FDR < 0.1, dark grey FDR < 0.12) in MSi2 
pulldown versus control. We identified enriched motifs by running differentially 
bound peak regions in MEME separately on 3'UTR and CDS binding site 
sequences (Supplementary Online Methods). 
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S. Figure 1.1: TDP-43 negatively regulates antiviral gene expression. 
 
(A) Fluorescent images of GFP-TDP-43 protein in TDP-43-depleted cells. U2OS cells expressing 
GFP-TDP-43 were transfected with a control siRNA or two independent siRNA sequences 
targeting TDP-43 and fluorescent images were taken 72 hrs post transfection. 
(B) Western blot for TDP-43 protein in TDP-43-depleted cells. Mouse lung fibroblasts were were 
transfected with a control siRNA or two independent siRNA sequences targeting TDP-43 and S. 
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Figure 1.1 (Continued): TDP-43 protein levels in cell lysates were assessed in resting and 
Sendai virus (SeV)-stimulated cells 72 hours later. 
(C) mRNA levels for interferon-stimulated genes in TDP-43-depleted human lung cells. Primary 
human bronchial epithelial (HBE) cells were transfected with siRNA targeting a control sequence 
or TDP-43. HBE were infected with infected with Influenza A/dNS1 (A/dNS1) (MOI 2) for 8 hrs 
and the relative expression of antiviral genes was assessed by Nanostring nCounter. 
(D) mRNA levels (qPCR) for IFNb and CXCL10 in primary mouse microglia. Primary mouse 
microglia were infected with shRNA targeting a control sequence (shRFP) or with two 
independent shRNA targeting TDP-43. Following selection with puromycin, cells were infected 
with Influenza A/PR8 (A/PR8) (MOI 2) for 18 hrs and gene expression was assessed by qPCR. 
(E) mRNA levels (qPCR) for IFNb and IFIT3 in TDP-43-depleted HEK293T cells. HEK293T cells 
were transfected with siRNA targeting control sequences or TDP-43. Cells were transfected with 
Influenza A/PR8 viral RNA (A/PR8/vRNA) for 18 hrs and gene expression was assessed by 
qPCR. *p<0.05, **p<0.01. 
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S. Figure 1.2: TDP-43 protein levels are carefully regulated. 
 
(A) Fluorescent images of TDP-43 localization in GFP-TDP-43 overexpressing cells. U2OS cells 
stably expressing GFP-WTTDP-43 (top panel) or GFP-TDP-43A315T (bottom panel) under a 
tetracycline-inducible promoter were treated with tetracycline for 24 hrs. Then, cells were infected 
with SeV (MOI 5) over a time course (0, 4, 16 hr). Cells were fixed and stained with antibodies 
targeting GFP (green), nuclei (blue), or IRF3 (red) and imaged. 
(B) Western blot for TDP-43 protein in cells overexpressing TDP-43. HEK293T cells were 
transfected with plasmids encoding an empty vector, WT TDP-43, TDP-43A315T, or TDP- S. 
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Figure 1.2 (Continued): 43M337V. 24 hrs later, cells were infected with SeV (MOI 5) for 18 hrs 
and TDP-43 protein was measured from cell lysates by Western blotting. 
(C) Western blot for TDP-43 protein in cells overexpressing TDP-43. U2OS cells stably 
expressing GFP-WTTDP-43 were treated with tetracycline for 24 hrs at several doses (0, 0.0039, 
0.0156, 0.0625, 0.25, and 1 ug/ml) and TDP-43 protein levels in cell lysates were assessed by 
Western blotting. 
(D) Western blot for TDP-43 protein in U2OS cells infected with SeV. U2OS cells were infected 
with SeV (MOI 5) over a time course (0,1,2,4,6,8,10,12 hr) and TDP-43 protein levels in cell 
lysates was assessed by Western blotting. 
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S. Figure 1.3: TDP-43 remains nuclear in response to viral sensing. 
 
(A) mRNA levels (qPCR) of TDP-43 in response to DNA sensing. U2OS cells were transfected 
with immunostimulatory DNA (ISD)(120 ng/ml) over a time course (0,2,4,6,8,10 hr) and TDP-43 
transcript levels were assessed by qPCR. 
(B) Fluorescent imaging showing nuclear versus cytosolic localization of TDP-43 protein in 
response to A/PR8 infection in human cells. U2OS cells were infected with A/PR8 (MOI 5) over a 
time course (0,2,4,6,8,10,12,18 hr). Cells were fixed and stained with fluorescent antibodies 
targeting TDP-43 (green) or TIAR (blue). Quantification of cytoplasmic versus nuclear TDP-43 
fluorescent signal (right). 
(C) Western blot showing nuclear versus cytoplasmic localization of TDP-43 in response to 
A/PR8 infection in mouse cells. MLF were infected with A/PR8 (MOI 5) for 10 hrs. Cytoplasmic 
and nuclear fractionation was performed and TDP-43 protein levels were assessed by Western 
blot. 
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S. Figure 1.4: Localization of TDP-43 domain mutant expression. 
 
(A) Fluorescent imaging of Cherry-tagged TDP-43 protein in HEK293T cells in response to A/PR8 
infection. HEK293T cells were transiently transfected with plasmids encoding an empty vector 
(pmCherry vector), or pmCherry fused to WTTDP-43, TDP-43A315T, TDP-43M337V, TDP-43ΔC-
terminus, TDP-43ΔN-terminus, TDP-43ΔRRM1, or TDP-43ΔRRM2. Cells were infected with 
A/PR8 for 8 hrs, then fixed and imaged. 
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S. Figure 1.5: Intact antiviral signaling is required for the TDP-43-mediated antiviral 
phenotype. 
 
(A) mRNA levels (qPCR) for IFNb transcript in MAVS-/- cells. MAVS+/+ or MAVS-/- mouse 
embryonic fibroblasts (MEF) were infected with shRNA targeting a control sequence or TDP-43. 
After selection with puromycin, cells were infected with SeV (MOI 2) for 18 hrs. IFNb transcript 
levels were assessed by qPCR. 
 
  
 
 
S. Figure 1.6: TDP-43 associates with the 3’ UTR of innate immune transcripts in vitro. 
 
(A) Western blot for crosslinked RNA pull down of innate immune 3’ UTR. HEK293T cells were 
infected with SeV (MOI 5) for 18 hrs. Lysates were prepared and biotinylated 3’UTR sequences 
corresponding to a control sequence (Control RNA, GAPDH) or TDP-43-target transcripts (actinb, 
IFNa, IFNb, CXCL10, IFIT1, IFIT3, TNF) were incubated with the lysates for 2 hrs. The 
protein:RNA interactions were immobilized by UV crosslinking and the lysates were RNase A 
digested. Proteins were resolved on an SDS-PAGE gel and TDP-43 protein was probed with a 
specific antibody.  
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S. Figure 1.7: Perturbation of TDP-43 stabilizes polyadenylation sequences in the 3’ UTR of 
IFNb and IFNa. 
 
(A) Distribution of massively parallel reporter assay (MPRA) tagged sequences in cells grown at 
high versus low confluency. HEK293T cells at high versus low confluency were transfected with 
our MPRA plasmid pool. Relative enrichment for stabilized (red) and destabilized (green) tile tags 
is shown. 
(B) MPRA mRNA sequence enrichment for IFNb and IFNa 3’ UTR. HEK293T cells were 
tranfected with siRNA targeting a control sequence or TDP-43, then transfected with our MPRA 
plasmid pool. Relatively stabilized tile tags (red dot) are shown. 
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Supplementary Table 2: 
 
MPRA 
gene list:    
    
Gene: Protein name: RefSeq ID 
MPRA 
peaks? 
    
ACTB ACTB NM_001101.3  
ADAR 
Double-stranded RNA-specific 
adenosine deaminase NM_001111.4 Y 
ATF3 ATF3 NM_001040619.1 Y 
Axl axl receptor tyrosine kinase NM_021913.3 Y 
bst2 tetherin NM_004335.2  
C3  complement component 3 NM_000064.2  
CCND1 cyclin D1 NM_053056.2  
cdk6 cyclin dept kinase 6 NM_001145306.1 Y 
CNN1 calponin NM_001299.4 Y 
CXCL10 CXCL10 NM_001565.3 Y 
DDX58 RIG-I NM_014314.3 Y 
Eif2ak2 Eif2ak2 NM_002759.2 Y 
Fus Fus/TLS NM_004960.3 Y 
GAPDH GAPDH NM_002046.3  
GRN  granulin NM_002087.2  
HDAC1 HDAC1 NM_004964.2 Y 
HDAC4 HDAC4 NM_006037.3 Y 
HDAC5 HDAC5 NM_005474.4 Y 
HDAC6 HDAC6 NM_006044.2  
HDAC8 HDAC8 NM_018486.2  
IFI16 IFI16 NM_005531 Y 
Ifih1 interferon induced helicase c NM_022168.2 Y 
IFIT1 IFIT1 NM_001548.3  Y 
IFIT3 IFIT3 NM_001549.4 Y 
IFITM3 IFITM3 NM_021034.2  
IFNA2 interferon alpha NM_000605.3 Y 
IFNB1 interferon beta NM_002176.2 Y 
IFNg interferon gamma NM_000619.2 Y 
IL-6 IL-6 NM_000600.3 Y 
IL12B IL-12p40 NM_002187 Y 
IRF3 IRF3 NM_001197123.1  
IRF7 IRF7 NM_004031.2  
IRF9 IRF9 NM_006084.4  
IRGM immunity-related GTPase family, M NM_001145805.1  
ISG 15 ISG 15 NM_005101.3  
lrrc47 lrrc47 NM_020710.2  
MAVS MAVS NM_020746.4 Y 
MX1 MX1 NM_001144925.1  
NEFL neurofilament NM_006158.3  
OAS1 OAS1 NM_016816.2  
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OASL OASL NM_003733.2  
Plk1 polo like kinase 1 NM_005030.3  
SHISA5 SHISA5 NM_025858.2 Y 
SOD1 SOD1 NM_000454.4  
STAT1 STAT1 NM_009283.3 Y 
STAT2 STAT2 NM_005419.3  
TARDBP TDP-43 NM_007375.3 Y 
TNF TNF NM_000594.2 Y 
VIM vimentin NM_003380.3 Y 
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Appendix 2: Chapter 3 Supplementary Information 
 
 
S. Figure 3.1: Characterization of Msi2 deleted hematopoietic cells.  (A) 
Peripheral blood analysis from control and conditional Msi2 deleted mice.  White 
blood cells (WBC) and red blood cells (RBC) at indicated time points post pIpC, 
(n=6-7) are shown.  (B) Overall cell counts in mice from (A) in the bone marrow 
(BM) and spleen (SP), (4wk; n=4, 12/18wk; n=9,10).   (C) Combined flow 
cytometric analysis of the frequency of different mature hematopoietic 
populations from indicated live cells from bone marrow at 12wks or 18wks, 
Mac1+ Gr1- (Mac1), Mac1+ Gr1+ (Gran), IgM- B220+ (Immature), CD71+ Ter119+ 
(CD71/Ter119), CD71- Ter119+ (CD71lo TER119), CD71+ Ter119- (CD71), (n=6-
9).  (D) Flow cytometric analysis as in (C) from the spleen, IgM+ B220+ (B-cell), S. 
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Figure 3.1 (Continued): CD4+ (CD4 T-cells), CD8+ (CD8, T-cells), (n=6-9). (E) 
Frequencies from bone marrow of indicated mice injected with pIpC at indicated 
time points (LSK; 4wk, n=4, 12/18wk; 6-8), (HSC; 4wk, n=4, 12/18wk; 8-10).  
Data error bars are SEM and (ns not significant, +p<0.05, *p<0.01, **p<0.001).   
 
 
S. Figure 3.2: Msi2 deleted cells have reduced repopulating activity in the 
myeloid compartment.  (A) Chimerism analysis of the mature populations in 
peripheral blood of primary transplanted animals at indicated time points (n=4,5). 
Statistics--. (B)  Chimerism of myeloid and lymphoid lineages in spleen of primary 
transplanted mice shown in Figure 2A.  (C) Chimerism of myeloid and lymphoid 
lineages in bone marrows of transplanted mice that were allowed to engraft and 
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S. Figure 3.2 (Continued): examined at 18 weeks post-pipc (same as Figure 
2G). Data error bars are SEM and (ns not significant, +p<0.05, *p<0.01, 
**p<0.001).   
 
S. Figure 3.3: Reduced myeloid recovery after replicative stress in Msi2 
deleted animals.  (A) Blood analysis of non-competitively transplanted animals. 
Measurements of neutrophils (upper panel) and monocytes (lower panel) at 
indicated time points were normalized back to the same animal before 5-
Flourouracil (5-FU), (n=5, 8) and after 6-weeks post pIpC injections (see also 
Figure 3B-C). (Data error bars are SEM and (ns not significant, +p<0.05, 
*p<0.01). (B) Chimerism analysis of myeloid and lymphoid lineages in peripheral 
blood of mice shown in Figure 3B.  Data error bars are SEM and (**p<0.001).   
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S. Figure 3.4: Differentially expressed genes in Msi2 deleted Hematopoietic 
stem and progenitor cells.  (A) Microarray heat map of top 40 differentially 
downregulated expressed genes based on ranked t-test values (n=4), (4 weeks 
post pIpC) sorted LSKs.  (B) Same as in (A) except selected heat map is for 
genes unregulated in Msi2 deleted LSKs.   
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S. Figure 3.5: MSI2 binds to multiple components of the TGFb signaling 
pathway.  Integrative Genomics Viewer (IGV) mapped sequence reads from the 
HITS-CLIP experiment with empty vector infected K562s (Control) and FLAG-
MSI2 (MSI2) transduced cells.  Peak reads are in the same scale and 
comparable between samples.  
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S. Figure 3.6: Comparable RNA expression of Tgfb pathway components in 
Msi2 deleted hematopoietic stem and progenitor cells. LSK cells analyzed for 
the expression of indicated Tgfb pathway member i.e Smads (Smd) normalized 
to Gapdh, (n=4-6).  Data error bars are SEM and (ns not significant, *p<0.01).   
 
 
 
 
 
 
 
 
 
 
 
 
